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Abstract 
Improving adherence to medications is an opportunity that can yield great improvements in 
health outcomes and reducing health costs. Supporting adherence to medicines requires 
insight into a patient’s medication-taking behaviour and their reasons for non-adherence. 
Adherence interventions that show most promise include multifaceted interventions, and 
those targeted to non-adherent patients and/or tailored to patient-specific reasons for non-
adherence. To identify non-adherent patients and their reasons for non-adherence in the 
practice setting, I argue that we require inexpensive measures that are easy to use and can 
inform the discussion with patients about their adherence. Adherence scales are 
inexpensive, easy-to-administer and have the potential to explore both medication-taking 
behaviour and reasons for behaviour.  
The overall aim of the thesis is to determine if a targeted and tailored intervention based on 
a discussion informed by validated adherence scales, will improve adherence to a recently 
initiated cardiovascular medication. I hypothesise that targeting and tailoring an intervention 
to non-adherent participants based on a discussion informed by adherence scales, will 
improve adherence at three months as measured by the four-item Medication Adherence 
Questionnaire (MAQ). I will also test whether improvements in adherence at three months 
are sustained at six months and explore the changes in adherence and reasons for non-
adherence over time. 
The first part of the thesis involved identifying validated adherence scales suitable for use in 
the intervention. A systematic review was conducted on adherence scales to explore their 
use and validation. We found that adherence scales measured different aspects of 
adherence: medication-taking behaviour, barriers to adherence and beliefs associated with 
adherence. Adherence scales have been validated in different disease populations and 
against different measures of adherence. We selected two adherence scales for our study: 
the MAQ and Beliefs about Medicines Questionnaire-Specific (BMQ-S). The MAQ is one of 
the most commonly used adherence scales that has been validated in many disease 
populations and against different measures of adherence including electronic monitoring. 
The BMQ-S has been extensively used to elicit medication beliefs associated with 
medication adherence and validated in a number of diseases including cardiovascular 
disease, asthma and depression. 
A randomised controlled trial was conducted to determine if a targeted and tailored 
intervention would improve medication adherence. Four hundred and eight patients were 
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assessed for eligibility from two community pharmacies, from which 152 patients were 
enrolled into the study. All enrolled participants completed the MAQ, BMQ-S and Brief Illness 
Perceptions Questionnaire (BIPQ). There were 120 participants identified as non-adherent 
using the MAQ, who were randomised into an intervention or control group. The remaining 
32 participants were identified as adherent. In the intervention group, the results from the 
MAQ, BMQ-S, and BIPQ were used by the researcher (TN) to identify reasons for non-
adherence and inform the implementation of a tailored strategy. There was no difference 
between the mean MAQ scores at baseline: 1.58 ± 0.79 (intervention) and 1.60 ± 0.67 
(control) (p=0.9008). At three months, the mean MAQ score in the intervention group was 
significantly lower than the control group, reflecting an improvement in adherence (mean 
MAQ 0.42 ± 0.59 v 1.58 ± 0.65; p<0.001). The significant improvement in the mean MAQ 
score in the intervention group compared to control was sustained at six months (0.48 ± 
0.68 vs 1.48 ± 0.83; p<0.001). 
The intervention consisted of an interview and the implementation of a tailored strategy. The 
participant’s reasons for non-adherence were explored using their responses to the MAQ, 
BMQ-S and BIPQ. Where possible the researcher used responses to the adherence scales 
to inform further discussion regarding the participant’s adherence and the factors that 
supported or impeded them taking their medicine. The researcher and participant then 
selected and implemented an evidence-based tailored strategy to support the participant’s 
adherence based on the information discussed in the interview. Tailored strategies included 
reminders, cognitive-educational strategies, both a reminder and cognitive-educational 
strategy, behavioural-counselling and social support. For example, if the main barrier to 
adherence is identified as forgetfulness, then the participant will receive a reminder strategy.  
Changes in the responses to the questionnaires were explored in the adherent, intervention 
and control groups, and also within the different types of strategies. In the intervention group, 
patients who received a cognitive-educational strategy had improved perceived 
understanding of their illness corresponding to improvements in their adherence score on 
the MAQ. As expected, patients who received a reminder strategy on its own had no 
significant changes in their beliefs about medicines and illness perceptions. 
An intervention that targeted non-adherent participants and tailored to the participant-
specific reasons for non-adherence was successful at improving medication adherence. 
Better understanding how a patient’s adherence and beliefs about their medicines change 
over time, will inform improved interventions to support adherence. This intervention was 
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quick and easy to administer and has the potential for clinical implementation if proven 
successful in larger studies that assess clinical outcomes. 
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CHAPTER ONE: LITERATURE REVIEW 
 
1.1 Introduction 
 
Medication non-adherence has been identified as one of the greatest areas of opportunity 
to improve health outcomes and reduce health expenditure.1-3 Poor adherence to medicines 
affects approximately 50% of patients taking chronic medicines,1,4-10 leading to adverse 
health outcomes.11,12  
Interventions have been employed to improve adherence to medications. These include: 
reminder interventions (e.g. telephone reminders), educational interventions (e.g. 
informational pamphlets), behavioural interventions (e.g. motivational interviewing) and 
social support (e.g. peer support therapy).13-15 Adherence interventions have not always 
been successful at improving medication adherence in clinical trials.13,15 This reflects the 
complex nature of adherence. 
Supporting a patient’s adherence to their medicines requires insight into their medication-
taking behaviour and the reasons for their behaviour. An intervention that targets non-
adherent patients and tailored to the patient-specific reasons for non-adherence that is 
practical to translate into clinical practice is required. Adherence scales are easy to 
administer, inexpensive and can explore both adherence and reasons for non-adherence. 
This thesis explores an intervention that is targeted to non-adherent participants and tailored 
to their specific reasons for non-adherence, informed by validated self-report adherence 
scales. 
This chapter outlines the issues associated with medication non-adherence, the measures 
of adherence, the barriers to and determinants of adherence and the current interventions 
implemented to improve adherence. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
1.2 Terms and Concepts Used to Describe Adherence  
 
The benefits of effective medicine use depend on a patient taking their medication. 
Historically, this was referred to as “compliance.” Compliance is the degree to which the 
patient follows the treatment instructions given by the health provider. This suggests that 
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the health provider knows what is best for the patient and would prescribe the ideal treatment. 
It implies that patients play a passive role in their medical management and that deviating 
from these instructions would put the blame on the patient.16-19 With healthcare adopting a 
more patient-focussed approach, the terms to describe medication-taking behaviour have 
evolved over time from “compliance” to “adherence." The shift from “compliance” to 
“adherence” represents a desire to emphasise the patient’s active role in decision-
making.1,20  
 
The World Health Organisation (WHO) defines adherence as: 
 
“The extent to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a 
health care provider.”1 
 
The definition of “adherence” acknowledges the importance of the shared agreement 
between the patient and the health care provider. Shared decision-making, which may be 
implicit, involves the patient in the treatment decision process. It explores the ideas, fears 
and expectations of the patient, with both the patient and health provider coming to a final 
agreement on the treatment decision (Figure 1.1).21,22 By acknowledging shared decision-
making, the definition of adherence incorporates patient-provider collaboration focusing on 
patient autonomy and patient-centred care. Therefore, the term “adherence” is preferred 
over “compliance.”1,20 There are a few methods to explore whether shared decision-making 
occurs, including tape recording medical consultations and computerised shared decision 
support tools.22-24 Although shared decision-making is central to adherence, it is not how 
adherence is typically operationalised. 
Another term that is often used in adherence research is concordance. “Concordance” refers 
to the agreement between the patient and physician about the therapeutic regimen. This 
term implies active patient participation in the discussion and decisions about the treatment 
plan.25 
Given the difficulties of exploring shared decision-making, most research operationalises 
adherence in terms of medication-taking behaviour. Medication-taking behaviour is 
assessed by measuring the number of medicine doses taken, dose frequency and dose 
administration according to the instructions on the dispensing label.20 Good medication-
taking behaviour in patients with high cardiovascular risk, such as in ischaemic heart disease, 
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has been shown to improve cardiovascular event-free survival.12,26,27 Furthermore, poor 
medication-taking behaviour with antibiotics can lead to an increased likelihood of 
developing bacterial resistance to antimicrobial agents.28-30 Measuring medication-taking 
behaviour is important and hence why many studies on adherence have focused on this.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The shared decision-making model 31 
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Medication adherence and non-adherence can be further described in a number of different 
ways.18,19,32,33 Adherence to medications has been described in terms of primary and 
secondary non-adherence, the dynamic nature of adherence and unintentional and 
intentional non-adherence.  
 
1.2.1 Primary and Secondary Non-Adherence 
Patients who are non-adherent can exhibit primary or secondary non-adherence.18 Primary 
non-adherence refers to when an initial prescription is not dispensed or when dispensed but 
the medication never taken. Less research has been conducted on primary non-adherence; 
however, there is an emerging interest in this area.34-36 Most adherence research has 
studied secondary non-adherence: when prescriptions are filled, but the patient later 
discontinues taking the medicine.37 
These terms of describing medication non-adherence do not take into consideration the 
complexity and dynamic nature of medication-taking behaviour. Section 1.2.2 and 1.2.3 
introduces newer concepts in describing adherence.  
  
1.2.2 New Taxonomy  
Vrijens et al. developed a new taxonomy for medication adherence and defines adherence 
in terms of medication-taking behaviour. This adherence taxonomy separates adherence 
into three different phases: initiation, implementation and discontinuation. Initiation refers to 
when the patient takes the first dose of a prescribed medication. Discontinuation occurs 
when the prescribed medication is ceased. The extent that the patient’s actual dosing 
regimen corresponds with the prescribed dose from initiation of treatment to the 
discontinuation of treatment is termed implementation.38 A patient may be described as non-
adherent when they: do not initiate a prescription, delay initiating a prescription, implement 
the regimen poorly or discontinue the prescription early.  
This taxonomy is relatively new and is not yet well-established in the literature; however 
presents as a significant opportunity for improving the consistency of describing medication-
taking behaviour. The taxonomy is relatively simple; however, identifies adherence solely 
based on medication-taking behaviour. To strengthen the conceptualisation of adherence, 
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explicit recognition of the shared decision between the patient and healthcare professional 
is required. Furthermore, methods to clearly identify initiation, implementation and 
discontinuation of treatment would reinforce this taxonomy. 
 
 1.2.3 Dynamic Nature of Adherence  
Most studies measuring adherence have been conducted using a cross-sectional study 
design. Adherence has generally been dichotomously categorised: patients are adherent or 
non-adherent at a single point in time. Though simple, describing adherence in this way has 
a number of problems. Classifying patients as non-adherent does not distinguish between 
different patient behaviours, such as not filling the prescription, reducing the dose, taking 
medication sporadically or prematurely discontinuing the medication.39 Further, 
dichotomously categorising adherence at a single time point implies that adherence is static, 
when in fact it can change depending on a patient’s circumstances, information and 
beliefs.40-44 Gearing et al. conceptualises adherence into six dynamic stages (Figure 1.2).19 
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Figure 1.2 The six-phase dynamic adherence model: the continuum of adherence 
decisions 19  
 
 
The initial phase, treatment initiation, occurs when the patient is prescribed a medication 
and either decides to accept or decline the treatment. If the patient is non-adherent in this 
phase, it is known as primary non-adherence, as discussed in Section 1.2.1. In the second 
phase, treatment trial, the patient has the prescription dispensed and takes the medicine; 
however, the medication is discontinued before the next prescription refill. The partial 
treatment acceptance phase refers to when patients fill the initial prescription, begins and 
continues partial treatment (adjusted dosage or dose frequency) for an extended time period. 
In the intermittent treatment adoption phase the patient accepts the full treatment as agreed 
but discontinues after months of adherence and subsequently returns to partial or 
intermittent adherence. The premature discontinuation following treatment adoption phase 
refers to patients who are fully adherent and then prematurely discontinue treatment. The 
last phase is when patients are fully adherent to treatment.19 
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Adherence is not static and is influenced by many different factors, which can change over 
time. These six distinct phases represent decision points and incorporates patients’ varying 
degrees of intent to take their medication as agreed. This dynamic system of adherence 
also acknowledges the movement of patients between phases.19  
 
1.2.4 Unintentional and Intentional Non-Adherence  
Non-adherence can be described as unintentional or intentional or a mix of both.18,32,33,45-48 
Unintentional non-adherence is characterised as poor medication-taking behaviour due to 
circumstances beyond the patient’s control.32 Reasons why patients may be unintentionally 
non-adherent include forgetfulness, carelessness, cognitive impairment and socioeconomic 
issues.18,49,50 Intentional non-adherence arises when a patient makes a conscious decision 
not to take the prescribed medication.48,50 It is important to distinguish  between these types 
of medication non-adherence to better implement appropriate interventions. For example, 
patients identified as intentionally non-adherent are unlikely to benefit from the 
implementation of dose administration aids, but may benefit from behavioural-counselling 
interventions, such as motivational interviewing.32 
 
 
1.3 Epidemiology of Medication Non-Adherence 
 
Non-adherence to medications is highly prevalent, with approximately 50% of patients 
consistently identified as non-adherent in studies focussing on chronic disease.4-8,51-58  
Medication non-adherence can lead to adverse health outcomes, increased  hospitalisations 
and health care costs.3,12,18,55,59 The adverse impact of medication non-adherence grows as 
the burden of chronic diseases increases.1 
This section discusses the prevalence of non-adherence, and the clinical outcomes, 
hospitalisations and health care expenditure associated with medication non-adherence.  
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1.3.1 Prevalence  
The proportion of patients identified as non-adherent, commonly defined as taking less than 
80% of their medicine, is similar across different disease states.5,53,60-63 This 80% cut-off has 
been correlated with significantly improved clinical measures, such as blood pressure.18,64  
Non-adherence rates to medicines are typically higher among patients with chronic 
conditions in comparison with those suffering from acute illnesses.65,66 A study using a 
prescription claims database showed that non-adherence to statins was present in 60% of 
patients suffering from acute coronary syndromes, 64% with coronary artery disease and 
75% for primary prevention of cardiovascular disease.65 Self-report adherence scales 
identified 54% of patients with schizophrenia, 38% of patients with hypertension, 26% of 
patients with diabetes, as non-adherent to their medication.5,53  
There is a tendency for medication adherence in chronic illnesses to decline over time.7,8,56 
Non-adherence to recently initiated statins increased between one-month and twelve 
months in: hypertension (18% versus 47.9%), heart failure (16.3% versus 50%) and 
coronary heart disease (28.2% versus 38.3%) populations.7 Alendronate non-adherence in 
patients with osteoporosis increased, particularly during the first six to twelve months after 
the initial prescription.8 Non-adherence to antiretroviral therapy in HIV increased from 48% 
at one-month after initiating the therapy to 61% non-adherence at the six-month follow-up.60 
This increasing trend in non-adherence suggests the need to measure adherence at 
different time points. It has been suggested that important factors are involved during the 
process of obtaining the initial prescription and treatment continuation.7 Patient 
circumstances, information and beliefs may change over time.42 Therefore reasons for non-
adherence and interventions should be reassessed at different time points to maintain good 
medication-taking behaviour. Changes in adherence over time support the dynamic model 
of adherence, as described in Section 1.2.3. 
 
1.3.2 Clinical Outcomes  
Non-adherence to medications can lead to adverse health outcomes and an increase in 
hospitalisation rates across various disease populations. Most of the literature has focused 
on adverse outcomes associated with non-adherence in cardiovascular disease, diabetes, 
schizophrenia and HIV.  
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Non-adherent patients with cardiovascular disease are more likely to have adverse health 
outcomes in comparison with adherent patients.12,67,68 Medication non-adherence 
contributes to poor blood pressure control, which can lead to further cardiovascular 
complications including coronary heart disease and heart failure.69 Hospitalisation rates 
were significantly higher in patients with poor medication adherence suffering from diabetes, 
hypercholesterolaemia, hypertension and congestive heart failure.3,70 Gehi et al. determined 
that medication non-adherence was associated with a greater than two-fold increase in the 
rate of cardiovascular events in patients with stable coronary artery disease.12 Patients with 
heart failure who were non-adherent to digoxin had a significant increase in the number and 
duration of hospitalisations in comparison with adherent patients.70 Poor prescription refill 
adherence (less than 40%) was significantly associated with a three-fold increase in the 
incidence of hospitalisation due to heart failure compared with good prescription refill 
adherence (at least 80%).71 
Medication non-adherence in diabetes has been associated with poorer health outcomes 
and an increase in hospitalisations.72,73 Non-adherence has been significantly associated 
with a higher glycosylated haemoglobin level (HbA1c), reflecting poor management of 
diabetes. A high HbA1c (greater than 7%) can increase the risk of developing cardiovascular 
diseases, ocular problems and neurological complications.74,75 
Non-adherence to antipsychotics can lead to symptom relapse, worse prognosis and 
increased risk of hospitalisations.76-78 Patients with schizophrenia who did not fill their 
antipsychotic prescription within the first week after hospital discharge had a higher risk of 
early rehospitalisation.79,80 Poor adherence in schizophrenia has also been associated with 
greater use of emergency psychiatric services, poorer mental functioning and violence. Non-
adherence has also been significantly associated with poorer life satisfaction, more alcohol-
related problems and more arrests.81  
In order to suppress viral replication and reduce the risk of viral resistance in HIV, patients 
should have good medication adherence.60,82,83 Non-adherence to HIV treatments has been 
shown to cause treatment failure, clinical deterioration and development of viral resistance, 
which leads to the increase risk of transmission of resistant virus.83,84  
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1.3.3 Increased Health Care Expenditure 
Non-adherence to medications can lead to worsening of health outcomes and increased 
hospitalisations, which results in an increase in health care costs. The costs of medication 
non-adherence are largely derived from exacerbations of illnesses that require emergency 
medical attention and hospitalisations.71 A reduction in medical costs offsets the cost of 
medications and can thus lead to an overall reduction in health care costs.3 A government 
report suggests that medication non-adherence costs the Australian health system 
approximately $660 million annually, in terms of preventable hospital admissions.85 In the 
United States, the annual burden of medication non-adherence has been estimated to be 
$100 billion.20,86 More specifically, non-adherence to diabetes medication has been 
estimated to cost the United States health system $5 billion per year. Medication non-
adherence plays a significant role in the financial burden upon health care systems. 
Therefore, improving medication adherence should be a key goal for health care systems 
and policy makers.1,73 
 
1.4 Barriers to and Determinants of Medication Adherence 
 
A number of factors can affect medication adherence. The WHO has divided the factors that 
can affect medication adherence into five dimensions: social and economic, health system 
and health care team, condition-related, therapy-related and patient-related factors.1 
Although there has been extensive research into the barriers to and determinants of 
medication adherence, more than half of the studied factors have not been consistently 
associated with adherence (Table 1.1).18 Most of the studies below have defined adherence 
as taking 80% of the medication; for example, in regards to dose counts, taking at least 80% 
of your medicine would be defined as adherent. Some patients may have good reasons for 
non-adherence. Determining the barriers to and determinants of medication adherence may 
aid the implementation of tailored interventions to improve medication adherence.1,39 
 
 Sociodemographic and economic factors  
Sociodemographic and economic factors such as age, sex, race, socioeconomic status and 
education level have some association with medication adherence.4,8,54,57,87-91 Race has 
been shown to have some impact on adherence, which can be explained by varying cultural, 
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health and medicinal beliefs.92 Studies showing a significant relationship between age and 
adherence, have found that older patients were likely to be more adherent than younger 
patients.8,50,57,87,93-95 However, the risk of cognitive and functional impairment increases with 
age which can increase the likelihood of non-adherence in the elderly.96 Younger patients 
may decide not to adhere to the treatment or may forget due to competing priorities in life.97 
 Health system and health care team factors  
Less research has been conducted on the effects of health system and health care team 
factors on medication adherence.1 Modifying cost at a health system level can improve 
adherence to medications.98 Poor communication from health care professionals, shorter 
patient-provider consultations and poorly developed health services can negatively impact 
medication adherence.99-101 It has been shown that non-adherent patients were significantly 
less likely to have established a close therapeutic alliance (the relationship between a 
patient and health professionals) during hospitalisation, see Table 1.1.77  
 
 Health condition-related factors  
Condition-related factors such as duration of the disease and co-morbidities can affect 
medication adherence. In particular, severity of symptoms, cognitive impairment and 
substance abuse have been shown to have a negative impact on medication 
adherence.87,93,96,102-104 Many studies have found that patients with predominantly 
asymptomatic conditions, such as hypertension are less adherent.105 Co-morbidities that 
can impact adherence include depression and substance abuse.58,77,89,93,106 
 Therapy-related factors 
Therapy-related factors, such as the complexity of the medication regimen, duration of 
therapy, route of administration and side effects have been noted to affect 
adherence.88,90,94,107-109 The greater the number of medications and higher dose frequencies 
have been consistently associated with non-adherence.110,111 Patients with chronic 
obstructive pulmonary disease (COPD) on once-daily dosing regimens had significantly 
higher adherence than those on multiple daily dosing regimens.108 Another factor that can 
impact adherence is the cost of the therapy. The greater the cost of the medication, the less 
likely that patients will be adherent to the medication. The impact of cost is mitigated by the 
patients beliefs towards how necessary their medicine is to them. If patients perceive their 
medicine to be unnecessary, the cost of the medicine would theoretically not impact on their 
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decision to take their medicine. Patients will not pay for a medicine no matter how much it 
costs if the patients believe the medicine is unnecessary.35,112,113 
 
 Patient-related factors 
Patient-related factors include a patient’s tendency to forget to take their medications, 
knowledge, attitude, beliefs and perceptions of their illness and medicines. Forgetting to take 
medication is a common reason that has been consistently associated with non-
adherence.46,67,105,114-116 
Patient medication beliefs and how these beliefs affect medication adherence have also 
been extensively studied.4,41,42,44,88,89,117-122 One of the most commonly used adherence 
scales, the Beliefs about Medicines Questionnaire-Specific (BMQ-S), elicits beliefs about 
the necessity of medicines and concerns about medicines.4,49,87-89,118,123,124 These beliefs 
have been shown to reflect a patient’s perceptions of illness and adherence.95,125,126 
Generally, patients that believe their medicines are necessary and have minimal concerns 
about their medicines have better medication adherence.95,120,126-131  
Patient’s perceptions and understanding of their illness and treatment have been shown to 
be associated with medication adherence.40,95,125-127,132-135 There are a number of different 
scales used to assess health perceptions including the Health Perception Questionnaire 
(HPQ), Illness Perception Questionnaire (IPQ), Illness Perception Questionnaire – Revised 
(IPQ-R) and Brief Illness Perception Questionnaire (BIPQ).136-139 The IPQ was developed 
based on the Self-Regulatory Theory to assess the cognitive representations of illness: 
identity (symptoms perceived associated with illness), cause (patient ideas about aetiology), 
timeline (perceived illness duration), consequences (expected effects and outcomes) and 
cure control (how patient controls/recovers from illness).137 IPQ-R and BIPQ are shorter 
forms of the IPQ and have been used extensively in the literature. Using the IPQ, it was 
found that perceptions of poor personal ability to control illness, greater perceived effect of 
illness on life and lower emotional response was significantly associated with better 
medication adherence in patients with hypertension.95 In a chronic pain population, 
perceptions of illness as chronic and uncontrollable, measured using the IPQ-R, were 
associated with less concerns about their medicines and greater adherence. Patients in this 
chronic pain population who perceived serious illness consequences had stronger beliefs 
that medicines are necessary and were more adherent. Patients were less adherent to their 
medication when they have a greater emotional response to their illness.125 Patients with 
high blood pressure who were more likely to be adherent, had greater perceived personal 
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ability to control blood pressure, exhibited greater concerns about their illness and had less 
emotional burden, based on the BIPQ.135 
Past medication adherence has been shown to predict adherence.77,140 For example, the 
best single predictor of future adherence in patients with schizophrenia was found to be non-
adherence in the prior six months.140 Furthermore, past  prescription-refill behaviour was a 
significant predictor of adherence to statins.141 
 
Table 1.1 shows factors that have been studied in association with medication adherence. 
There are factors which are consistently associated with non-adherence (e.g. forgetfulness, 
beliefs about medicines) and factors where the association appear less clear (e.g. 
socioeconomic status). Studies differ in the diseases included, methods used to measure 
adherence, how adherence is defined and sample size.1,109 This may explain some of the 
inconsistency in the association of factors with medication adherence.  
Review articles exploring various barriers to and determinants of adherence, have 
suggested the need to address a full range of influencing factors to improve adherence.68,142 
Many studies have globally implemented interventions without identifying why the patient is 
non-adherent. We need to better understand the patient-specific reasons for non-adherence 
to better implement tailored interventions to improve adherence.68,143,144 
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Table 1.1 The studies which show significant association or no association between a 
number of different factors and medication adherence 
Factor Significant Association No Association 
Sociodemographic Factors   
Socioeconomic status Akincigil57, Barclay87, Devold8, 
Maqutu91 
Gatti89, George100, 
Khanderia103, Kleeberger90, 
Laba94, Maqutu91 
Employment status Ediger145 Fawzi88, Gatti89, Kim146 
Education level Burra115, Ross95, Ruppar107s Devold8, Fawzi88, Gatti89, 
Jacobs96, Khanderia103, Kim146, 
Kleeberger90, Laba94, Mo147 
Literacy  - Gatti89 
Age Atkins50, Barclay87, 
Broekmans54, Cohn93, Devold8, 
Ediger145, Gatti89, Jessop132, 
Khanderia103, Krousel-Wood68, 
Laba94, Mo147, Ross95 
Bhattacharya148, Jacobs96, 
Kim146, Kleeberger90, Raebel92, 
Ruppar107, Shah  
Sex Jessop132, Maqutu91, Ross95 Bhattacharya148, Fawzi88, 
Gatti89, Jacobs96, 
Khanderia103, Kim146, Krousel-
Wood68, Laba94, Mo147, 
Raebel92, Shah35 
Race Kleeberger90, Krousel-Wood68, 
Raebel92  
Gatti89, Khanderia103 
Marital status Devold8, Sajatovic114 Fawzi88, Khanderia103, Kim146, 
Mo147 
Social support network Dean116, Fraser99,   Frain149 
Private health insurance Raebel92 Akincigil, Khanderia103, 
Kleeberger90, Laba 
Health literacy level - Gatti89 
Number of people in household Gatti89 Khanderia103, Kim146, Laba 
Healthcare Team and System 
Factors 
  
Patient-provider relationship Fraser99, George100 Frain149 
Provider knowledge George100  - 
Follow-ups - Akincigil57, Kim146, Raebel92 
   
Condition-Related Factors   
Severity of disease/symptoms Khanderia103, Phillips102 Frain149, Jacobs96, Mo147,  
Level of disability - Fraser99, Mo147 
Co-morbidities Raebel92 Akincigil57, Barclay87, Jacobs96, 
Kim146, Shah35 
Duration of condition Mo147 Jacobs96 
Cognitive impairment Barclay87, George100 , Jacobs96 - 
Psychiatric disorders Dean116, Gatti89, Manning106, 
Sajatovic114 
Akincigil57, Bartlett150, 
Jacobs96, Raebel92,  
Anxiety Sundbom104 Jacobs96 
Substance abuse Akincigil57, Barclay87, Cohn93, 
Mazer151, Raebel92, Sajatovic114 
Cohn93, Kleeberger90 
  15 
Factor (cont.) Significant Association 
(cont.) 
No Association (cont.) 
Therapy-Related Factors   
Complexity of medical regimen 
(Number and Frequency) 
Akincigil57, Dean116, Devold8, 
Llor110, Kleeberger90, 
Laliberte111, Raebel92, 
Ruppar107, Toy108 
Gatti89, Jacobs96, Kim146, 
Phillips102, Ross95, Ruppar107 
Duration of treatment Mo147 Bhattacharya148, Burra115, 
Kim146, Kleeberger90 
Previous treatment failures - Bhattacharya148 
Use of CAMs Dean116 - 
Dosage form Brnabic152 - 
Cost  Castaldi112, Shah35 Fawzi88, Frain149, Raebel92 
History of medication-taking Laba94 - 
Access to medications - Khanderia103 
Side effects Fawzi88, Laba94 George100, Kim146 
   
Patient-Related Factors   
Knowledge, Attitudes, Expectations George100 George (Expectations)100, 
Kim146 
Forgetfulness Addison67, Burra115, Dean116, 
Gadkari46, McHorney105, 
Sajatovic114,  
- 
Concerns about medicines 
(Beliefs) 
Berglund128, Fawzi88, Gatti89, 
Laba94, Mardby4 
Aakre123, Frain149, Ruppar107 
Necessity of medicines (Beliefs) Berglund128, Bhattacharya148, 
Burra115, Clifford153, Fawzi88, 
Gatti89, Laba94, Ross95, 
Ruppar107,120 
Aakre123 
Poor attendance to follow-ups Kleeberger90 - 
Lifestyle (Change in Routine etc.) Burra115 George100 
Manual dexterity George100 - 
Self-efficacy Barclay87, Gatti89, Kim146 Fraser99 
Personality Ediger145, Williams154 - 
Missed prenatal vitamins Cohn93  - 
Sleep quality Phillips102 Burra115  
 
NB: The surnames of the first author of the papers have been used in this table. These papers are written in collaboration 
with other authors (et al.)  
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1.5 Measuring Medication Adherence 
 
Accurate measurement of medication-taking behaviour is required to identify non-adherence 
and help inform interventions to support adherence. Methods to measure medication-taking 
behaviour can be categorised into two broad groups: objective and subjective 
measures.18,155,156  
 
 1.5.1 Objective Measures  
Objective measures include: direct observations of medication-taking, measurement of 
clinical outcomes, dose counts, pharmacy records, electronic monitoring of medication 
administration (e.g. the Medication Event Monitoring System, MEMS), ingestible sensor (e.g. 
Raisin SystemTM) and blood or urine drug concentrations.157-163 Objective measures can be 
either direct (e.g. blood drug concentrations) or indirect (e.g. dose counts and pharmacy 
records). These types of adherence measures can provide detail on dose administration 
over time. Measuring clinical outcomes include blood pressure for patients on hypertension 
medications, blood glucose levels and HbA1c levels for diabetes and viral suppression in 
HIV.64,72,83,157 Counting the number of medicine doses remaining in the container can be 
conducted at home or in clinic and may be announced or unannounced. Unannounced dose 
counts tend to be more accurate because it reduces the chances of dose dumping.164 
Information about prescription refills can be obtained from pharmacy records to provide a 
measure of medication-taking behaviour over long periods of time.20,158 Electronic 
monitoring (e.g. MEMS) can record the time of dose-taking and can provide detailed 
information on medication-taking behaviour.165-167 A newer form of electronic monitoring 
known as the DoPill® has 28 compartments which can contain multiple tablets in each slot. 
The DoPill® electronic dispenser beeps and flashes to remind patients to take their 
medicines and consists of sensors which can send signals to health professionals alerting 
a dose has been released.161 The Raisin SystemTM recently developed by Proteus 
Biomedical is an ingestible micro-sensor that can be incorporated into each oral solid 
dosage form. The sensor can obtain information on date and time of ingestion and 
communicates this data with an externally-worn seven-day wear adhesive monitor that can 
be routed to a software program.163  
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Objective measures (excluding those that utilise clinical outcomes) have been shown to 
better predict clinical outcomes compared to subjective measures of adherence.83,168-172 For 
example, Wu et al. found that adherence measured by MEMS, but not by a self-report 
adherence scale, independently predicted event-free survival in patients with heart failure.168 
Objective measures have some limitations (Table 1.2). First, objective measures are more 
expensive and may not always be applicable, particularly in a setting with limited 
resources.162,173 Second, although the ultimate aim of any intervention is to improve clinical 
outcomes, using clinical outcomes as a proxy of adherence can be impacted by variability 
in patient response to medicines, independent of medication-taking behaviour. This poses 
challenges in using clinical outcomes to validate measures of adherence.175 A lack of 
change in a clinical outcome may occur in an individual who is adherent to their medication 
due to other factors impacting on their disease. Individual clinical response to a medicine 
can be affected by diet, lifestyle, family history, genes and renal function.20,67,71,168,174,175 For 
example, a patient on antihypertensive therapy may have uncontrolled blood pressure 
despite being adherent to their medication. This could be due to an increase in their dietary 
salt intake, or increases in body weight or alcohol consumption.71,174,175 Furthermore, a 
patient may have genetic differences in their drug metabolising enzymes resulting in either 
lack of activation of the drug (e.g. clopidogrel) or rapid metabolism of the drug (e.g. 
warfarin).175 Third, objective measures, when used alone, are unable to identify the type of 
non-adherence or the patient-specific barriers to adherence. These measures offer little 
insight into why a patient may be non-adherent and thus implementing an appropriate 
intervention would be difficult. 
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Table 1.2 Advantages and disadvantages of objective measures of adherence 
Adherence Measure Advantages Disadvantages 
Direct observation of 
medication-taking 176 
 
 
- Considered most 
accurate measure of 
medication-taking 
behaviour 
- Impractical, particularly 
in an outpatient setting 
- Patients may not swallow 
medication 
 
Pharmacy prescription 
dispensing records 158,177 
-  
 
- Low burden and efficient 
- Inexpensive 
- Can provide estimates in 
large populations over 
extended periods of time  
- Can be used to assess 
primary adherence as 
dispensed prescription is 
first step to measure 
adherence 
 
- Does not capture 
detailed medication-
taking behaviour 
- Estimates medication 
possession and not 
consumption.  
- Cannot be used for 
short-term regimens  
- Not practical in real-time 
- Limited to specific 
location, requires closed 
pharmacy system 
Pill counts 156,176 - Accurate 
- Inexpensive 
- Can provide data over 
extended periods of time 
- Easy to conduct 
- Possible risk of dose 
dumping 
- Potential bias from not 
having all pills at the time 
- Time-consuming 
- Labour intensive 
Drug concentrations in 
biological fluids (e.g. blood, 
urine) 66,176 
- Accurate 
 
- Expensive 
- Difficult in community 
setting 
- Invasive 
- Labour intensive 
- Affected by dose, dose 
timing and 
pharmacokinetics and 
drug interactions  
 
Medication Event 
Monitoring System (MEMS) 
caps 159,165 
- Accurate 
- Records data and time 
of bottle opening 
- Provides continuous 
data and real-time 
tracking 
- Considered gold 
standard 
- Non-invasive 
- Expensive 
- One cap per drug 
- Not all medicines can be 
packaged in a bottle 
- Risk of malfunctioning 
- Can over- or under-
report 
- Patient may not swallow 
medication 
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Adherence Measure 
(cont.) 
Advantages (cont.) Disadvantages (cont.) 
Intelligent Drug 
Administration System 
(IDAS)166 
- Provides visual and 
audible reminders 
- Has to be customised to 
accommodate specific 
blister packs 
- Not all medicines are 
packed in blisters 
Smart Blister167 
 
- Can be used on 
commercial blisters 
- Can easily download 
adherence data 
- Provides visual and 
audible reminders 
- Technology not sensitive 
enough to detect 
individual tablet opening 
- Not all medicines are 
packed in blisters 
Ingestible sensor (Raisin 
SystemTM by Proteus 
Biomedical Inc.)163 
- Accurate 
- Can obtain data on 
dose, data and time of 
ingestion 
- Can also monitor heart 
rate, body temperature 
and blood pressure 
- Expensive 
- Limited research and 
experience on its use 
- Ethical issues due to 
invasive nature of 
measure 
Clinical outcome (e.g. blood 
pressure control, HIV viral 
load)64,72,83,157 
- Important - May be confounded by 
factors such as lifestyle, 
diet and family history 
- Labour intensive 
- Time consuming 
 
 
 1.5.2 Subjective Measures 
Subjective measures of adherence rely on patient’s reporting their medication-taking 
behaviour, barriers to adherence and/or their beliefs associated with adherence. Most 
subjective measures are simple, inexpensive and relatively easy to administer.178 Subjective 
measures include caregiver or physician adherence reports, patient interviews, self-reports 
and adherence scales.4,18,179-181 Subjective measures, for example adherence scales can 
identify medication-taking behaviour, categorise patients into types of non-adherence, 
explore beliefs associated with adherence and explore patient-specific barriers to and 
determinants of adherence.18,33,117,181  
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 1.5.3 Self-Report Adherence Scales 
Many self-report adherence scales are available and these have been briefly described in 
two systematic reviews.178,182 Adherence scales are relatively easier to administer and can 
provide an alternative to, or supplement objective measures of adherence. However, self-
report scales rely on respondents to recall information and provide truthful answers and 
hence are prone to recall bias and social desirability bias.179,182 Adherence scales vary in 
the number of items, measure different aspects of adherence and are validated against 
different measures of adherence. Table 1.3 lists adherence scales that have been validated: 
defined as scales that have been tested against a comparison measure of medication-taking 
behaviour (objective or subjective).  
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Table 1.3 Validated adherence scales 
Name of Adherence Scale Abbreviation 
Adherence Attitude Inventory 183 AAI 
Adherence Self-Report Questionnaire 184 ASRQ 
Adherence Starts with Knowledge-12 185 ASK-12 
Adherence Starts with Knowledge-20 186 ASK-20 
Adherence to Refills and Medications Scale 187 ARMS 
Adherence Visual Analogue Scale 164 VAS 
Barroso et al. 30-day Adherence Question 60 - 
Beliefs about Medicines Questionnaire 117 BMQ 
Beliefs and Behaviour Questionnaire 188 BBQ 
Bell et al. Adherence Question 189 - 
Brief Adherence Rating Scale 181 BARS 
Brief Evaluation of Medication Influences and Beliefs 79 BEMIB 
Brief Medication Questionnaire 190 - 
Brooks Medication Adherence Scale 191 BMAS 
Centre for Adherence Support Evaluation Adherence Index 192 CASE 
Choo et al. Questionnaire 156 - 
Compliance Questionnaire Rheumatology 193 CQR 
Drug Attitude Inventory 53 DAI 
Fodor et al. Adherence Questionnaire 194 - 
Gehi et al. Adherence Question 12 - 
Godin et al. Self-Reported Adherence Questionnaire 195 - 
Grymonpre et al. Adherence Question 196 - 
Hill-Bone Compliance Scale 10 55 - 
Hill-Bone Compliance Scale 14 197 - 
Immunosuppressant Therapy Adherence Scale 198 ITAS 
Kerr et al. Adherence Question 199 - 
Maastricht Utrecht Adherence in Hypertension Questionnaire 200 MUAH 
Medication Adherence Assessment Tool 201 MAAT 
Medication Adherence Questionnaire 18 MAQ 
Medication Adherence Reasons Scale 202 - 
Medication Adherence Rating Scale 51 MARS 
Medication Adherence Rating Scale - 5 127 MARS-5 
Medication Adherence Self-Efficacy Scale 203 MASES 
Medication Adherence Self-Efficacy Scale - Revised 204 MASES-R 
Morisky Medication Adherence Rating Scale 205 MMAS 
Osteoporosis-Specific Morisky Medication Adherence Scale 206 OS-MMAS 
Patterns of Asthma Medication Use Questionnaire 207 - 
Paediatric Inhaler Adherence Questionnaire 208 PIAQ 
Reported Adherence to Medication Scale 117 RAM 
Self-Efficacy for Appropriate Medication Use Scale 209 SEAMS 
Self-Reported Adherence Questionnaire 210 SERAD 
Simplified Medication Adherence Questionnaire 211 SMAQ 
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Stages of Change for Adherence Measure 212 SOCA 
 
 
 
Validated self-report adherence scales have been developed using a number of different 
approaches (Figure 1.3). Adherence scales have been developed from literature reviews, 
expert panels, patient focus groups, other adherence scales, a number of health models 
and for clinical trials. Many of the adherence scales were developed from literature reviews 
and expert panels. Adherence scales developed using these techniques (literature reviews 
and expert panels) differ in focus (e.g. different diseases, identifying barriers as opposed to 
identifying medication-taking behaviour) as these studies were conducted on the basis of 
different study aims.190,197,207 Other scales based their survey questions on themes that 
surface from patient focus groups.192,193,200 Some adherence scales (AAI, BBQ, BMQ and 
BEMIB) were based on a number of different health models.79,117,183,188 Adherence scales, 
such as MMAS, MARS, ARMS and ASRQ have derived from previously developed 
adherence scales. The majority of the scales that came from previous adherence scales 
have been developed based on the 4-item Morisky Medication Adherence Questionnaire 
(MAQ).18,51,187,191,198,205,211 Some of the adherence scales utilise a combination of strategies; 
for example, the SEAMS was based on a literature review, patient focus groups and an 
expert panel.209 
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Figure 1.3 Adherence scales originate from a number of different sources (Original source unspecified: Barroso, Bell, Fodor, Grymonpre and VAS Scale)
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Different self-report adherence scales measure different aspects of adherence: medication-
taking behaviour, barriers to adherence, beliefs associated with adherence or a combination 
of these aspects.213 Adherence scales have been correlated with a number of different 
comparison measures of medication-taking behaviour including electronic monitoring, pill 
counts, healthcare outcomes and pharmacy refill records. Chapter Two presents a 
systematic review of validated adherence scales and discusses the validation of adherence 
scales and what aspects of adherence each explores. 
 
There are numerous methods to measure adherence, but no single method performs well 
on all criteria (e.g. ease of administration, inexpensive, accurate, quick to complete, well-
validated in many diseases).20,176 An accurate measure of medication adherence would be 
able to identify patients who are non-adherent to their medication, and inform an intervention 
to support adherence. The following section discusses the interventions that have been 
implemented to improve adherence.  
 
 
1.6 Interventions to Improve Adherence 
 
 1.6.1 Introduction 
Many interventions have been implemented to improve medication adherence in patients 
with chronic diseases. However, most interventions have not significantly improved 
medication adherence or clinical outcomes.13-15,214-221 Interventions that show promise in 
improving medication adherence were multifaceted interventions.217,222,223 These 
interventions employ a number of different strategies to improve adherence. Multifaceted 
interventions address a greater number of potential barriers to adherence and thus tend to 
be more successful than single interventions.223 However, multifaceted interventions are 
intensive and have only produced modest improvements in adherence and clinical 
outcomes.13,15,217,223  
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Adherence interventions have largely been implemented on a non-targeted population, that 
is most of these studies did not identify patient’s adherence to their medication prior to 
inclusion in the study. Interventions are thus implemented on a population without knowing 
if the patient is adherent or non-adherent to their medications.215,224-227 This means that 
interventions are implemented on patients who may be adherent at the time the intervention 
was employed; therefore, would observe no improvement in adherence. This may explain 
why some studies of plausible adherence interventions have not demonstrated an 
improvement in adherence. By identifying patients at greater risk of medication non-
adherence, interventions can be targeted to those who would most benefit.228 An example 
of a targeted intervention is Measurement-Guided Medication Management (MGMM), which 
uses MEMS data on the patient’s adherence as feedback to guide the discussion on 
adherence and implementation of an intervention.214 
As discussed in Section 1.4, patients are non-adherent due to many different reasons, and 
may be subjected to different types of non-adherence concurrently (Section 
1.2.4).1,18,87,89,90,93,96,100,114,115,145,147 Both are important to consider when selecting an 
appropriate intervention to address non-adherence.33 Identifying the reasons for non-
adherence facilitates a strategy to address these reasons, which can be described as a 
tailored intervention. In the literature, tailored interventions are described in a number of 
different ways. Some interventions were “tailored” to a specific disease population.229 Others 
have selected a specific type of intervention and “tailored” that intervention to the 
patient.130,153,230-233 For example, Insel et al. individualised memory strategies to improve 
adherence in older patients.230 Greater focus is required on identifying the primary cause for 
the patient’s non-adherence and tailoring interventions to these specific reasons for non-
adherence.68,130,228,234 For example, forgetfulness is one of the most common reasons for 
non-adherence; however, implementing a reminder intervention would not improve 
adherence if the patient is non-adherent due to negative beliefs about the medicine.224,235 
To improve the outcomes of adherence interventions, interventions should be targeted to 
patients identified as non-adherent and tailored to the patient-specific reasons for non-
adherence.  
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 1.6.2 Examples of Interventions Focusing on a Single Aspect of Adherence 
 
Current adherence interventions can be classified into five main categories: reminder 
systems, behavioural-counselling, social support, cognitive-educational and measurement-
guided interventions, according to Demonceau et al.214 Examples include dose 
administration aids, telephone reminders, education about illness and motivational 
interviewing.13,215 Below are some examples and outcomes of the adherence interventions 
to date: 
 
Reminder interventions 
Reminder interventions may benefit those that forget to take their medications by reminding 
them. There are many reminder interventions that have been implemented, including 
reminder phone calls, texts, pagers, interactive voice response systems and treatment 
simplification interventions.130,220,236-243  Reminder packaging (dose administration aids, 
dosette boxes and dose sachets) assembles medicine doses into days and/or times when 
the medication has to be taken. This has been shown to increase the proportion of doses 
taken, leading to a significantly reduced diastolic blood pressure and also HbA1c levels.244 
A study using MEMS which consisted of electronic medication reminder caps with 
medication-taking recording cards significantly improved adherence by 17% and reduced 
systolic and diastolic blood pressure by 4.8 and 8.6 mmHg, respectively.245 Postal reminders, 
dose administration aids and both used in combination all significantly improved medication 
adherence, measured using pharmacy refill records, in patients with hypertension.246 Short 
text message reminders was shown to reduce the rate of missed doses and delayed doses, 
according to self-report in the general population.238Telephone and early postal reminders 
implemented on patients taking pravastatin did not significantly improve self-reported 
adherence.235  
Cue-dose training involves advising patients to use cues as reminders to take their 
medicines; for example, meal times, alarms (incorporated in MEMS) and locating medicines 
in more noticeable areas. Cue-dose training in patients with type 2 diabetes significantly 
improved adherence to metformin, but did not improve diabetes control.247  
Simplification of drug and dose regimen has consistently improved medication adherence. 
14,15,240-243 A systematic review on interventions implemented to improve adherence in 
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patients with hypertension found that simplifying dosing regimens increased adherence in 
seven out of nine studies, with a relative increase of 8 to 19.6%.15 Patients on once-daily 
trandolapril had significantly better adherence compared to patients on twice-daily captopril 
treatment for hypertension, as measured using MEMS.240 Self-report adherence was 
significantly higher in patients taking sustained-release nicardipine twice daily than 
conventional nicardipine three times daily.241 Patients treated with a single combination 
tablet regimen for hypertension had significantly less cardiovascular events compared to 
those taking the components individually. This retrospective cohort study identified patients 
on a number of different combination therapies for hypertension found that single 
combination tablet regimens compared to the individual component treatment led to a 
reduction in hospital costs, as measured using pharmacy prescription refill data.234  
 
 
Behavioural-counselling interventions 
Behavioural-counselling adherence interventions aim to change medication-taking 
behaviour by modifying beliefs and motivating patients to make positive changes. Many 
adherence interventions have used behavioural-counselling strategies to improve 
adherence.15,130,248,249 A systematic review showed that 10 out of 24 interventions led to 
small improvements in medication adherence.15  
Health coaching aims to promote positive health behaviour changes, by establishing the 
patient’s goals and beliefs about treatments and helping the patient to attain these goals. 
Person-to-person health coaching every three months and telephone health coaching every 
month over 12 months in patients with hypertension significantly improved adherence, as 
measured by dose counts.250 Health coaching patients with hypertension from health 
professional students significantly improved adherence, as measured by the Brief 
Medication Questionnaire.226 
Motivational interviewing involves counselling patients to recognise the discrepancy 
between the patient’s behaviour and goals in the hope of eliciting positive behavioural 
changes.251 Motivational interviewing and cognitive approaches in a convenience sample of 
patients with schizophrenia or major depression showed no significant improvement in 
adherence, measured with an adherence scale (DAI).252 Using MEMS to measure 
adherence, pharmacist-led motivational counselling in patients on a diuretic for heart failure 
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showed a significant improvement in adherence.221 The number of medicine doses taken 
according to MEMS was significantly increased in patients with hypertension using 
motivational interviewing.219  
Personalised nurse-counselling on modifiable and unmodifiable cardiovascular risk factors 
was shown to significantly improve self-reported adherence to statins and lower low-density 
lipoprotein cholesterol.253  
“Adherence Therapy” is a patient-centred approach that explores patient attitudes and 
beliefs about medicines in a manner similar to motivational interviewing. Once negative 
beliefs about medicines are identified, patients generate evidence to support these beliefs 
and the therapist modifies these beliefs to improve adherence. Adherence Therapy has 
mainly been tested in psychiatric illnesses, in particular schizophrenia. There is no standard 
approach to Adherence Therapy; varying in length ranging from four to eight sessions lasting 
20 minutes to three-and-a-half hours.129,254-258 The most promising study using Adherence 
Therapy to improve medication adherence was targeted to patients who were non-adherent, 
resulting in significantly improved blood pressure and adherence measured using dose 
counts.129  
 
 
Social support interventions 
 
Social support interventions include family support and peer support groups.259-261 A study 
demonstrated that a supportive family environment was associated with better adherence 
to diabetes medications.261 A six-month American study found that peer counselling for 
adolescents did not have an effect on self-reported treatment completion rates.262 Peer 
support group therapy for adolescents with HIV showed no change in adherence, according 
to physician reports.263 A five-month clinic-wide social marketing campaign was conducted 
to improve adherence to antiretroviral therapy. The campaign did not demonstrate an 
improvement in medication adherence according to self-reported adherence.264 An online 
social support intervention involving an interface that allows participants on antiretroviral 
therapy to interact, self-report their adherence and watch videos about living with HIV, 
significantly improved self-reported adherence. By targeting the online social support 
intervention to patients reporting “imperfect” adherence, this may have improved the 
outcomes of the intervention.259 
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Cognitive-educational interventions 
Poor knowledge has been associated with medication non-adherence. Cognitive-
educational interventions involves providing information to improve a patient’s knowledge 
on their medications and illnesses to better inform their medication-taking behaviour. Some 
cognitive-educational interventions have been shown to improve medication adherence, 
however, results have been inconsistent.215,218,225,226 Patient education alone has been 
largely unsuccessful in improving medication adherence.15,231,265-268 A trial involving nurse 
counselling via telephone increased the proportion of children with latent tuberculosis 
completing treatment from 65% to 94%.269 Nurse-delivered home visits providing information 
on HIV and the importance of medication adherence was associated with an increased  
likelihood of patients reporting 100% adherence.215 A study on asthma patients showed that 
repeated instructions on inhalation techniques significantly improved adherence measured 
using the BMAS.225 Pharmacy-based education and counselling on adherence did not 
improve medication adherence, measured using pill counts.270 Educating patients on 
adherence and their medication by a pharmacist via weekly telephone calls for 12 weeks 
did not significantly improve adherence to lipid-lowering medications in the short-term (6 
weeks and 12 weeks). However, long-term (12 months and 24 months) adherence was 
improved according to dose counts.229 Educational videotapes containing information on the 
prescribed medicine and the respective medical condition did not improve medication 
adherence, according to pharmacy records, in patients with chronic disease.267 Enhanced 
in-hospital counselling on medications and adherence barriers by pharmacists coupled with 
communication of discharge medications to community pharmacists and physicians did not 
significantly improve adherence to aspirin and statins, as measured using pharmacy 
records.231 In comparison, patients who received counselling sessions with a community 
pharmacist at the start of statin treatment demonstrated greater adherence according to 
pharmacy records.271 A mailed newsletter discussing the importance of adherence and 
lifestyle modifications showed no improvement in adherence, as measured using physician 
reports.266 Automated telephone patient monitoring and counselling on adherence and blood 
pressure control led to an increase in self-reported adherence and a significant decrease in 
diastolic blood pressure.220 Meducation®, calendars listing information about cardiovascular 
medications, such as medication name, dose, dose frequency and clinical indication, did not 
significantly improve adherence as measured using prescription refill data and self-report. 
The Meducation® intervention did not significantly improve blood pressure control or 
cholesterol levels.272 
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Electronic Adherence Monitoring Feedback Interventions 
Measurement-Guided Medication Management (MGMM) is an approach to using drug 
dosing history data as feedback to patients on their medication-taking behaviour to improve 
adherence.273 This information facilitates a focused discussion between a health 
professional and their patient about their medication-taking behaviour, reinforcing other 
adherence interventions. Electronic monitoring feedback interventions showed improvement 
in adherence.214 MGMM interventions have relatively consistent outcomes in improving 
adherence. Electronically compiled drug dosing histories provide detailed information on a 
patient’s medication-taking behaviour that can assist health professionals in identifying and 
addressing the reasons for poor medication-taking behaviour. Participants provided with 
weekly feedback on their medication-taking behaviour obtained from MEMS and repeated 
instructions on improving adherence to bupropion had a significant improvement in 
adherence.274 A pharmaceutical care program involved reviewing compiled drug history 
using MEMS by both the patient and pharmacist, significantly improved medication 
adherence.275 Interventions that were based on discussion informed by adherence feedback 
using electronically compiled medication-taking history have consistently improved 
adherence to medications. These interventions involve some degree of tailoring 
interventions to non-adherent patients. 
 
 
1.7 Summary 
 
This literature review has raised a number of key issues surrounding medication adherence 
scales and interventions to improve adherence. 
There are a large number of adherence scales available. Deciding which adherence scale 
to use is a difficult task. An important factor to consider when selecting an adherence scale 
is validity; however there is no single measure of validity for an adherence scale. Further, 
how the scales measure adherence differs. To address some of the issues surrounding the 
use of adherence scales, we conducted a systematic review of self-reported adherence 
scales which have been validated against a comparison measure of adherence (Chapter 
Two).  
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Interventions to improve medication adherence have not universally improved adherence. 
As discussed in Section 1.6, interventions that have shown some improvement in adherence 
were complex and improvements in adherence were only modest. We believe that part of 
the reason for these inconsistent results is that interventions have not been sufficiently 
targeted to patients who are non-adherent nor tailored to the patient-specific reasons for 
non-adherence. Self-report adherence scales provide the opportunity to identify some of the 
reasons for non-adherence and may be used in a similar manner to MEMS in a MGMM 
approach. These scales can either directly assess the patient’s medication-taking behaviour 
and/or attempt to identify barriers to good medication-taking behaviour, as discussed in 
Chapter Two. This provides information on how best to target and tailor interventions to 
improve adherence.  
A quick and simple intervention that is tailored to non-adherent patients would be good to 
improve adherence in practice. An intervention applicable to the clinical setting is practical, 
easily incorporated into clinical practice and used in more than one disease population. 
Current interventional studies on medication adherence tend to focus on one disease state 
as this would minimise the variability of adherence and improve understanding of adherence 
in that disease state.219,226,227,269,276-279  
The literature review and systematic review of validated adherence scales will allow the 
selection of adherence scales that will be able to identify non-adherent patients with chronic 
cardiovascular disease and explore the patient-specific reasons for non-adherence. 
Responses to the validated adherence scales will facilitate further discussion between the 
patient and researcher, which will guide the implementation of a tailored strategy to improve 
adherence. Patients diagnosed with hypertension, type II diabetes, dyslipidaemia or 
cardiovascular disease will be included in the study. These medical conditions are common 
and contribute extensively to the burden of chronic diseases.280 
 
The aim of the thesis is to determine if a targeted and tailored intervention based on a 
discussion informed by validated scales, would improve adherence to a recently initiated 
cardiovascular medication.  
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It is hypothesised that: 
H1 Targeting and tailoring an intervention based on a discussion informed by adherence 
scales in participants identified as non-adherent using the MAQ, will improve adherence at 
three months. 
H2 Improvements in adherence at three months, identified by the MAQ, will be sustained at 
six months. 
H3 Adherence, and reasons for non-adherence, will change over time in all groups studied. 
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CHAPTER TWO: SYSTEMATIC REVIEW 
OF VALIDATED SELF-REPORT 
MEDICATION ADHERENCE SCALES 
(PUBLISHED) 
 
2.1 Introduction 
Many self-report adherence scales are available. Adherence scales are relatively simple, 
easy to administer and inexpensive. Adherence scales may provide information on a 
patient’s medication-taking behaviour and may also provide the opportunity to identify some 
of the barriers to adherence. The available adherence scales have been briefly described in 
two reviews.178,182 Although these reviews identified and briefly described some of the 
available adherence scales, these reviews did not provide detailed information on what 
adherence scales measured and how they were validated. A systematic review of validated 
self-report adherence scales was conducted to determine what adherence scales really 
measured and how these scales have been validated. The following paper has been 
published in the British Journal of Clinical Pharmacology.213 
 
2.2 Published Paper 
Nguyen TMU, La Caze A, Cottrell WN. What are validated self-report adherence scales 
really measuring?: a systematic review. Br J Clin Pharmacol 2014;77(3):427-45. 
 
 2.2.1 Abstract 
Background Medication non-adherence is a significant health problem. There are numerous 
methods for measuring adherence, but no single method performs well on all criteria. 
Objectives The purpose of this systematic review is to (i) identify self-report medication 
adherence scales that have been correlated with comparison measures of medication-
taking behaviour, (ii) assess how these scales measure adherence and (iii) explore how 
these adherence scales have been validated. 
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Method Cinahl and PubMed databases were used to search articles written in English on 
the development or validation of medication adherence scales dating to August 2012. The 
search terms used were medication adherence, medication non-adherence, medication 
compliance and names of each scale. Data such as barriers identified and validation 
comparison measures were extracted and compared. 
Results Sixty articles were included in the review, which consisted of 43 adherence scales. 
Adherence scales include items that either elicit information regarding the patient’s 
medication-taking behaviour, and/or attempts to identify barriers to good medication-taking 
behaviour or beliefs associated with adherence. The validation strategies employed 
depended on whether the focus of the scale was to measure medication-taking behaviour 
or identify barriers or beliefs. 
Conclusions Supporting patients to be adherent requires information on their medication-
taking behaviour, barriers to adherence and beliefs about medicines. Adherence scales 
have the potential to explore these aspects of adherence, but currently there has been a 
greater focus on measuring medication-taking behaviour. Selecting the “right” adherence 
scale(s) requires consideration of what needs to be measured and how (and in whom) the 
scale has been validated.  
 
 2.2.2 Introduction 
There are many effective medicines available to treat illness, but the benefits of these 
medicines will only accrue to the patients that take them. The World Health Organisation 1 
defines adherence as: 
 
The extent to which a person’s behaviour – taking medication, following a diet, and/or 
executing lifestyle changes, corresponds with agreed recommendations from a 
health care provider.  
 
Medication non-adherence is common, with studies in a range of settings identifying up to 
50% of patients as non-adherent to a medicine.4,5,53,54,88 Poor medication adherence results 
in adverse health outcomes3,12,55 and increased healthcare costs.3 
 
Patients may be non-adherent due to different beliefs, barriers and a range of other factors. 
Patients may intentionally decide not to take their medicines based on well-informed or 
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mistaken beliefs about the benefits and risks of their medicines.49,117 Patients can 
unintentionally non-adhere to medicines due to forgetfulness, carelessness, health literacy 
and socioeconomic factors. Non-adherence can also occur at different stages of the 
medication-taking process. A patient may exhibit non-adherence at the initiation of treatment, 
during treatment (where the patient may exhibit sub-optimal implementation of the treatment 
regimen), or the patient may discontinue the treatment early.38 Strong evidence for any 
single approach to improve medication adherence is lacking, but interventions that are 
tailored to a patient’s specific reasons and stage of non-adherence can be expected to better 
support good medication-taking behaviour.13-15,216,236  
Adherence to medicines is measured for different purposes. Common reasons to measure 
adherence include better informing the assessment of an intervention (as unrecognised non-
adherence may lead to an underestimation of possible treatment effects); determining 
influences on adherence to medicines in people with specific disease states (such as 
hypertension or HIV); and identifying patients requiring education or support to improve 
medication use. Ideally, clinicians and researchers wanting a comprehensive assessment 
of adherence need measures that are inexpensive, relatively easy to administer, accurately 
identify the patient’s current medication-taking behaviour, and any barriers or beliefs that 
influence the patient’s use of medicines.  
There are a number of ways of measuring adherence. Objective measures, including 
measurement of clinical outcomes, dose counts, pharmacy records, electronic monitoring of 
medication administration (e.g. the Medication Event Monitoring System, MEMS) and drug 
concentrations,157-160 seemingly provide the best measure of a patient’s medication-taking 
behaviour in many contexts.83,168-172 It is important to recognise that, while objective, most 
of these measures have drawbacks. MEMS, arguably the best objective measure of 
medication-taking behaviour, records package opening or device actuation, rather than 
actual medication-taking; the possibility of intentional dose dumping remains. MEMS, or 
MEMS-like devices, are also expensive and not readily available for some dose forms 159,165-
167. While clinical outcomes are the ultimate aim of any intervention to improve adherence, 
the use of clinical outcomes as a proxy of adherence can be confounded by disease-specific 
factors independent of medication-taking behaviour. 
Subjective measures of adherence include physician or family reports, patient interviews 
and self-report adherence scales.117,179-181,205 These measures have the potential to identify 
the specific reasons for a patient’s non-adherence. Subjective measures can be relatively 
simple to use and are less expensive; however, are prone to recall bias and the prospect 
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that respondents provide answers that conform to their perceived expectations of their 
interviewer.281,282 There are a large number of adherence scales that are suitable for use in 
research or clinical settings. A number of well-validated adherence scales have been 
strongly correlated with objective measures of adherence in several different populations of 
patients.  
There is a need for scales that are easy to administer and correctly identify medication-
taking behaviour, key barriers to adherence and beliefs associated with medication use that 
influence adherence. There have been few systematic attempts to describe the available 
self-report adherence scales and their benefits and limitations with respect to both 
medication-taking behaviour and the identification of barriers and beliefs associated with 
adherence.178,182 The aim of this review is to (i) identify self-report medication adherence 
scales that have been correlated with a comparison measure of medication-taking behaviour, 
(ii) assess how these scales measure adherence and (iii) explore how these adherence 
scales have been validated. 
 
2.2.3 Methods 
A literature search for adherence scales was conducted using Cinahl and PubMed electronic 
databases. The initial search terms used to identify the articles were: medication adherence, 
medication non-adherence, medication compliance and medication non-compliance. This 
broad database search identified the names of the adherence scales, which were then 
searched individually. This search was limited to English-language studies published 
between 1981 and 2012. The date of the last search was on the 1st August, 2012. The 
reference lists of the relevant studies were searched to identify additional articles.  
 
Inclusion and exclusion criteria 
Adherence scales were included if they had been correlated against a comparison measure 
(objective or subjective) of medication-taking behaviour. To be included there needed to be 
a full-text article, written in the English-language on the development and/or validation of the 
adherence scale. Studies that used the self-report adherence scale without correlating the 
adherence scale against a comparison measure of medication-taking behaviour were 
excluded. The list of scales was reviewed for completeness with two adherence researchers.  
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Data extraction and analysis 
The data extracted from the studies included: the number of items in the adherence scale, 
study setting, criteria for identifying non-adherence, response rate and time to complete the 
adherence scale. Each validated self-report adherence scale was categorised according to 
whether it contained items that elicited information on (i) specific medication-taking 
behaviours: dose taken, dose frequency, dose administration and prescription refills; (ii) 
barriers to adherence: e.g. forgetfulness, treatment complexity and side effects; and/or (iii) 
beliefs associated with adherence: e.g. perceived necessity of medicines and concerns 
about medicines. Adherence scales were also assessed on whether or not the scale 
identified the initiation, implementation or discontinuation of treatment as per the taxonomy 
proposed by Vrijens et al.38  
To assess the quality of the correlation study, the following criteria were extracted: how the 
adherence scale was administered, sample size, the adherence comparison measures, 
internal consistency, and where reported, the sensitivity and specificity of the scale against 
a standard of adherence. Information on criterion, content and construct validity was also 
extracted to assess the validation of the adherence scale. The results of the studies were 
reviewed and compared. 
 
2.2.4 Results 
Search Strategy  
The study selection process is illustrated in Figure 2.1. Twenty-one articles were retrieved 
using the Cinahl search engine and the remaining were identified using the same strategy 
in the PubMed database and from reference lists. Some adherence scales were excluded, 
as shown in Table 2.1.  
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Figure 2.1 Flow chart of study selection process
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Table 2.1 Excluded self-report adherence scales 
Excluded Adherence Scale Reason for Exclusion 
Adult AIDS Clinical Trials Group 
(AACTG) Adherence Scale 283 
No validation studies were found in the 
literature search 
Basel Assessment of Adherence Scale 
(BAAS) 284 
No validation studies were found in 
literature search.  
Medication Adherence Evaluation Scale 
(MASS) 285 
 
No full-text article available 
Medication Adherence Measure (MAM) 
interview 180 
Semi-structured interview and thus was 
not consistent between patients 
Multicentre Aids Cohort Study (MACS) 
adherence form 90 
No adherence comparison measure 
 
 
The literature search retrieved 60 articles that met the inclusion criteria (Figure 2.1, 
Table 2.2). The sample size of the studies ranged from 40 to 1367 (Table 2.3).190,211 
The median sample size of the studies was 228. Twenty-two of the studies reported 
the response rate, ranging from 29 to 98%. The average response rate was 72% (Table 
2.3). Forty-three self-report adherence scales were identified from the included studies. 
 
 
  40 
Table 2.2 Comparing the self-report adherence scales 
Self-Report Adherence Scale Based On Number 
of 
Questions 
Time to 
Complete 
Barriers 
Identified 
Stage of 
Medication-
Taking 
Identified 
Number of 
Development and 
Correlation Studies 
GROUP 1: Medication-Taking Behaviour       
Adherence Self-Report Questionnaire (ASRQ) 
184 
CQR  1 Not 
reported 
- Nil Implementation 2 
Adherence Visual Analogue Scale (VAS) 
Computerised 164 
Literature 
review 
1 Not 
reported 
- Nil Implementation 1 
Brief Adherence Rating Scale (BARS) 181 CATIE trial  4 Not 
reported 
- Nil Implementation 1 
Barroso et al. 30-day Adherence Question 60 Did not specify 1 Not 
reported 
- Nil Implementation 1 
Bell et al. Adherence Question 189 Did not specify 1 Not 
reported 
- Nil Implementation 1 
Centre for Adherence Support Evaluation 
(CASE) Adherence Index 192 
 
Literature 
review 
3 Not 
reported 
- Nil Implementation 1 
Gehi et al. Adherence Question 12 Expertise 1 Not 
reported 
- Nil Implementation 1 
 
      
Grymonpre et al. Adherence Question 196 Did not specify 1 Not 
reported 
- Nil Implementation 1 
Kerr et al. Adherence Question 199 Expertise 1 Not 
reported 
- Nil Implementation 1 
Medication Adherence Report Scale – 5 
(MARS-5) 127,286 
 
MARS-10 5 Not 
reported 
- Nil Implementation 
Discontinuation 
3 
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Stages of Change for Adherence (SOCA) 212 Stages of 
Change model 
2 Not 
reported 
- Stages of 
change 
 
Initiation 
Implementation 
1 
GROUP 2: Medication-Taking Behaviour AND Barriers      
Adherence to Refills and Medications Scale 
(ARMS) 187 
Literature 
review, MAQ 
and Hill-Bone 
Compliance 
Scale 
12 Not 
reported 
- Correct 
administratio
n 
- Forgetfulness 
- Prescription 
refill ability 
Implementation 
Discontinuation 
1 
Adherence Starts with Knowledge-12 (ASK-
12) 185 
ASK-20 12 Not 
reported 
- Patient-
perceived 
barriers 
- Inconvenienc
e 
- Forgetfulness 
- Medication 
beliefs 
Implementation 
Discontinuation 
1 
Adherence Starts with Knowledge-20 (ASK-
20) 186 
Literature 
review, patient 
focus groups 
and expert 
panel input 
20 Not 
reported 
- Medication-
taking 
behaviour 
- Patient-
perceived 
barriers 
Implementation 
Discontinuation 
2 
Brief Medication Questionnaire 190 Literature 
review and 
patient 
feedback 
9 Not 
reported 
- Evaluates 
regimen  
- Medication-
taking 
problems 
Implementation 1 
Brooks Medication Adherence Scale (BMAS) 
191 
MAQ 4 Less than 
5 minutes 
- Forgetfulness 
- Carelessness 
Implementation 
Discontinuation 
2 
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- Adverse 
effects and 
efficacy 
Choo et. al. 5-item Questionnaire 156 Brief 
Medication 
Questionnaire 
5 Not 
reported 
- Unintentional 
and 
intentional 
non-
adherence 
Implementation 1 
Fodor et al. Adherence Questionnaire 194 Did not specify 9 Not 
reported 
- Blood 
pressure 
awareness 
Implementation 
Discontinuation 
1 
Godin et al. Self-Reported Adherence 
Questionnaire 195 
Expertise 6 5 minutes - Barriers to 
adherence 
Implementation 1 
Hill-Bone Compliance Scale – 10 55 The Hill-Bone 
Compliance 
Scale - 14 
10 Not 
reported 
- Adherence 
- Appointment-
making 
- Sodium intake 
Implementation 1 
Hill-Bone Compliance Scale – 14 197 Literature 
review and 
Clinical 
expertise 
14 5 minutes - Adherence 
- Appointment-
making 
- Sodium intake 
Implementation 1 
Immunosuppressant Therapy Adherence 
Scale (ITAS) 198 
MAQ 4 Less than 
5 minutes 
- Forgetfulness 
- Carelessness 
- Adverse 
effects 
Implementation 
Discontinuation 
1 
Medication Adherence Assessment Tool 
(MAAT) 201 
Literature 
review and 
Expert 
clinicians 
12 Not 
reported 
- Previous 
history 
- Adverse 
effects 
- Access to 
medications 
Implementation 1 
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Morisky Medication Adherence Scale 
(MMAS) 205 
 
 
MAQ 8 Not 
reported 
- Forgetfulness 
- Medication-
taking 
behaviour 
- Adverse 
effects and 
problems 
Implementation 
Discontinuation 
3 
Osteoporosis-Specific Morisky Medication 
Adherence Scale (OS-MMAS) 206 
MMAS 8 Not 
reported 
- Forgetfulness 
- Medication-
taking 
behaviour 
- Adverse 
effects and 
problems 
Implementation 
Discontinuation 
1 
Pediatric Inhaler Adherence Questionnaire 
(PIAQ) 208 
Literature 
review, 
expertise and 
focus groups, 
6 1  to 3 
minutes 
- Missed and 
additional 
doses 
- Barriers to 
adherence  
Implementation 1 
Reported Adherence to Medicine (RAM) 
Scale 117 
Literature 
review 
4 Not 
reported 
- Forgetfulness 
- Dose 
adjustments 
Implementation 2 
Self-Reported Adherence (SERAD) 
Questionnaire 210 
SERAD study 13 Not 
reported 
- Dose 
frequency 
adherence 
- Barriers to 
adherence 
Implementation 1 
Simplified Medication Adherence 
Questionnaire (SMAQ) 211 
MAQ 6 Not 
reported 
- Forgetfulness  
- Adverse 
effects 
Implementation 
Discontinuation 
1 
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The Patterns of Asthma Medication Use 
Questionnaire 207 
Literature 
review, 
Expertise 
5 Not 
reported 
- Forgetfulness  
- Medication-
taking 
strategy 
Implementation 1 
GROUP 3: Barriers to Adherence       
Adherence Attitude Inventory (AAI) 183 
 
Health Belief 
Model, Health 
Promotion 
Model, 
Reasoned 
Action 
28 
 
Not 
reported 
- Cognitive  
functioning 
- Patient-
Provider  
- Self-efficacy 
- Commitment  
Implementation 1 
Medication Adherence Questionnaire (MAQ) 
18 
5-item survey 
by Green et al. 
4 Not 
reported 
- Forgetfulness 
and 
Carelessness 
- Adverse 
effects and 
Efficacy 
Implementation 
Discontinuation 
8 
Medication Adherence Self-Efficacy Scale 
(MASES) 203 
Patient 
interviews 
26 Not 
reported 
- Self-efficacy 
- Access to 
medications 
- Adverse 
effects  
- Lifestyle 
barriers 
Implementation 1 
Medication Adherence Self-Efficacy Scale 
Revised (MASES-R) 204 
MASES 13 Not 
reported 
- Self-efficacy 
- Lifestyle 
barriers 
- Adverse 
effects 
Implementation 1 
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Medication Adherence Reasons Scale 202 Literature 
review 
15 Not 
reported 
- Managing 
issues 
- Beliefs 
- Multiple 
medication 
issues 
- Availability 
issues 
- Forgetfulness 
Implementation 
Discontinuation 
1 
The Self-Efficacy for Appropriate Medication 
Use Scale (SEAMS) 209 
Literature, 
expertise and 
patient 
interviews 
13 Not 
reported 
- Specific 
problem 
areas 
- Self-efficacy 
Nil 
 
1 
GROUP 4: Beliefs associated with Adherence      
Beliefs about Medicines Questionnaire 117 Health Belief 
Model and 
Patient Beliefs 
18 Not 
reported 
- Medication 
necessity 
beliefs 
- Medication 
concerns 
Nil 4 
Drug Attitude Inventory (DAI) 53 Literature 
review and 
patient reports 
30 Not 
reported 
- Attitudes 
towards 
medications 
- Beliefs on 
medications 
Discontinuation 1 
GROUP 5: Barriers AND Beliefs       
Beliefs and Behaviour Questionnaire (BBQ) 
188 
Interviews of 
COPD patients 
30 Not 
reported 
- Beliefs 
- Experiences 
Nil 1 
Brief Evaluation of Medication Influences 
and Beliefs (BEMIB) 79 
Health Belief 
Model and 
Patient/ 
8 Less than 
5 minutes 
- Forgetfulness 
- Access to 
medications 
Implementation 1 
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Investigator 
feedback 
- Support 
network 
- Benefits of 
medication 
Compliance Questionnaire Rheumatology 
(CQR) 287 
Patient 
interviews 
19 ~ 12 
minutes 
- Forgetfulness 
- Value of 
doctor 
instructions 
Implementation 2 
Maastricht Utrecht Adherence in 
Hypertension (MUAH) Questionnaire 200 
Patient 
interviews  
25 Average 
25 
minutes 
- Medication 
attitude 
- Discipline and 
aversions 
- Coping with 
health 
problems 
Implementation 1 
Medication Adherence Report Scale (MARS) 
51 
MAQ and DAI 10 Not 
reported 
- Forgetfulness 
- Adverse 
effects 
- Value of 
medication 
- Behaviour 
and attitudes 
Implementation 
Discontinuation 
2 
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Content of the scales 
The adherence scales can be categorised into five groups based on the information they 
seek to elicit (the number of scales is given in parentheses, full details in Table 2.2): Group 
1 scales seek information only on medication-taking behaviour (11), Group 2 scales seek 
information on medication-taking behaviour and barriers to adherence (19), Group 3 scales 
seek information only on barriers to adherence (6), Group 4 scales seek information only 
on  beliefs associated with adherence (2) and Group 5 scales seek information on barriers 
and beliefs associated with adherence (5).  
Thirty of 43 scales contained items that asked specific questions about medication-taking 
behaviour (Group 1 and 2). Most of these adherence scales measure the number of doses 
taken12,42,181,184-186,189,195,196,199,206,208 and contain items such as “how many days over the 
past month did you take less than prescribed?181” and “did you miss a tablet yesterday? 189” 
Other adherence scales measuring medication-taking behaviour do so through exploring the 
frequency of patients not refilling their prescription on time.185-187,190 
Twenty adherence scales measuring medication-taking behaviour specified a timeframe for 
the questions. The timeframe specified ranged from one day to 12 
months.12,60,156,164,181,184,190-192,195,198,212 189,199,205-208,210,211 
Thirty scales contained items that elicited information on barriers to, and determinants of 
adherence (Group 2, 3 and 5). Some of these adherence scales are disease-specific and 
thus explore common barriers that may influence adherence in these disease 
populations.191,193,206-208 For example, the Pediatric Inhaler Adherence Questionnaire (PIAQ) 
explores adherence in patients with asthma and assesses the patient’s difficulty in using 
asthma inhalers and the cost of inhalers.208 Most of these adherence scales explore 
forgetfulness as a barrier to adherence and identify some of the situations where 
forgetfulness may be more common, such as when working or travelling.55,183,197,203,209 Some 
adherence scales also explore physical barriers to adherence, such as vision problems, 
dexterity issues and dysphagia.190,202,208 
Seven scales elicited information on the patient’s beliefs about their medicines that may 
relate to adherence (Group 4 and 5). These scales included items identifying beliefs that 
medicines are necessary, harmful and unnatural.51,53,79,117,188,193,200 For example, the Beliefs 
about Medicines Questionnaire explores whether the patient holds beliefs that their 
medicines are necessary as well as whether they have any concerns about their medicines.  
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Forty of the 43 scales contained items that sought to identify aspects of adherence that are 
consistent with the taxonomy provided by Vrijens et al.38 Most scales contain items that seek 
to assess the extent of implementation of a dosing regimen (39/43) (Table 2.2). Thirteen of 
the scales also contain items that seek to identify the discontinuation of treatment.18,185-
187,191,194,198,202,205,206,211,286,288 The DAI contained items that sought information on 
discontinuation (alone),53 and the SOCA scale identified the initiation of treatment.212 Three 
adherence scales do not contain any items that seek to identify the initiation, implementation 
or discontinuation of treatment.117,188,209 
 
Administration of the scales 
The adherence scales have been administered in different ways. Indeed, for the scales with 
more than one validation or correlation study, the additional studies often administered the 
scale in a slightly different way. Details of who completed the scale (i.e. patient, clinician or 
researcher) and where the scale was administered are provided in Table 2.3. There was a 
roughly even split between studies that requested the patient to complete the scale and 
those that had the researcher or clinician complete the scale in consultation with the patient. 
The location of administration (clinic, home, via telephone or internet) varied between the 
scales (as reported in Table 2.3). The time to complete the scale was reported in eight of 
the 43 adherence scales. Reported times varied from less than five minutes79,191,198,208 to 
approximately 25 minutes (Table 2.2).200 The scales taking less than five minutes to 
complete consisted of 4 to 14 items. Twelve minutes was required to complete a 19-item 
scale and 25 minutes to complete a 25-item scale.200,287  
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Table 2.3 Self-report adherence scales - administration, response and validation 
Self-Report 
Adherence Scale 
Reference 
Number 
How Scale was 
Administered 
Response 
Rate 
Internal 
Consistency 
Sensitivity Specificity Correlation 
(Criterion 
Validity) 
Comparison 
Measure of 
Adherence 
Sample 
Size 
GROUP 1: Medication-Taking Behaviour 
Adherence Self-
Report 
Questionnaire 
(ASRQ) 
 
 
184 
 
 
289 
Clinician-administered 
(Other HCP)  
 
Clinician-administered 
(Primary physician) 
Not 
reported 
 
53% 
Not reported 
 
 
Not reported 
Not reported 
 
 
Not reported 
Not reported 
 
 
Not reported 
Significant 
 
 
Not 
significant 
Electronic 
monitoring 
(MEMS) 
MEMS and Other 
scale (VAS) 
245 
 
 
78 
Adherence Visual 
Analogue Scale 
(VAS) 
Computerised  
164 Self-administered  
(Home, Internet) 
Not 
reported 
Not reported Not reported Not reported Significant Dose counts and 
Clinical outcome 
(Viral load) 
290 
Brief Adherence 
Rating Scale 
(BARS)  
181 Researcher-
administered (Clinic) 
Not 
reported 
α = 0.92 0.73 0.74 Significant MEMS 61 
Barroso et al. 30-
day Adherence 
Question  
60 Researcher-
administered (Clinic) 
Not 
reported 
Not reported Not reported Not reported Significant Clinical outcome 
(Viral load) 
93 
Bell et al. 
Adherence 
Question  
189 Self-administered  
(Clinic, Absent) 
80% Not reported Not reported Not reported Not 
significant 
MEMS and Dose 
count 
80 
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Centre for 
Adherence 
Support 
Evaluation 
(CASE) 
Adherence Index  
192 Clinician-administered 
(Primary physician) 
Not 
reported 
Not reported 0.70 0.71 Significant Clinical outcome 
(Viral load) and 
Self-report 
524 
Gehi et al. 
Adherence 
Question  
12 Researcher-
administered (Clinic)  
Not 
reported 
Not reported Not reported Not reported Significant Clinical outcome 
(Cardiovascular 
events) 
1015 
Grymonpre et al. 
Adherence 
Question  
196 Researcher-
administered (Home) 
Not 
reported 
Not reported Not reported Not reported Significant  Pharmacy records 
and Dose counts 
135 
Kerr et al. 
Question  
199 Researcher-
administered (Clinic)  
Not 
reported 
Not reported Not reported Not reported Not 
significant 
Pharmacy records 88 
Medication 
Adherence 
Report Scale – 5 
(MARS-5) 127 
5 
 
286 
Clinician-administered 
(Primary physician) 
Self-administered  
(Clinic, Present) 
Not 
reported 
Not 
reported 
Not reported 
 
α = 0.78 
0.085 
 
Not reported 
0.97 
 
Not reported 
Not 
significant 
Significant  
Pharmacy records 
 
Drug levels and 
Self-report 
128 
 
255 
 
Stages of 
Change for 
Adherence 
(SOCA)  
212 Self-administered 
(Clinic, Absent) 
Not 
reported 
Not reported Not reported Not reported Significant  MEMS and Other 
scale (BMAS) 
731 
GROUP 2: Medication-Taking Behaviour AND Barriers        
Adherence to 
Refills and 
Medications 
Scale (ARMS)  
187 Researcher-
administered (Clinic) 
89% α = 0.81 Not reported Not reported Significant  Clinical outcome 
(BP control), 
Pharmacy records 
and Scale (MAQ) 
435 
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Adherence Starts 
with Knowledge-
12 (ASK-12)  
185 Self-administered  
(Clinic, Absent) 
Not 
reported 
α = 0.75 Not reported Not reported Significant  Pharmacy record 
and Other scale 
(MAQ) 
112 
Adherence Starts 
with Knowledge-
20 (ASK-20)  
186 
 
290 
Self-administered  
(Home, Internet) 
Self-administered  
(Clinic, Present) 
Not 
reported 
Not 
reported 
α = 0.85 
 
α = 0.76 
Not reported 
 
Not reported 
Not reported 
 
Not reported 
Significant 
 
Significant 
(Scale only) 
Self-report 
 
Pharmacy records 
and Scale (MAQ) 
605 
 
112 
 
Brief Medication 
Questionnaire  
190 Researcher-
administered (Clinic) 
92% Not reported 0.80 1.00 Significant  MEMS 43 
Brooks 
Medication 
Adherence Scale 
(BMAS)  
191 
 
291 
Self-administered 
(Unclear) 
Self-administered 
(Home) 
86% 
 
63% 
α = 0.69 
 
α = 0.86 
Not reported 
 
Not reported 
Not reported 
 
Not reported 
- 
 
Significant  
Nil 
 
Pharmacy records 
and Self-report 
294 
 
98 
Choo et. al. 5-
item 
Questionnaire  
156 Researcher-
administered 
(Telephone) 
Not 
reported 
Not reported Not reported Not reported Significant MEMS 286 
Fodor et al. 
Adherence 
Questionnaire  
194 Researcher-
administered (Clinic) 
Not 
reported 
Not reported Not reported Not reported Significant Clinical outcome 
(BP control) 
359 
Godin et al. Self-
Reported 
Adherence 
Questionnaire  
195 Self-administered  
(Clinic, Absent) 
Not 
reported 
Not reported 0.71 0.72 Not 
significant 
Clinical outcome 
(Viral 
suppression) 
256 
Hill-Bone 
Compliance 
Scale – 10  
 
55 Researcher-  and  self-
administered (Clinic) 
Not 
reported 
α = 0.79 Not reported Not reported Significant Clinical outcome 
(BP control) 
98 
  52 
Hill-Bone 
Compliance 
Scale – 14  
197 Researcher- and self-
administered (Clinic) 
Not 
reported 
α = 0.84 Not reported Not reported Significant Clinical outcome 
(BP control) 
718 
Immunosuppress
ant Therapy 
Adherence Scale 
(ITAS)  
198 Self-administered  
(Home) 
91% α = 0.81 Not reported Not reported Significant 
(all) 
Pharmacy 
records, Drug 
levels and Clinical 
outcome 
(Rejection) 
222 
Medication 
Adherence 
Assessment Tool 
(MAAT)  
201 Self-administered  
(Clinic) 
29% α = 0.80 Not reported Not reported Significant Pharmacy records 289 
Morisky 
Medication 
Adherence Scale 
(MMAS)  
 
 
205 
 
158 
 
292 
Researcher-
administered (Clinic) 
Self-administered 
(Unclear) 
Researcher-
administered (Clinic) 
98% 
 
66% 
 
82% 
α = 0.83 
 
Not reported 
 
α = 0.56 
0.93 
 
Not reported 
 
0.73 
 
0.53 
 
Not reported 
 
0.36 
Significant 
 
Significant 
 
Significant 
Clinical outcome 
(BP control)  
Pharmacy records 
 
Pharmacy records 
1367 
 
87 
 
151 
 
Osteoporosis-
Specific Morisky 
Medication 
Adherence Scale 
(OS-MMAS)  
206 Self-administered 
(Home) 
39% α = 0.82 Not reported Not reported Significant 
 
 
Other scale 
(Beliefs about 
Medicines 
Questionnaire) 
197 
Pediatric Inhaler 
Adherence 
Questionnaire 
(PIAQ)  
208 Self-administered  
(Clinic, Absent) 
Not 
reported 
Not reported 0.63 0.91 
 
Significant Dose counts 64 
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Reported 
Adherence to 
Medicine (RAM) 
Scale  
117 
 
42 
Self-administered  
(Clinic, Absent) 
Self-administered 
(Home) 
Not 
reported 
Not 
reported 
α = 0.72 
 
Not reported 
Not reported 
 
Not reported 
Not reported 
 
Not reported 
- 
 
Significant 
Nil 
 
Other scale 
(Beliefs about 
Medicines 
Questionnaire) 
524 
 
271 
Self-Reported 
Adherence 
(SERAD) 
Questionnaire  
210 Researcher-
administered (Clinic) 
Not 
reported 
Not reported Not reported Not reported Significant 
(all) 
MEMS, Dose 
counts and Drug 
levels 
530 
Simplified 
Medication 
Adherence 
Questionnaire 
(SMAQ)  
211 Clinician-administered 
(Primary physician) 
 
Not 
reported 
α = 0.75 0.72 0.91 Significant 
(all) 
Electronic 
monitoring 
(MEMS) and 
Clinical outcome 
(Viral load) 
40 
The Patterns of 
Asthma 
Medication Use 
Questionnaire  
207 Self-administered 
(Home) 
70% Not reported Not reported Not reported Significant 
(all) 
Pharmacy records 
and  Clinical 
outcome 
(Asthma) 
176 
GROUP 3: Barriers to 
Adherence 
        
Adherence 
Attitude Inventory 
(AAI)  
183 Self-administered  
(Clinic, Absent) 
Not 
reported 
α = 0.90 Not reported Not reported Not 
significant 
Self-report 165 
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Medication 
Adherence 
Questionnaire 
(MAQ)  
18 
 
 
293 
 
 
5 
 
 
294 
 
 
 
72 
 
 
295 
 
 
37 
 
 
296 
Researcher-
administered (Clinic) 
 
Researcher-
administered (Clinic) 
 
Clinician-administered 
(Primary physician) 
 
Researcher-
administered (Clinic) 
 
 
Researcher-
administered (Clinic) 
 
Researcher-
administered (Home) 
 
Researcher-
administered (Clinic) 
 
Researcher-
administered (Clinic) 
73% 
 
 
 
Not 
reported 
 
Not 
reported 
 
Not 
reported 
 
 
32% 
 
 
88% 
 
 
Not 
reported 
 
81% 
α = 0.61 
 
 
α = 0.32 
 
 
Not reported 
 
 
Not reported 
 
 
 
Not reported 
 
 
α = 0.42 
 
 
Not reported 
 
 
α = 0.62 
 
0.81 
 
 
Not reported 
 
 
0.32 
 
 
Not reported 
 
 
 
Not reported 
 
 
Not reported 
 
 
Not reported 
 
 
 
 
 
 
 
Not reported 
0.44 
 
 
Not reported 
 
 
0.73 
 
 
Not reported 
 
 
 
Not reported 
 
 
 
Not reported 
 
 
Not reported 
 
 
 
Not reported 
Significant 
 
 
 
Significant 
 
 
Not 
significant 
 
Significant  
 
 
 
Significant  
 
 
 
Not 
significant 
 
Significant 
 
 
Significant 
Clinical outcome 
(BP control) 
 
Pharmacy records 
 
 
Pharmacy records 
 
 
MEMS, Dose 
counts and Drug 
levels 
 
Clinical outcome 
(Diabetes control) 
 
Dose counts 
 
 
Dose counts 
 
 
Clinical outcome 
(Diabetes control) 
290 
 
 
377 
 
 
128 
 
 
385 
 
 
 
186 
 
 
319 
 
 
413 
 
 
294 
Medication 
Adherence Self-
Efficacy Scale 
(MASES)  
 
203 Self-administered 
(Unclear) 
Not 
reported 
α = 0.95 Not reported Not reported Not 
significant 
Clinical outcome 
(BP control) 
72 
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Medication 
Adherence Self-
Efficacy Scale 
Revised 
(MASES-R)  
 
204 Self-administered  
(Clinic, Present) 
Not 
reported 
α = 0.91 Not reported Not reported Significant   MEMS and Other 
scale (MAQ) 
168 
Medication 
Adherence 
Reasons Scale  
 
202 Self-administered  
(Home, Internet) 
Not 
reported 
α = 0.65 Not reported Not reported Significant Other scale 
(MAQ) 
840 
Self-Efficacy for 
Appropriate 
Medication Use 
Scale (SEAMS)  
 
209 Self-administered 
(Clinic) 
Not 
reported 
α = 0.89 Not reported Not reported Significant Other scale 
(MAQ) 
436 
Beliefs about 
Medicines 
Questionnaire  
117 
 
 
4  
 
 
124  
 
 
89 
Self-administered  
(Clinic, Absent) 
 
Self-administered  
(Clinic, Absent) 
 
Self-administered 
(Clinic) 
 
Self-administered  
(Clinic, Present) 
Not 
reported 
 
57% 
 
 
Not 
reported 
 
 
93% 
α = 0.70 
 
 
Not reported 
 
 
α = 0.73 
 
 
Not reported 
Not reported 
 
 
Not reported 
 
 
Not reported 
 
 
Not reported 
Not reported 
 
 
Not reported 
 
 
Not reported 
 
 
Not reported 
Significant 
 
 
Significant 
 
 
Significant 
 
 
Significant 
Other scale 
(RAM) 
 
Other scale 
(MARS-5) 
 
Other scale 
(MAQ) 
 
Other scale 
(MMAS) 
524 
 
 
324 
 
 
192 
 
 
275 
Drug Attitude 
Inventory (DAI)  
53 Self-administered 
(Home) 
Not 
reported 
 
α = 0.93 0.72 0.63 Significant Therapist report 150 
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Legend: Home – completed adherence scale at home; Clinic – completed adherence scale in clinic, researcher or clinician may be present or absent while patient fills out form;  Telephone – patients completed 
adherence scale over the telephone; Primary physician = Patient’s usual physician; Other HCP = Other health care professionals looking after patient; α = Cronbach’s alpha of reliability; BP = Blood 
pressure 
GROUP 5: Barriers AND 
Beliefs 
        
Beliefs and 
Behaviour 
Questionnaire 
(BBQ)  
188 Self-administered  
(Home, Post) 
53% α = 0.65 Not reported Not reported Significant Other scale 
(MARS) 
276 
Brief Evaluation 
of Medication 
Influences and 
Beliefs (BEMIB) 
79 Self-administered  
(Clinic, Absent) 
Not 
reported 
α = 0.63 0.83 0.71 Not 
significant  
Pharmacy records 
and Other scale 
(DAI) 
63 
Compliance 
Questionnaire 
Rheumatology 
(CQR)  
193 
 
 
287 
Researcher-
administered (Home) 
 
Self-administered 
(Home) 
Not 
reported 
 
82% 
α = 0.71 
 
 
Not reported 
0.98 
 
 
0.62 
0.67 
 
 
0.95 
Significant 
 
 
Significant 
Self-report 
 
 
MEMS 
127 
 
 
127 
Maastricht 
Utrecht 
Adherence in 
Hypertension 
(MUAH)  
200 Researcher-
administered (Clinic)  
90% α = 0.74 Not reported Not reported Significant 
(all) 
MEMS, Pharmacy 
records and Other 
scale (Brief 
Medication 
Questionnaire) 
255 
Medication 
Adherence 
Report Scale 
(MARS)  
51 
 
 
 
 
297 
Self-administered  
(Clinic, Absent)  
 
 
Self-administered  
(Clinic, Absent) 
Not 
reported 
 
 
Not 
reported 
α = 0.75 
 
 
 
 
α = 0.62 
Not reported 
 
 
Not reported 
Not reported 
 
 
Not reported 
Significant 
(Drug 
levels only) 
Significant 
Drug levels or 
Caregiver report 
 
Caregiver report 
66 
 
 
277 
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Figure 2.2 illustrates the conditions in which the scales have been validated. Most of the 
adherence scales have been validated in a single disease population (Figure 
2.2).12,53,55,60,156,187,189-192,194,195,197-199,208,210 The Medicines Adherence Questionnaire (MAQ), 
which is a simple 4-item questionnaire, has been validated in a broad range of diseases, 
including hypertension, dyslipidaemia, heart failure and Parkinson’s disease.18,37,293,294 
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Figure 2.2 Disease populations used to validate self-report adherence scales
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Approaches to assessing self-report adherence scales 
Assessing the validity of self-report adherence scales differed among the 60 included 
studies. Details of the studies, assessment of internal consistency, comparison measures 
and whether the scale was significantly correlated to the comparison measure is provided 
in Table 2.3. Similar approaches to validation were seen from scales with similar content.  
 
Medication-taking behaviour 
The primary method for assessing Group 1 and Group 2 scales was to determine the 
correlation between the scale and an objective measure of adherence. Twenty-eight of the 
30 scales included in Group 1 and 2 assessed how well the scale correlated with an objective 
measure of adherence, eight of these scales have been assessed against MEMS and 12 
against clinical outcomes (Figure 2.3).  
  60 
 
Figure 2.3 Comparison measures of medication-taking behaviour used to validate the self-report adherence scales
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Barriers and beliefs 
Scales in Groups 3–5 were more likely to rely on alternative approaches to validation. 
Content validity was typically assessed via a panel of subject matter experts. A range of 
approaches were utilised for construct validity, including item analysis against tools validated 
to elicit specific types of health beliefs and factor analyses of responses to other scales or 
semi-structured interviews. 
Three of the six Group 3 scales (scales that contain items that elicit information on barriers 
to adherence only) have been assessed against an objective measure of adherence (one 
using MEMS, one using clinical outcomes and one using MEMS and clinical outcomes). All 
six of these scales have been tested for content validity18,183,202-204,209 and four have also 
been tested for construct validity.18,183,202,203 
Adherence scales that solely focus on eliciting information regarding a patient’s beliefs about 
their medicines (Group 4) have not been assessed against objective measures of adherence.  
The Beliefs about Medicines Questionnaire and DAI have been significantly correlated with 
other adherence scales (Table 2.3). Both scales have been tested for content validity, in 
addition the Beliefs about Medicines Questionnaire has also been tested for construct 
validity.53,117 
Two out of the five Group 5 scales (beliefs and barriers) have assessed the correlation 
between the scale and an objective measure of adherence (both against MEMS). All five of 
the adherence scales have been correlated with subjective measures: other scale (n=3), 
self-report (n=1) and caregiver reports (n=1). Four of these adherence scales have also 
been correlated with objective measures of adherence (Figure 2.3). All of these adherence 
scales have been tested for content validity and three (BBQ, BEMIB and MARS-10) have 
been tested for construct validity.51,79,188 
 
Identifying Non-Adherence 
Many self-report adherence scales have recommended cut-offs for identifying non-adherent 
patients. Twenty-eight scales categorised medication adherence by determining the overall 
score and separating the population into two groups: adherent and non-
adherent.12,42,53,60,79,156,181,183,185-187,189,191-199,201,204,207-211 Where reported, the cut-off point to 
identify non-adherence is most commonly the score that corresponds to patients that took 
80% of their medicines as ascertained by an objective measure of adherence such as 
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MEMS. Some scales, such as the Beliefs and Behaviour Questionnaire (BBQ),188 suggest 
a cut-off point that corresponds to the score of another self-report adherence scale which 
has been seen to correspond to patients that took 80% of their medicines according to an 
objective measure. Other adherence scales, such as the DAI, AAI and MASES-R first split 
the population into adherent and non-adherent based upon responses to questions about 
whether medicines were taken or not, and then compared the mean scores of the adherence 
scales to determine the cut-off.53,183,204 The SERAD and Gehi et al. Adherence Question 
contain direct medication-taking behaviour questions and answers to these questions are 
utilised to determine the percentage of adherence and thus dichotomise adherence.12,210 
A small number of adherence scales have taken a different approach at assigning the 
adherence cut-off. The MAQ, MMAS, Brief Medication Questionnaire, ASRQ and VAS 
divided non-adherence into more than two groups, ranging from three to 
seven.18,164,184,190,205 This categorisation further differentiated between different levels of 
patient’s adherence to their medicines. The MAQ and MMAS categorised the population into 
high, medium and low levels of adherence.18,205 The MMAS cut-off points were selected 
based on the correlation with blood pressure control. The Brief Medication Questionnaire 
grouped the study population into repeat, sporadic and no non-adherence.190 The ASRQ 
and VAS classified non-adherence into six and seven levels, respectively based on the 
researchers’ expertise.164,184  
A small number of scales (12) have assessed the sensitivity and specificity of their cut-off 
against an objective measure of adherence. The results of these studies are reported in 
Table 2.3. 
 
 2.2.5 Discussion 
We identified 43 adherence scales that have been correlated with a comparison measure of 
adherence. The identified adherence scales elicit information regarding different facets of 
adherence including medication-taking behaviour, barriers to and determinants of 
adherence and beliefs associated with adherence. This information, where accurate, can be 
put to different uses. Self-report adherence scales can (i) measure medication-taking 
behaviour, where use of the scale either complements objective measures, or is used as an 
alternative to objective measures and/or (ii) identify reasons for a patient’s non-adherence, 
by identifying patient-specific barriers or beliefs that impede adherence. The data obtained 
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in this systematic review provides information on how well specific adherence scales can be 
expected to perform these tasks.  
Most of the scales identified as Group 1–3 focus on measuring medication-taking behaviour 
by asking direct questions about medication-taking behaviour or eliciting barriers to good 
medication-taking behaviour. Group 3 scales focus on barriers to adherence and have the 
potential to both measure medication-taking behaviour and identify barriers to adherence. 
The purpose of some Group 3 scales is to measure medication-taking behaviour by eliciting 
information on barriers, as opposed to providing a comprehensive assessment of patient 
barriers to adherence. The Medication Adherence Questionnaire (MAQ), for example, is a 
short four-item Group 3 scale that has been well validated against objective measures of 
adherence. The demonstration of a significant correlation between the adherence scale and 
a suitable objective measure in patients with the same disease seems a reasonable minimal 
requirement on the use of a scale as an alternative to an objective measure. Of the 36 Group 
1–3 adherence scales, 20 have been significantly correlated with either MEMS or clinical 
outcomes. Nine of the 36 adherence scales exploring medication-taking behaviour 
significantly correlated with the MEMS. The MEMS can record the time of dose actuation 
and can provide detailed information on medication-taking behaviour over time.165-167 Fifteen 
Group 1–3 adherence scales have been correlated with clinical outcomes. Few scales have 
been shown to be correlated with MEMS or clinical outcomes in multiple disease states, 
making the choice of a scale more difficult in patient groups other than those included in the 
validation studies. 
A link between specific levels of adherence and clinical outcomes has been demonstrated 
in some disease states (e.g. HIV60,82,83 and cardiovascular disease12,67,68). For the vast 
majority of disease states, however, no such link has been made.  Most scales provide 
suggested cut-offs for identifying “non-adherent” patients. Cut-offs permit the identification 
of patients who may be non-adherent and benefit from education or support. However, the 
arbitrary nature of the cut-offs provided for most self-report adherence scales needs to be 
kept in mind. Dichotomising adherence does not differentiate between types of non-
adherence, repeat versus sporadic adherence or patients at different stages of the 
medication-taking process. Recent taxonomies of adherence recognise the dynamic nature 
of patient medication-taking behaviour. Vrijens et al. acknowledges that the process of 
medication-taking starts when the patient takes the first dose of medicine (initiation) 
continues with the implementation of the regimen and ends when the patient discontinues 
the medicine.38 Gearing et al. proposes a six-phase dynamic model of adherence: treatment 
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initiation, treatment trial, partial treatment acceptance, intermittent treatment adoption, 
premature discontinuation and adherent.19 An important area for future research is the use 
of self-report adherence scales to identify the different types of non-adherence suggested 
by Vrijens et al. 38 and Gearing et al.19 
A substantial number of scales have been validated against clinical outcomes, but no direct 
measure of medication-taking behaviour such as MEMS; examples include the Barroso 30-
day Adherence Question and the Hill-Bone Compliance Scales. A demonstrated correlation 
between a self-report adherence scale and clinical outcomes in a specific patient population 
has relatively clear benefits for use of the scale in similar populations of patients. Knowing 
when this evidence is transferrable into new populations of patients, however, is challenging. 
For most disease states there are influences on clinical outcomes in addition to medication-
taking behaviour. Factors that influence clinical outcomes play a part in addition to the many 
factors that may separate measures of adherence by self-report adherence scales from 
actual medication-taking behaviour. No doubt some of these scales have focused on clinical 
outcomes due to the availability of clinical data and the relative cost or availability of MEMS. 
However, validation of a scale against both clinical outcomes and direct measures of 
medication-taking behaviour is beneficial. 
Scales included in Group 2 to 5 include items that elicit reasons a patient may be non-
adherent. These scales may identify barriers the patient is experiencing to good medication-
taking behaviour, and any patient-specific beliefs about their medicines that may influence 
adherence. While some Group 3 scales focus more on measuring medication-taking 
behaviour (e.g. the Medication Adherence Questionnaire (MAQ)), others seek more detailed 
information on barriers that an individual may be experiencing (e.g. the Pediatric Inhaler 
Adherence Questionnaire). Scales included in Group 4 and 5 seek to identify patient beliefs 
about medicines that may influence adherence. Of these scales, the most extensively 
assessed is the Beliefs about Medicines Questionnaire (BMQ). The BMQ-Specific identifies 
whether patients hold the belief that their medicine is necessary as well as whether the 
patient has concerns about their medicine.  
Scales that focus on identifying reasons for non-adherence appropriately employ validation 
strategies focused on content and construct validity. The BMQ is a good example of a self-
report adherence scale focused on measuring an aspect of adherence other than 
medication-taking behaviour. The items of the BMQ have been validated through 
confirmatory principle components analysis and the criterion and divergent validity assessed 
against similar items in the Illness Perceptions Questionnaire and the Sensitive Soma 
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Scale.117 The BMQ-Specific has been shown to correlate well with medication-taking 
behaviour measured by self-report adherence scales. Patients who believe their medicine 
to be necessary and have fewer concerns have consistently been shown to be more 
adherent in a range of diseases.95,127-130 
Scales such as the BMQ are not stand-alone comprehensive adherence scales. But, like 
scales that focus on identifying barriers to adherence, they provide the opportunity for a 
more comprehensive assessment of a patient’s adherence—and the drivers behind that 
adherence—than subjective or objective measures that focus on measuring medication-
taking behaviour. The information provided by self-report adherence scales that seek to 
identify barriers and beliefs that are influencing adherence may prove useful in addition to 
accurate information on the patient’s medication-taking behaviour. Specifically, these scales 
may help inform tailored interventions to improve medication adherence, but their use for 
this purpose is yet to be assessed.   
Limitations 
This systematic review only included studies of self-report adherence scales that included a 
comparison measure of medication-taking behaviour. This was deemed appropriate given 
the importance of measuring medication-taking behaviour in assessing adherence. A 
consequence of this criterion is that this study does not provide a comprehensive analysis 
of the validation of self-report adherence scales.  
 
 2.2.6 Conclusions 
Self-report adherence scales have the potential to measure both medication-taking 
behaviour, and identify barriers and beliefs associated with adherence. Selecting an 
adherence scale requires consideration of what the adherence scale measures and how 
well it has been validated. Research on validating and using the existing adherence scales 
as a measure for medication-taking behaviour is relatively strong. There has been less focus 
on assessing how information gained from scales that identify patient-specific barriers and 
beliefs associated with adherence may be used to support wise medicine use. This presents 
an important and exciting avenue for further research.  
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2.3 Additional Notes 
Since publishing the systematic review on validated medication adherence scales in the 
British Journal of Clinical Pharmacology (BJCP), a number of new adherence scales have 
been developed. The Reasoning and Regulating Medication Adherence Instrument is 
currently in the initial stages of development testing. This 16-item adherence scale is 
designed to identify barriers to adherent behaviour in patients with coronary artery 
disease.298 Krousel-Wood et al. recently developed a four-item adherence scale and 
validated the scale in patients with uncontrolled hypertension against the MMAS and Hill-
Bone Compliance Scale. This adherence scale measures both medication-taking behaviour 
and barriers to adherence.299 A new adherence scale was developed to assess a number 
of structural barriers to adherence in patients prescribed antiretroviral therapy. The barriers 
to adherence identified using this adherence scale included stigmatism from others, 
forgetfulness, preference to use complementary medicines and cost barriers.300 The 
Adherence Barriers Questionnaire was recently developed to identify barriers to adherence 
and has been validated in participants with atrial fibrillation.301 Kleepe et al. developed the 
Probabilistic Medication Adherence Scale and validated in elderly patients taking chronic 
medications.302 A number of the adherence scales in the systematic review, such as the 
MARS and OS-MMAS have been further validated.303,304  
 
2.4 Summary 
Self-report adherence scales have the potential to measure medication-taking behaviour, 
and/or identify some of the barriers and beliefs that may be associated with adherence. 
Selecting an adherence scale requires consideration of what the adherence scale measures 
and how well it has been validated. Research on validating and using the existing self-report 
adherence scales as a measure of medication-taking behaviour is relatively strong. There 
has been less focus on assessing how information gained from scales that identify patient-
specific barriers and beliefs associated with adherence may be used to support wise 
medicine use. This presents an important and exciting avenue for further research. Chapter 
Three presents the methods of the randomised controlled trial of a targeted and tailored 
intervention to improve adherence and how the MAQ and BMQ-S are integrated within this 
intervention.  
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CHAPTER THREE: METHODS OF 
RANDOMISED CONTROLLED TRIAL TO 
IMPROVE MEDICATION ADHERENCE 
 
3.1 Introduction  
 
Improving adherence to medications can reduce the risk of adverse health outcomes and 
health care expenditure (Section 1.3). Insight into the patient’s medication-taking behaviour 
and reasons for behaviour may aid the implementation of tailored strategies to support 
patients to adhere to their medications. There are many objective and subjective measures 
of adherence that can provide information in relation to a patient’s medication-taking 
behaviour.15,231,245,256,268 Objective measures of adherence, include electronic monitoring of 
medication administration (e.g. Medication Event Monitoring System, MEMS), prescription 
records and dose counts. These measures are often good at measuring medication-taking 
behaviour, but can be expensive, labour-intensive and do not provide information on 
reasons for behaviour. Subjective measures of adherence include physician reports, self-
report and adherence scales. Subjective measures are prone to recall and social desirability 
bias, but they are often easy to administer and provide the opportunity to explore why the 
patient may be non-adherent.  
Many interventions have been implemented to improve adherence to medications, including: 
reminder systems (text reminders, dose administration aids); behavioural-counselling 
(motivational interviewing); social support (peer support therapy); cognitive-educational 
(verbal information) and measurement-guided management (Section 1.6).214,305 Many 
adherence interventions have failed to improve adherence to medications and clinical 
outcomes when tested in clinical trials.13-15,217 A systematic review by Haynes et al., found 
36 out of 83 interventions improved adherence to a chronic medication and only 25 of the 
interventions were shown to improve a clinical outcome.306 One of the challenges in this 
area is that few studies of adherence interventions are sufficiently powered to show benefit 
in important clinical outcomes. These studies may be reported as a negative result despite 
an improvement in measures of adherence.306 
Further reasons for the lack of success seen when assessing adherence interventions in 
clinical studies are that many have not been targeted to participants who are non-
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adherent215,221,225,227,229 or tailored to the participant-specific reasons for non-
adherence.13,15,217,223 Although a targeted and tailored approach to improve medication 
adherence has been suggested in the literature,1,126,187,203 few studies to date have adopted 
this approach.216,247 Measurement-Guided Medication Management (MGMM), which uses 
electronic data on the patients’ medication-taking behaviour from MEMS to inform 
discussion between the patient and their health professional about potential barriers to 
adherence, is a good example of a targeted and tailored approach that has been observed 
to improve medication adherence.214 We conducted a systematic review on validated 
adherence scales (Chapter Two), and found that adherence scales were relatively easy to 
administer and may elicit information in addition to medication-taking behaviour, such as 
barriers to adherence and beliefs associated with adherence.213 A number of adherence 
scales may be selected to identify key aspects of adherence required for the study. We 
believe that validated adherence scales can be used to inform a measurement-guided 
medication management approach to adherence in a way that is very similar to how MEMS 
has been used.  
This chapter will describe the methods of a randomised controlled trial of a targeted and 
tailored intervention to improve adherence to cardiovascular medications. We chose 
cardiovascular medications for this study because cardiovascular disease is a great burden 
on society, particularly in developed countries.1 Over 50% of patients on cardiovascular 
medications are non-adherent,7,65 resulting in increased hospital admissions and 
cardiovascular events (See Section 1.3.2). Other risk factors for cardiovascular disease 
include dyslipidaemia, hypertension and hyperglycaemia. Diabetes is considered a strong 
independent risk factor for cardiovascular disease and as described in section 1.3.2, non-
adherence to diabetic medications resulting in hyperglycaemia increases the likelihood of 
people developing cardiovascular disease.1,72,73 Therefore due to the close link between 
medication non-adherence in these diseases and poor clinical outcomes, it was decided that 
our target population should include both cardiovascular and diabetes medications.  
 
3.2 Aims and Hypotheses 
 
The primary aim of the study was to determine if a targeted and tailored intervention based 
on a discussion informed by validated adherence scales, would improve adherence to a 
recently initiated cardiovascular medication. 
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The secondary aims of the study were exploratory. We hoped to learn about changes in 
adherence over time, in the groups studied. 
It was hypothesised that: 
H1 Targeting and tailoring an intervention based on a discussion informed by adherence 
scales in participants identified as non-adherent using the MAQ, will improve adherence at 
three months. 
H2 Improvements in adherence at three months, identified by the MAQ, will be sustained at 
six months. 
H3 Adherence, and reasons for non-adherence, will change over time in all groups studied.  
 
3.3 Methods                                                    
This was a randomised controlled trial recruiting participants who recently initiated a 
medicine for chronic cardiovascular disease (hypertension, dyslipidaemia, type II diabetes 
and other cardiovascular diseases). The recruitment of participants occurred between the 
25th of March, 2013 and 24th July, 2013 at one of two community pharmacies in Brisbane. 
Participants were followed for six months from recruitment, the last participant contact 
occurring on the 10th February, 2014. This trial is registered on the Australian New Zealand 
Clinical Trials Registry, which can be accessed at http://www.anzctr.org.au/ using trial ID 
ACTRN12613000162718. Ethical approval was obtained from the School of Pharmacy 
Ethics Committee, University of Queensland (approval number 92013/5) (Appendix A). 
 
 
 3.3.1 Setting  
Participants were recruited from two community pharmacies in Brisbane, Australia. The two 
pharmacies were selected based on convenience as the researcher has an established 
relationship with these pharmacies. The pharmacies selected for participation in the study 
serviced a broad range of patients with chronic diseases. These pharmacies were 
approached by the researcher and were provided with information on the study. Once the 
pharmacies agreed to the study taking place, the dates for participant recruitment were 
organised.  
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Individuals waiting in the pharmacy for their prescription(s) to be dispensed were recruited 
by the researcher. The researcher asked the individual if they were willing to take part in a 
study and if they agreed to participate, the individual was provided with verbal and written 
information about the study. If the individual still wished to participate in the study after reading 
the provided information (Appendix B), written informed consent (Appendix C) was obtained. 
Participants were interviewed in the semi-private counselling area of the pharmacies. 
 
 3.3.2 Inclusion Criteria 
The inclusion of an individual in the study depended on the individual’s attendance at one 
of the selected pharmacies on the days that the researcher was present at the pharmacy.  
Individuals who were over 18 years of age, who were recently prescribed a medication for 
hypertension, type 2 diabetes, dyslipidaemia or other cardiovascular diseases (myocardial 
infarction, heart failure, arrhythmias, and stroke) within the last four to 12 weeks were 
included in the study. If multiple medications were prescribed within the last four to 12 weeks, 
then the most recently initiated medication was selected. This standardises the sample as 
all participants would be at a similar phase of taking their medicine. All participants would 
have had the opportunity to take their recently initiated medicine for at least four weeks and 
thus have some experience with their medicine. Individuals were approached if they had 
recently initiated an ACE inhibitor, angiotensin II receptor antagonist, calcium channel 
blocker, lipid-lowering agent or an oral hypoglycaemic drug. Clinical practice guidelines were 
taken into account and participants recently initiated on a diuretic for hypertension were not 
included in the study. Individuals who were unable to complete the survey tool were 
excluded from the study. 
 
 3.3.3 Participant Interviews 
The Medication Adherence Questionnaire (MAQ) was used to identify medication-taking 
behaviour based on the MAQ score. Participants with a MAQ score of zero were classified 
as adherent and were enrolled and followed for six months. Participants with a MAQ score 
of 1 to 4 were classified as non-adherent. Non-adherent participants were then randomised 
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into either the intervention or control group, using block randomisation and followed for six 
months (Figure 3.1). The random allocation sequence was generated by an internet-based 
randomisation software (Research Randomiser). The block size was ten, providing an 
allocation ratio of 1:1 (e.g. ABBABABAAB). The intervention group received a tailored 
intervention at baseline to improve medication adherence. Due to the nature of the 
intervention, neither the researcher, nor the participants were blinded to the allocation at the 
baseline interview. No data analysis occurred prior to completion of the study. 
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Figure 3.1 Participant flow diagram: from identifying participants’ medication-taking 
behaviour to final follow-up 
 
 
Screened for eligibility 
Enrolment of patients 
ADHERENT Non-Adherent 
Randomised 
INTERVENTION CONTROL 
Follow-Up                    
at 3 months 
 
Follow-Up                    
at 3 months 
 
Follow-Up                    
at 3 months 
 
Final Follow-Up          
at 6 months 
 
Final Follow-Up          
at 6 months 
 
Final Follow-Up          
at 6 months 
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All interviews were conducted by the principal researcher (TN), who is a registered 
pharmacist. The researcher (TN) conducted the initial interview and follow-up telephone 
calls at three and six months. The survey instruments used in the interview included the: 
MAQ, Beliefs about Medicines Questionnaire – Specific (BMQ-S) and Brief Illness 
Perception Questionnaire (BIPQ). Field notes were taken during the interviews.  
Baseline demographic characteristics of the participants were also collected (Appendix D). 
All participants were followed for six months with telephone interviews at three- and six-
month time points to complete the same three validated scales: the MAQ, BMQ-S and BIPQ. 
 
Medication Adherence Questionnaire (MAQ) 
The four-item MAQ was selected because it has been well-validated to identify adherence 
in a number of chronic cardiovascular disease populations and scores have been shown to 
correlate well with a range of objective adherence measures, as described in Chapter 
Two.18,72,293,296 The MAQ has also been used to explore reasons for non-adherent 
behaviour.18 Specifically, the MAQ has been used to identify unintentional non-adherence, 
intentional non-adherence or a mix of both.49  
Participants answering no to all items of the MAQ (MAQ score = 0) were identified as 
adherent to their medicine (Table 3.1).72,95,204,307 These participants were followed for six 
months in the “adherent” group. Participants answering yes to at least one of the MAQ items 
(MAQ score = 1 to 4) were identified as “non-adherent” and were randomised to either the 
intervention or control group. This cut-off was chosen for the study because it has been used 
in the literature in previous studies,72,95,204,307 and the cut-off at this value provides a highly 
sensitive tool for identifying medication non-adherence. It should be noted that the MAQ was 
used as a measure of adherence, and does not differentiate between frequently missed 
doses and occasional missed doses. 
Participant responses to the MAQ were also used to identify the participant’s reasons for 
non-adherence, for instance: unintentional non-adherence due to being forgetful or careless, 
or intentional non-adherence by ceasing their medicines when they felt better or worse and, 
a mix of both types (Table 3.1).  
Unintentional non-adherence: participant answers yes to items 1 or 2 and no to both items 
3 and 4 
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Intentional non-adherence: participant answers no to both items 1 and 2 and yes to items 3 
or 4 
Both types (mixed): participant answers yes to items 1 or 2 and also yes for items 3 or 4 
 
Table 3.1 The Medication Adherence Questionnaire (MAQ) 
Item Question YES NO Score 
1 Do you ever forget to take your medicine?    
2 Are you careless at times about taking your medicine?    
3 When you feel better, do you sometimes stop taking your 
medicine? 
   
4 Sometimes, if you feel worse when you take the 
medicine, do you stop taking it? 
   
Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication 
adherence. Med Care 1986;24(1):67-74. 
 
 
 Beliefs about Medicines Questionnaire – Specific (BMQ-S) 
The BMQ-S has been validated in many disease populations, including hypertension, 
coronary heart disease, asthma and depression, as shown in Chapter Two (Table 3.2).117,124 
The BMQ-S elicits an individual’s beliefs about their medicines in the domains of necessity 
of medicines and concerns about medicines. In general, individuals who have strong 
concerns about their medicines or believe their medicines are not necessary tend to be less 
adherent.4,117,126,131,153 
All participants were interviewed using the BMQ-S to measure perceived necessity of and 
concerns about medicines.117 The BMQ-S consists of ten statements about medicines: five 
of the statements are related to beliefs about the necessity of medicines and the remaining 
five statements are related to concerns that individuals may have about their medicines. 
Statements 1, 3, 4, 7 and 10 refer to beliefs that medicines are necessary and statements 
2, 5, 6, 8 and 9 refer to concerns about medicines (Table 3.2).  The participants rated each 
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of the statements on a five-point Likert scale: strongly agree, agree, uncertain, disagree and 
strongly disagree. The responses for each statement were scored as follows: strongly agree 
= 5, agree = 4, uncertain = 3, disagree = 2 and strongly disagree= 1. Therefore, the scores 
for the necessity or concerns domains range from 5 to 25. The information obtained from 
the BMQ-S further informed the discussion to help tailor the adherence support strategy to 
the participant based on their necessity and/or concerns score and therefore their beliefs 
towards their medicines. 
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Table 3.2 The Beliefs about Medicines Questionnaire - Specific (BMQ-S) 
Item Statement Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
1 My health at present, 
depends on my medicines 
     
2 Having to take medicines 
worries me 
     
3 My life would be impossible 
without my medicines 
     
4 Without my medicines I 
would be very ill 
     
5 I sometimes worry about 
long-term effects of my 
medicines 
     
6 My medicines are a mystery 
to me 
     
7 My health in the future will 
depend on my medicines 
     
8 My medicines disrupt my life      
9 I sometimes worry about 
becoming too dependent on 
my medicines 
     
10 My medicines protect me 
from becoming worse 
     
Horne R, Weinman J, Hankins M. The Beliefs about Medicines Questionnaire: the development and evaluation 
of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14(1):1-24. 
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Brief Illness Perception Questionnaire (BIPQ) 
Illness representations identified in the BIPQ has been associated with adherence to 
medications.135,139 For example, patients with hypertension were more likely to be adherent 
if they felt they had good control over their illness, better understanding of their illness and 
were not emotionally affected by their illness. The BIPQ consists of nine items that assess 
the cognitive and emotional representations of illness.139 The first eight items were rated on 
a scale of 0 to 10 (Table 3.3). This questionnaire provided insight into a participant’s 
perceptions and understanding of their illness and treatment. The participant’s perceptions 
and understanding of their illness and treatment was elicited to explore why the participant 
may be non-adherent to their medication. 
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Table 3.3 The Brief Illness Perception Questionnaire 
How much does your illness affect your life? 
 
0               1               2              3             4             5            6            7            8            9           10 
no affect                                                                                                                                      severely affects 
at all                                                                                                                                            life 
 
How long do you think your illness will continue?  
 
0               1               2              3             4             5            6            7            8            9           10 
a very                                                                                                                                            forever                                           
short time 
                                                                                                                                              
How much control do you feel you have over your illness? 
 
0               1               2              3             4             5            6            7            8            9           10 
absolutely                                                                                                                                    extreme  
no control                                                                                                                                    amount of    
                                                                                                                                                    control 
                                                                                                                                                
How much do you think your treatment can help your illness? 
 
0               1               2              3             4             5            6            7            8            9           10 
not at all                                                                                                                                       extremely 
                                                                                                                                                     helpful 
                                                                
How much do you experience symptoms from your illness? 
 
0               1               2              3             4             5            6            7            8            9           10 
no symptoms                                                                                                                              many severe                                     
at all                                                                                                                                            symptoms 
 
How concerned are you about your illness? 
 
0               1               2              3             4             5            6            7            8            9           10 
not at all                                                                                                                                       extremely                          
concerned                                                                                                                                    concerned        
                       
How well do you feel you understand your illness? 
 
0               1               2              3             4             5            6            7            8            9           10 
don’t understand                                                                                                                          understand                                       
at all                                                                                                                                             very clearly 
 
How much does your illness affect you emotionally? (e.g. does it make you angry, scared, upset or 
depressed? 
 
0               1               2              3             4             5            6            7            8            9           10 
not at all                                                                                                                                        extremely                              
affected emotionally                                                                                                                      affected   
                                                                                                                                                      emotionally         
              
Please list in rank-order the three most important factors that you believe caused your illness. The 
most important causes for me:    1. ________________ 2. _________________ 3. __________________ 
                                                                                                
Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. J Psychosom Res 
2006;60(6):631-7. 
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3.3.4 Intervention 
This study employed a form of measurement-guided medication management to improve 
adherence (Section 1.6.2). The intervention consisted of the following. Non-adherent 
participants were identified using the MAQ. The participant’s type and reasons for non-
adherence were explored using their responses to the MAQ, BMQ-S and BIPQ. Where 
possible the researcher used responses to the adherence scales to prompt further 
discussion regarding the participant’s adherence and the factors that supported or impeded 
them to take their medicine. Any issues with the participant’s other medications that were 
brought up during the interview were discussed and formed part of the individualised 
conversation with the participant. Any issues that could not be resolved were referred to the 
pharmacist on duty in each pharmacy (See case examples in Chapter Five for more details). 
From the information discussed in the interview, the researcher and participant then selected 
and implemented a strategy from an evidence-based toolkit (based on literature review, 
Section 1.6) to support the participant’s adherence. The evidence-based toolkit consisted of 
strategies shown to improve adherence in specific situations. For example, some 
participants who stated they forget to take their medicine on the MAQ may be asked: How 
often they forget? Where they store their medicines? Or why they think they forget to take 
their medicine? This information helped determine whether the participant would benefit 
from a reminder and the specific type of reminder. Participants who indicated that they 
intentionally ceased their medicine on the MAQ and indicated that they had a poor perceived 
understanding of their illness on the BIPQ, were asked what they knew about their illness 
and/or medicine to help tailor education or information provided to them on their illness or 
medicines (cognitive-educational intervention). Notes from the discussion were transcribed 
immediately after the interview.  
Strategies employed to support the participant’s adherence included13,14,214,305: 
 reminder systems (dose administration aids, dosette boxes, alarm clock reminders, 
text reminders, treatment simplification);  
 cognitive-educational interventions (pharmacist verbal information, written 
information);  
 reminder systems coupled with cognitive-educational interventions;  
 behavioural-counselling interventions (reinforcing behaviour, empowering individuals 
to actively participate in their healthcare and problem-solving) and 
 social support interventions (family member support). 
 80 
 
 
Case Example  
Below is an example of how interventions were tailored based on the survey responses and 
discussion with the participant. For in-depth discussion on how the interventions were 
tailored, see Chapter Five.   
 
A married and retired 66 year old female participant with tertiary qualifications currently takes 
four prescription medications for the treatment of hypertension, dyslipidaemia and 
hypothyroidism. The participant has recently started ezetimibe 10mg once daily to lower 
blood cholesterol levels. 
Intervention 
MAQ: The participant had a MAQ score of 1 and identified as unintentionally non-adherent 
due to forgetfulness. 
BMQ-S: The participant’s perceived necessity beliefs outweighed her concerns about the 
medicine 
BIPQ: The BIPQ suggests that she perceives her medicine as highly valuable and has a 
good understanding of her illness. 
Discussion: To better understand her medication-taking behaviour, the participant was 
asked to elaborate where she stored her medicines and circumstances when she would 
forget to take her medicines. The researcher learnt that the participant stored the medicines 
in many different places (e.g. a medicine in her handbag when leaving home, in the kitchen 
and some in the bathroom). She often forgets to take her medicines when she is out, when 
she is busy with a task and often when travelling. 
Adherence Strategy: The researcher recommended keeping all her medicines together at 
one convenient location. The researcher also suggested using an alarm clock to help remind 
her to take medicines on time and using a dosette box, especially when travelling.  
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 Summary of Intervention 
The MAQ was used to identify participants who were non-adherent to their medication and 
to determine whether participants were exhibiting unintentional, intentional or both types of 
non-adherence. The BMQ-S elicited beliefs about medicines in regards to whether the 
participant believed their medication was necessary and whether they had any concerns 
towards their medication. The BIPQ was used to explore illness perceptions, such as the 
effect of the illness on their lives, whether they believed their medication was helpful in 
treating their illness and their understanding of their illness. The responses to the MAQ, 
BMQ-S and BIPQ informed the discussion with the participant, which guided the 
implementation of a tailored strategy to improve their adherence. 
 
3.3.5 Outcome Measures 
The primary outcome was the difference in the mean MAQ score between the intervention 
and control group at three months. The difference in mean MAQ score between the 
intervention and control group was also tested at six months. A post hoc analysis was 
conducted to assess whether changes in survey responses were consistent with the specific 
adherence strategy employed. 
 
 3.3.6 Sample Size  
A power calculation was conducted based on the effect size observed in a hypertension 
adherence study by Morisky et al.260 Morisky et al. implemented an educational intervention 
to improve adherence in people with hypertension and observed a difference in mean MAQ 
scores between intervention and control of 0.683, which was associated with a clinically 
significant improvement in blood pressure control. For our study, a one-sided t-test was 
conducted to calculate the target sample size. Forty-one participants per group (intervention 
and control) provided 80% power to detect a statistically significant change in adherence at 
a level of 0.05. Taking into account participants dropping out of the study, our sample size 
target would be 60 per group (intervention and control). 
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3.3.7 Statistical Analyses 
Baseline demographics of the intervention and control groups were compared using t-tests 
for continuous data and Pearson’s Chi-squared test and Fisher’s exact tests for categorical 
data.  
An independent-samples t-test was conducted to compare the mean MAQ score of the 
intervention and control group, based on an intention-to-treat and per protocol population 
using R (version 3.0.2) statistical software, at three months and six months.  
Changes in the questionnaires scores at three months and six were compared for each of 
the adherent, intervention and control groups using dependent-samples t-tests.  
Changes in the questionnaires scores at three and six months were also observed in the 
different strategy types in the intervention group. 
 
 
3.4 Summary 
 
This chapter describes the method of the randomised controlled trial of a targeted and 
tailored interventions to improve adherence in participants identified as non-adherent. 
Information obtained from the MAQ, BMQ-S, BIPQ and discussion with the participant was 
used to help tailor an intervention to improve adherence. Chapter Four addresses the results 
of the randomised controlled trial of a targeted and tailored intervention to improve 
adherence to medications in participants with chronic diseases.  
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CHAPTER FOUR: RESULTS 1 - A 
RANDOMISED CONTROLLED TRIAL OF A 
TARGETED AND TAILORED 
INTERVENTION TO IMPROVE 
MEDICATION ADHERENCE 
 
4.1 Introduction 
Chapter Three described the method of a randomised controlled trial of a targeted and 
tailored intervention in participants recently initiated on a medicine for the treatment or 
prevention of cardiovascular disease. The tailored strategy to improve adherence in non-
adherent participants was informed by a discussion with the participant, which was guided 
by the participant’s responses to the Medication Adherence Questionnaire (MAQ), Beliefs 
about Medicines Questionnaire-Specific (BMQ-S) and Brief Illness Perception 
Questionnaire (BIPQ). 
This chapter presents the main results of the randomised controlled trial of targeted and 
tailored interventions to improve medication adherence. 
Chapter Four addresses the following hypotheses: 
- Hypothesis 1: Targeting and tailoring an intervention based on a discussion informed 
by adherence scales in participants identified as non-adherent using the MAQ, will 
improve adherence at three months. 
- Hypothesis 2: Improvements in medication adherence, as measured by the MAQ, at 
three months will be sustained at six months. 
This chapter will report the beliefs and illness perceptions between the adherent, 
intervention and control groups.  
 
4.2 Results  
A total of four hundred and eight individuals, visiting the two community pharmacies, were 
assessed for eligibility, of which 152 participants were enrolled into the study (Figure 4.1). 
The results from the MAQ classified 32 participants as adherent and 120 participants were 
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classified as non-adherent. Participants classified as non-adherent were randomised 1:1 to 
intervention or control. At six months, there were 55 participants remaining in the 
intervention group and 45 participants in the control group. The movement of participants 
throughout the study is shown in Figure 4.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 85 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Participant flow diagram 
 
 
 
 
 
Screened for eligibility (n=408) 
Excluded (n =256)                             
- Not on a recently initiated medicine (n=163) 
- Not on medication of interest (n=76) 
- Declined to participate (n=12) 
- Judged unable to participate in study: (n=5) 
 
Enrolment of patients (n=152) 
ADHERENT (n=32) Non-Adherent (n=120) 
Randomised (n=120) 
INTERVENTION (n=60) CONTROL (n=60) 
3 Months (n=57) 3 Months (n=28) 
 
3 Months (n=52) 
6 Months (n=55)  
 
6 Months (n=45)  
 
6 Months (n=28)  
 
-Withdrew (n=8)   -Withdrew (n=3)   -Withdrew (n=4)   
-Withdrew (n=1)             
-Death (n=1)  
 
-Withdrew (n=6)             
-Death (n=1)  
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4.2.1 Participant Baseline Demographics 
Participants in the adherent group had a mean age of 64.6 years and 59.4% were female. 
The participants classified as non-adherent (intervention and control) using the MAQ had a 
mean age of 63.5 years. Of these participants, 66 (55%) were female and 98 (81.7%) had 
attained secondary school qualifications or higher. Most of these participants were married 
(60.8%), retired (52.5%) and had an annual salary of less than $30000 (46.7%). There were 
no significant differences in the demographics between the intervention and control groups 
at baseline. There were also no significant differences in the baseline demographics 
between the adherent and non-adherent (intervention and control) groups (Table 4.1). 
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Table 4.1 Baseline participant demographics 
 Adherent 
n=32 
Intervention 
n=60 
Control 
n=60 
       Age (years), mean (SD) 64.6 (13.6) 64.4 (11.3) 62.6 (13.4)                      
       Sex (males) 
 
13 (40.6%) 29 (48.3%) 25 (41.7%) 
Education level 
       Primary 
       Secondary 
       Tertiary 
 
 
6 (18.8%) 
16 (50.0%) 
10 (31.2%)  
 
13 (21.7%) 
32 (53.3%) 
15 (25.0%) 
 
9 (15.0%) 
37 (61.7%) 
14 (23.3%) 
Employment 
       Employed 
       Unemployed 
       Retired 
 
 
11 (34.4%) 
3 (9.4%) 
18 (56.2%) 
 
21 (35.0%) 
5 (8.3%) 
34 (56.7%) 
 
19 (31.7%) 
12 (20.0%) 
29 (48.3%) 
Annual Salary (before tax deduction) 
       ≤ $30 000 
       $31 000 - 50 000 
       $51 000 - 70 000 
       $71 000 - 90 000 
       Over $90 000 
 
 
13 (40.6%) 
5 (15.6%) 
7 (21.9%) 
2 (6.3%) 
5 (15.6%) 
 
30 (50.0%) 
10 (16.7%) 
9 (15.0%) 
8 (13.3%) 
3 (5.0%) 
 
26 (43.3%) 
11 (18.3%) 
16 (26.7%) 
4 (6.7%) 
3 (5.0%) 
Marital Status 
       Married 
       Divorced 
       Widowed 
       Single 
 
 
21 (65.6%) 
4 (12.5%) 
4 (12.5%) 
3 (9.4%) 
 
38 (63.4%) 
8 (13.3%) 
8 (13.3%) 
6 (10.0%) 
 
35 (58.3%) 
11 (18.3%) 
7 (11.7%) 
7 (11.7%) 
Total Number of Medicines 
       Medications, mean (SD) 
 
6.4 (3.2) 
 
5.7 (2.6) 
 
5.0 (2.6) 
       Complementary medicines,    
                               mean (SD) 
 
 
1.4 (1.4) 
 
 
0.85 (1.1) 
 
 
0.93 (1.3) 
 
Medical Conditions 
       Hypertension 
       Dyslipidaemia 
       Diabetes mellitus 
       Heart failure  
       Atrial Fibrillation 
       Myocardial infarction 
       Stroke 
       Asthma 
       COPD 
       Depression 
       Osteoarthritis 
       Osteoporosis 
       Gout 
       GORD 
       Thyroid conditions 
       Other 
 
26 (81.3%) 
21 (65.6%) 
12 (37.5%) 
3 (9.4%) 
6 (18.8%) 
5 (15.6%) 
3 (9.4%) 
7 (21.9%) 
1 (3.1%) 
7 (21.9%) 
10 (31.2%) 
0 (0.0%) 
0 (0.0%) 
4 (12.5%) 
1 (3.1%) 
7 (21.9%) 
 
49 (81.7%) 
39 (65.0%) 
24 (40.0%) 
8 (13.3%) 
7 (11.7%) 
5 (8.3%) 
4 (6.7%) 
9 (15.0%) 
2 (3.3%) 
12 (20.0%) 
19 (31.7%) 
6 (10.0%) 
2 (3.3%) 
10 (16.7%) 
3 (5.0%) 
17 (28.3%) 
 
48 (80.0%) 
39 (65.0%) 
25 (41.7%) 
5 (8.3%) 
4 (6.7%) 
10 (16.7%) 
5 (8.3%) 
9 (15.0%) 
1 (1.7%) 
12 (20.0%) 
17 (28.3%) 
3 (5.0%) 
5 (8.3%) 
5 (8.3%) 
3 (5.0%) 
20 (33.3%) 
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4.2.2 Intervention 
The mean length of the baseline interview for the adherent group was 10.2 ± 1.6 minutes, 
intervention group (including implementation of tailored strategy) was 13.5 ± 2.9 minutes 
and control group was 11.8 ± 2.8 minutes. 
The tailored strategies implemented by the principal researcher, are shown in Table 4.2. 
Reminder systems accounted for 45% of the strategies that were implemented. 
 
 
Table 4.2 Types of tailored strategies implemented to improve medication adherence 
 
 
4.2.3 Adherence 
The mean MAQ score at baseline in the intervention, 1.58: 95% CI [1.38, 1.78], and control, 
1.60: 95% CI [1.43, 1.77], groups were not statistically different. At three months, based on 
intention-to-treat, the mean MAQ score in the intervention group was significantly lower than 
the control group, reflecting an improvement in adherence (mean MAQ score 0.42: 95% CI 
[0.27, 0.57] vs 1.58: 95% CI [1.42, 1.75]; p<0.001). The significant improvement in MAQ 
score in the intervention group compared to control was sustained at six months (0.48: 95% 
Strategy Intervention 
Group 
n = 60 
Examples of the Strategy 
Reminder systems 27 (45.0%) - Dose administration aids 
- Alarm reminders 
- Simplifying treatment regimens 
Reminder systems and 
Cognitive-educational 
15 (25.0%) - Dosette box and verbal or written 
information 
Cognitive-educational 9 (15.0%) - Disease-specific and medication 
counselling  
- Written information 
Social support 
 
5 (8.3%) - Support from a family member 
Behavioural-counselling 4 (6.7%) - Health coaching 
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CI [0.31, 0.65] vs 1.48: 95% CI [1.27, 1.69]; p<0.001). This represents a statistically 
significant improvement in the primary endpoint at three and also at six months (p<0.001) 
(Figure 4.2). Similar results were observed on the per protocol analysis; mean MAQ score 
intervention vs control at 3 months and 6 months was 0.33 vs 1.54, p<0.001 and 0.42 vs 
1.44, p<0.001, respectively. From now on, only the results from the intention-to-treat 
analysis are presented.   
The mean MAQ score in the adherent group increased significantly from zero at baseline to 
0.22: 95% CI [0.05, 0.39] at three months (p < 0.05). The significant increase in mean MAQ 
score in the adherent group was not sustained at six months. 
 
On a more individual level, we observed that at three months, 53 of the 60 (88.3%) 
participants in the intervention group showed a reduction in their MAQ score, reflecting an 
improvement in adherence. In the control group, seven of the 60 (11.7%) participants 
showed an improvement in their MAQ score. The greatest individual improvement was a 
MAQ score of four to zero.  
 90 
 
 
 
Figure 4.2 Mean MAQ scores (± 95% CI) at baseline, 3-month and 6-month follow-ups, based on intention to treat analysis  
(*** p <0.001 – Mean MAQ score in intervention group was significantly lower than control at both three and six months)                                               
Note: decreasing MAQ score reflects improvement in medication adherence
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4.2.4 Changes in mean BMQ-S scores between the three groups over time  
The changes in the BMQ-S necessity and concerns scores at three and six months are 
shown in Table 4.3. At baseline there were no statistically significant differences in the mean 
BMQ-S necessity and concerns scores between the adherent and non-adherent 
(intervention and control) groups. At three and six months, the mean BMQ-S concerns 
scores were significantly lower in the adherent group compared to the control group, 
reflecting less concerns about their medicine in the adherent group. At six months, the mean 
BMQ-S necessity score was significantly higher in the adherent group than the control 
group, indicating that the adherent group had stronger beliefs that their medicine was 
necessary (Table 4.3). 
There were no statistically significant differences in the mean BMQ-S necessity score and 
concerns score at baseline, between the intervention and control (Table 4.3). At three 
months, the BMQ-S necessity score was significantly higher in the intervention group 
compared to control (p<0.05). This result was sustained at six months (p<0.001). The mean 
BMQ-S concerns score were not significantly different between the intervention and control 
at both three and six months.  
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Table 4.3 Mean BMQ-S necessity scores and concerns score at baseline, three months and 
six months between the groups 
 
BMQ 
Scores 
 
Time 
 
Adherent 
n=32 
 
Pa 
Non-Adherent  
n=120 
 
Pb 
Intervention 
n=60 
Control 
n=60 
Mean 
Necessity 
Score ± sd 
Baseline 
3 months 
6 months 
20.25 ± 4.84 
20.28 ± 4.17 
20.22 ± 3.89 
0.1925 
0.0515 
<0.05* 
19.60 ± 3.18 
19.80 ± 2.94 
20.25 ± 3.17 
18.48 ± 3.63 
18.53 ± 3.71 
17.95 ± 3.20 
0.0758 
<0.05* 
<0.05* 
Mean 
Concerns 
Score ± sd 
Baseline 
3 months 
6 months 
11.75  ± 
3.13 
11.41 ± 2.89 
10.78 ± 2.81 
0.0511 
<0.05* 
<0.05* 
13.48 ± 3.50 
13.00 ± 3.43 
12.32 ± 3.75 
12.63 ± 4.20 
13.05 ± 3.75 
12.92 ± 3.38 
0.2312 
0.9394 
0.3591 
pa: BASELINE - adherent vs. non-adherent (intervention and control) 
    : 3 MONTHS AND 6 MONTHS - adherent vs. control 
pb: intervention vs. control 
 
 
4.2.5 Changes in mean BIPQ scores between the three groups over time  
At baseline, the mean BIPQ treatment control score was significantly higher in the adherent 
group than the non-adherent participants (intervention and control groups). The mean BIPQ 
treatment coherence score was significantly higher in the adherent group compared to the 
non-adherent (intervention and control) group, at baseline. This indicates that at baseline, 
participants identified as adherent using the MAQ felt that their medicine was more helpful 
and felt they had a clearer understanding of their illness than participants classified as non-
adherent (Table 4.4). 
At three months, the mean BIPQ personal control score was significantly higher in the 
intervention group compared to the control. At both three and six months, the mean BIPQ 
treatment control and coherence scores were significantly higher in the intervention group 
compared to control. These scores indicate that the intervention group felt their treatment 
was more helpful and had a clearer perceived understanding of their illness than the control 
at three and six months. At all time points, the intervention group had a significantly higher 
BIPQ timeline score than the control group, reflecting that the intervention group believed 
their illness would last longer (Table 4.4). 
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Table 4.4 Mean scores of BIPQ at baseline, three months and six months, between groups 
 
Mean BIPQ 
Scores ± sd 
 
Time 
 
Adherent  
(n=32) 
 
 
pa 
 
Non-Adherent  
Pb Interventio
n (n=60) 
Control  
(n=60) 
Consequences  
How much does your 
illness affect your life? 
(0 = no affect at all – 10 = 
severely affects my life) 
Baseline 
3 months 
6 months 
5.13 ± 2.87 
5.03 ± 3.17 
4.06 ± 2.94 
0.7411 
0.9976 
<0.05* 
5.10 ± 3.02 
4.98 ± 3.07 
4.90 ± 2.86 
4.77 ± 3.01 
5.03 ± 3.09 
5.45 ± 2.92 
0.5459 
0.9292 
0.2995 
Timeline 
How long do you think 
your illness will continue? 
(0 = very short time – 10 = 
forever) 
Baseline 
3 months 
6 months 
8.72 ± 2.64 
8.94 ± 2.35 
9.09 ± 2.16 
0.3298 
0.9671 
0.9597 
9.57 ± 1.14 
9.90 ± 0.66 
9.83 ± 0.62 
8.85 ± 2.28 
8.92 ± 2.19 
9.12 ± 1.87 
<0.05* 
<0.05* 
<0.05* 
Personal Control 
How much control do you 
feel you have over your 
illness? 
(0 = absolutely no control – 
10 = extreme amount) 
Baseline 
3 months 
6 months 
6.53 ± 2.73 
7.22 ± 1.91 
7.47 ± 1.90 
0.2497 
<0.05* 
<0.05* 
 
5.70 ± 2.82 
6.50 ± 2.57 
5.90 ± 2.93 
6.08 ± 2.89 
5.53 ± 2.61 
4.98 ± 2.59 
0.4639 
<0.05* 
0.0723 
Treatment 
Control 
How much do you think 
your treatment can help 
your illness? 
(0 = not at all – 10 = 
extremely helpful) 
Baseline 
3 months 
6 months 
9.00 ± 1.44 
9.28 ± 1.39 
9.16 ± 1.42 
<0.05* 
<0.05* 
<0.05* 
 
8.20 ± 1.94 
8.55 ± 1.79 
8.58 ± 1.70 
8.00 ± 1.97 
7.63 ± 2.15 
7.22 ± 2.44 
0.5757 
<0.05* 
<0.05* 
Identity 
How much do you 
experience symptoms 
from your illness? 
(0 = no symptoms – 10 = 
many severe symptoms) 
Baseline 
3 months 
6 months 
3.63 ± 3.12 
4.16 ± 3.05 
3.56 ± 2.71 
0.2859 
0.7510 
<0.05* 
4.32 ± 2.83 
4.52 ± 3.06 
4.18 ± 2.78 
4.25 ± 2.90 
4.37 ± 2.95 
4.98 ± 2.69 
0.8988 
0.7850 
0.1121 
Concern 
How concerned are you 
about your illness? 
(0 = not at all concerned – 
10 = extremely concerned) 
Baseline 
3 months 
6 months 
5.53 ± 3.16 
5.34 ± 3.57 
4.47 ± 3.32 
0.8319 
0.5539 
<0.05* 
5.97 ± 3.46 
5.65 ± 3.21 
5.53 ± 3.32 
5.37 ± 3.11 
5.78 ± 2.96 
6.12 ± 2.92 
0.3204 
0.8135 
0.3093 
Coherence 
How well do you feel you 
understand your illness? 
(0 = don’t understand – 10 = 
understand very clearly) 
Baseline 
3 months 
6 months 
8.53 ± 1.92 
8.66 ± 1.82 
8.84 ± 1.74 
<0.05* 
<0.05* 
<0.05* 
 
7.28 ± 2.64 
8.37 ± 2.09 
8.37 ± 2.11 
7.35 ± 2.36 
7.12 ± 2.54 
6.63 ± 2.71 
0.8845 
<0.05* 
<0.05* 
Emotional  
How much does your 
illness affect you 
emotionally?  
(0 = not at all affected 
emotionally – 10 = extremely 
affected emotionally) 
Baseline 
3 months 
6 months 
3.56 ± 3.22 
4.16 ± 3.07 
3.38 ± 2.70 
0.3845 
0.7356 
<0.05* 
4.18 ± 3.41 
4.27 ± 3.15 
3.92 ± 3.02 
4.07 ± 3.05 
4.38 ± 3.04 
4.97 ± 2.91 
0.8436 
0.8366 
0.0547 
pa: BASELINE - adherent vs. non-adherent (intervention and control) 
    : 3 MONTHS AND 6 MONTHS - adherent vs. control 
pb: intervention vs. control 
 94 
 
 
4.3 Conclusions 
 
A targeted and tailored intervention guided by feedback from validated adherence scales 
and discussion with the participant improved adherence to a recently initiated medication at 
three months and this effect was sustained at 6 months. Use of validated adherence scales 
to prompt a structured discussion, provided insight into the participant’s medication-taking 
behaviour, beliefs towards their medicines and their illness perceptions. This is a variant of 
an approach that used MEMS data and has been successful at improving adherence to 
medications (MGMM).214 This intervention was easy to administer and quick enough that it 
could be incorporated into day-to-day practice, if proven successful in larger studies 
assessing clinical outcomes. 
Chapter Five provides details on how the intervention was tailored to participants. The 
changes in adherence, beliefs about medicines and illness perceptions in the adherent, 
intervention and control groups and for each of adherence strategies are explored in Chapter 
Six. Refer to Chapter Seven for discussion and the study limitations. 
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CHAPTER FIVE: RESULTS 2 - TAILORING 
OF THE INTERVENTIONS TO THE 
PARTICIPANT-SPECIFIC REASONS FOR 
NON-ADHERENCE 
 
5.1 Introduction 
 
In Chapter Two and Three we reported how adherence scales could be used to identify non-
adherence and the reasons for non-adherence. In Chapter Three we described the methods 
of a randomised controlled trial to test the use of validated scales in an MGMM approach to 
improve medication adherence. The intervention involved validated adherence scales, 
discussion with the participant and the implementation of a tailored strategy to improve 
adherence. Validated adherence scales were used to provide feedback on the participant’s 
adherence. The participant’s responses to the scales informed the discussion with the 
participants about their illnesses, medicines and/or reasons for their non-adherence to 
provide context. The discussion guided the implementation of a tailored strategy to improve 
adherence to a chronic cardiovascular disease. Chapter Four presented the results of the 
randomised controlled trial of a targeted and tailored intervention to improve adherence. 
This adherence intervention led to a significant improvement in adherence at three months 
and this improvement in adherence was sustained at six months (Chapter Four). 
It is important to explain how these interventions were tailored to the participant-specific 
reasons for non-adherence to explore how the intervention may have improved adherence. 
The purpose of Chapter Five is to describe how the information obtained from the validated 
tools and discussion with the participant informed the implementation of the tailored 
strategies. The tailored strategies included: reminder systems, cognitive-educational, 
behavioural-counselling and social support interventions.  
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5.2 Participant Baseline Interview  
 
The interview consisted of the: Medication Adherence Questionnaire (MAQ), Beliefs about 
Medicines Questionnaire - Specific (BMQ-S), Brief Illness Perceptions Questionnaire (BIPQ) 
and tailored strategy. The MAQ, BMQ-S and BIPQ were utilised to gather information about 
the participants’ adherence and reasons for non-adherence.  
 The MAQ was used for two purposes: (i) identify participant’s adherence, and (ii) 
identify the participant’s type of non-adherence (unintentional, intentional or a mix of 
both types), as described in Section 3.3.3.18 
 The BMQ-S elicited commonly-held beliefs about medicines, as described in Section 
3.3.3.117 The BMQ-S provided insight to whether the participant believed their 
medicines were necessary and whether participants had any concerns about their 
medicines. 
 The BIPQ was used to explore illness perceptions that may influence adherence to 
medications.135,139 Items 4 and 7 in particular were used to identify if participants held 
negative perceptions towards their medicines and whether or not they perceived that 
they understood their illness, respectively (Section 3.3.3). 
 
The participant’s responses to the validated tools informed further discussion regarding the 
participant’s adherence and barriers to adherence. A tailored strategy to support the 
participant’s adherence was selected and implemented based on the information discussed 
in the interview. 
 
 
5.3 Intervention 
 
 5.3.1 Overview of Strategies Implemented 
Guided by the adherence scales, the researcher and participant selected and implemented 
a strategy from an “evidence-based toolkit” to support the participant’s adherence to their 
medicine (Chapter Four: Table 4.2). The commons strategies employed to improve 
adherence were: reminder systems (45%), reminder system and a cognitive-educational 
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strategy (25%), a cognitive-educational strategy (15%), social support (8.3%) and a 
behavioural-counselling strategy (6.7%). 
 
5.3.2 Overview of Radar Charts of the Responses to the Scales for each 
Tailored Strategy and Case Examples 
For each of the tailored strategies, a radar chart has been used to provide a pictorial 
representation of how the responses to the scales guided the selection of the strategy. 
Figure 5.1 is a template of the radar chart. From the top of the radar chart, moving clockwise, 
the first four axis lines represents the proportion of participants (%) who responded positively 
to each of the MAQ items, indicating whether they were forgetful at taking their medicine, 
careless at taking their medicine, ceased their medicine when they felt better or when they 
felt worse. The next two axis lines represent the mean BMQ-S necessity and concerns 
scores (expressed as a percentage). The higher the BMQ-S necessity and concerns scores, 
the stronger the belief that their medicine was necessary and the greater the concerns were 
about their medicine, respectively. The remaining two lines on the left of the radar chart are 
the mean BIPQ treatment control and treatment coherence score, which are also expressed 
as a percentage. A high BIPQ treatment control score reflects strong beliefs that their 
medicine is helpful and a high BIPQ treatment coherence score indicates a clear perceived 
understanding of their treatment (Figure 5.1). The radar charts (Figure 5.2 – 5.6) visually 
depict key similarities and differences in responses to the survey tools at baseline between 
patients who received the different tailored strategies. Since the type of strategy 
implemented was informed by the participant’s responses to the MAQ, BMQ-S, BIPQ and 
discussion with the participant, these groups are not randomised. 
Individual examples are also provided below the individual radar charts, to explain and 
illustrate in more detail how the interview was used to inform the selection of the tailored 
strategy in specific participants.  
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Figure 5.1 Radar Chart template 
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5.3.3 Reminder System 
Reminder System Radar Chart 
Reading the radar chart (Figure 5.2) clockwise from the top, we can see that all participants 
who received a reminder to improve their medication adherence were identified as 
unintentionally non-adherent (either forgetful or careless with their medicines). The mean 
BMQ-S necessity score was high, indicating these participants had strong beliefs their 
medicine was necessary. The mean BMQ-S concerns score was low, reflecting minimal 
concerns about their medicine. The mean BIPQ treatment control and treatment coherence 
scores were high, reflecting that these participants believed their medicine was helpful and 
had a good perceived understanding of their illness (Figure 5.2). From these responses, 
unintentional non-adherence due to forgetfulness and carelessness were identified as the 
barrier to adherence and informed the discussion about adherence with these participants.  
 
Figure 5.2 Radar chart of questionnaire responses of REMINDER group at baseline 
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Case Examples of Individuals who received a Reminder System 
Below are three case examples of participants who were provided with a reminder strategy 
to improve their adherence (dose administration aid, self-managed dosette box and 
treatment simplification).  
 
Case 1: Participant 47 (Table 5.1) 
Participant 47 is 73 years of age and takes a total of eight prescription medicines and two 
vitamin supplements. She has been taking gliclazide modified-release (MR) tablets 60mg 
once daily for the previous 12 weeks for type 2 diabetes. 
 
Table 5.1 Individual scores to validated scales at baseline (Participant 47) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concern
s 
Treatment 
Control 
Treatment 
Coherence 
1 0 22 9 8 8 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 1, unintentionally non-adherent. 
BMQ-S: High necessity score and low concerns score – believes medicine is necessary and 
does not appear to be concerned about their medicine. 
BIPQ: The participant felt she had a decent amount of control over her illness and perceived 
her medicines to be very helpful. Participant 47 had a clear understanding of her illness and 
was not emotionally affected by her illness. 
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Discussion: It was ascertained that all her medicines were taken either once daily or twice 
daily. The discussion also determined that Participant 47 was usually careless and often 
forgets to take the evening dose of her medicine. Furthermore, the participant mentioned 
that she tended to forget to refill her repeat prescriptions on time. 
Adherence Strategy: Agreed in discussion with participant that a fortnightly dose 
administration aid would be helpful. This was initiated by her community pharmacy. A dose 
administration aid is commonly made up by the pharmacy to help patients who may find it 
difficult to organise and remember to take their medications, particularly if they are taking a 
great number of medications. It is a plastic tray that compartmentalises medicines into the 
appropriate days of the week and times of the day at which the medications should be taken. 
The dose administration aid may help to remind her to take the evening doses of her 
medicines and also shifts the responsibility of dispensing her repeat prescriptions to the 
pharmacy. 
 
 
Case 2: Participant 49 (Table 5.2) 
Participant 49 takes four prescription medicines and one complementary medicine. He has 
been taking perindopril 5mg, once daily for the past four weeks for hypertension. 
 
Table 5.2 Individual scores to validated scales at baseline (Participant 49) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
1 0 25 10 9 8 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
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Intervention 
MAQ: Score of 1, unintentionally non-adherent. 
BMQ-S: High necessity score and low concerns score – believes medicine is necessary and 
has minimal concerns about his medicine. 
BIPQ: The participant seems to have a good understanding of his illness and perceives his 
medicine as very helpful. 
Discussion: Through discussion with the participant it was discovered that he was using a 
once daily self-managed dosette box. Since he was also taking other medicines with a twice-
daily dosing regimen, he sometimes had difficulty distinguishing between the morning and 
evening doses when the tablets were in one compartment in the dosette box. 
Adherence Strategy: The researcher suggested a dose administration aid; however the 
participant felt that they would be losing control over his medication-taking behaviour. 
Therefore, the researcher and participant made a shared decision to use a twice-daily 
dosette box (compartments for morning and evening doses for each day of the week). 
 
 
Case 3: Participant 25 (Table 5.3) 
Participant 25 is 52 years old and has been taking metformin 500mg three times daily for 
the treatment of type 2 diabetes for the past twelve weeks. 
 
Table 5.3 Individual scores to validated scales at baseline (Participant 25) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
2 0 20 12 10 7 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
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Intervention 
MAQ: Score of 2, unintentionally non-adherent. 
BMQ-S: Participant’s perceived necessity beliefs outweighed his concerns about the 
medicine 
BIPQ: The BIPQ identified that the participant perceived that their medicines were extremely 
beneficial, had minimal concerns about their illnesses and had good understanding of their 
illnesses. 
Discussion: The participant was prescribed metformin three times daily. The participant 
advised that he tended to forget to take his noon dose while he was at work. The participant 
was forgetful at taking his medication as prescribed due to the complexity of the treatment 
regimen. 
Adherence Strategy: The researcher advised that if the GP agrees, changing metformin 
conventional dosage form to the extended release dosage form can reduce the dose 
frequency from three times daily to once daily. The researcher liaised with the GP and the 
GP agreed to replace the conventional metformin 500mg three times daily to extended-
release metformin 500mg three tablets once daily.  
 
 
Summary of Reminder Strategies 
A reminder strategy was implemented in participants identified with unintentional non-
adherence using the MAQ, with no other barriers identified using the BMQ-S, BIPQ and 
during the discussion. These strategies included dose administration aids, dosette boxes, 
alarm clock reminders and treatment regimen simplification. A shared decision was made 
on which strategy would be the most appropriate for each participant. Most reminder 
strategies involved employing a dose administration aid, which were organised by the 
pharmacy. In our study, some participants did not like the idea of a third party “controlling” 
their medicines (Case 2). For these participants, a dosette box was more ideal, as this allows 
the participant to organise their medicines. The reminder strategies implemented in this 
study are similar to those in the literature (Section 1.6.2).224,234,240,244,246 
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5.3.4 Cognitive-Educational Strategy 
Most participants who were provided with education to improve adherence were identified 
as intentionally non-adherent, with the majority scoring positively on questions 3 and/or 4 of 
the MAQ. Similar to the reminder group, the mean BMQ-S necessity score was high and 
BMQ-S concerns score was low. However, the mean BIPQ Treatment Coherence score was 
low, indicating that these participants may benefit from information on their illness and 
medicine to improve their adherence (Figure 5.3). In comparison to the participants who 
received a reminder system these participants were less likely to be unintentionally non-
adherent and have a low mean BIPQ treatment coherence score (Figure 5.2).  
 
Figure 5.3 Radar chart of questionnaire responses of the COGNITIVE-EDUCATIONAL 
strategy group at baseline 
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Case Examples of Individuals who received a Cognitive-Educational Strategy 
 
Case 4: Participant 5 (Table 5.4) 
Participant 5 is 62 years old and is currently on eight prescription medicines. He was recently 
prescribed rosuvastatin 5mg once daily for dyslipidaemia and for the secondary prevention 
of ischaemic stroke. The rosuvastatin was prescribed 12 weeks ago; however, he has taken 
rosuvastatin for a total of four weeks. 
 
Table 5.4 Individual scores to validated scales at baseline (Participant 5) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
3 2 25 14 8 2 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 3, both unintentionally non-adherent and intentionally non-adherent. 
BMQ-S: The BMQ-S showed that the participant strongly believed his medicines were 
necessary and had relatively minimal concerns. 
BIPQ: Indicated a poor of understanding of his conditions 
Discussion: The BIPQ indicated that the participant had a poor understanding of his illness. 
This information together with the responses to the MAQ was used to guide the discussion 
about his medication-taking behaviour and his current knowledge of his medication and 
illnesses. It was discovered that he had not been taking the rosuvastatin because he did not 
understand the purpose and importance of taking this medication. The participant self-
reported that he takes his other seven medicines “religiously” and also believed that the 
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rosuvastatin is causing his gout attacks. The participant also reported that his general 
practitioner (GP) was unaware that he had ceased the rosuvastatin. 
Adherence Strategy: The participant was educated on the purpose and benefits of the 
rosuvastatin. The participant was advised that the rosuvastatin was not only to help reduce 
cholesterol levels, but also to prevent another stroke incident along with his other medicines 
taken for stroke prevention. The importance of taking his medicines was emphasised 
throughout the interview. Since the participant believed that the rosuvastatin was causing 
his gout, education was also provided on the causes of gout and the management of gout. 
The researcher also provided information on his medications for gout (allopurinol for gout 
prevention and indomethacin for controlling gout attacks) and the participant was advised 
that it was unlikely that the rosuvastatin is the causing the gout. 
 
Case 5: Participant 16 (Table 5.5) 
Participant 16 was initiated on irbesartan 300mg once daily, five weeks ago for the treatment 
of hypertension.  
 
Table 5.5 Individual scores to validated scales at baseline (Participant 16) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
1 1 12 21 10 2 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 1, intentionally non-adherent (ceased medicine when feeling unwell). 
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BMQ-S: The participant’s concerns about her medicine outweighed beliefs that her medicine 
were necessary. 
BIPQ: The BIPQ showed that the participant believed the medicine was very helpful, but 
had a poor understanding of her treatment and condition. 
Discussion: The responses to the BMQ-S showed that the participant had concerns about 
their medication. Therefore, the interview with the participant involved discussing what her 
concerns were and why she had those concerns. The participant advised the researcher 
that she was experiencing palpitations ever since she started taking the irbesartan, which 
gave her concerns about the medication. Therefore, the participant ceased her irbesartan 
when she experienced palpitations. The BIPQ indicated that the participant did not have a 
good understanding of her illness and treatment. This was also picked up during the 
discussion with the participant about her medication-taking behaviour. Therefore, the 
participant was asked about what she felt she knew about her medication and illness and 
what she felt she did not know very well.  
Adherence Strategy: The participant was educated on hypertension and on how irbesartan 
will help with her hypertension. Information on the silent nature of hypertension, the causes 
of hypertension and risks of hypertension was provided. Counselling on the benefits and 
common adverse effects of irbesartan was provided, including how to manage the side 
effects. The participant was advised that because irbesartan reduces blood pressure, it can 
sometimes lead to an increase in heart rate and may explain her recent heart palpitations. 
The researcher also measured the participant’s blood pressure and provided the participant 
with a blood pressure monitoring diary, which included information on managing blood 
pressure. The participant was also referred to the GP to discuss her heart palpitations.  
 
 
Summary of Cognitive-Educational Strategies 
Educating individuals on their health can influence a change in adherence through changes 
in knowledge, attitudes and beliefs.144 A cognitive-educational strategy to support their 
adherence was implemented in participants identified as having poor knowledge on their 
medicines and medical conditions without other potential barriers to adherence (Figure 5.3). 
Information that was provided to the participants included the benefits of their medicine, the 
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adverse effects and how to manage the adverse effects (Case 4). Depending on the 
discussion with the participant, information on their medical condition and what to expect 
was also provided (Case 5). Some participants were also provided with pharmacy pamphlets 
on medical conditions when appropriate (Case 5). The cognitive-educational strategies 
utilised in this study were similar to those implemented in the literature as described in 
Chapter One, Section 1.6.2. 
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5.3.5 Reminder and Cognitive-Educational Strategy 
All participants who received both a reminder and educational strategy indicated that they 
were forgetful at taking their medicine according the MAQ (Figure 5.4). About 60% of the 
participants were careless at taking their medicine and some participants intentionally 
stopped taking their medicine when they felt well and when they felt worse. Similar to Figure 
5.2 and Figure 5.3, the mean BMQ-S necessity score was high and mean BMQ-S concerns 
score relatively low. The mean BIPQ treatment control score was also high, indicating that 
these participants believed their medicine was helpful. However, unlike the participants who 
received a reminder (Figure 5.2), the mean BIPQ treatment coherence score was noticeably 
lower, similar to that of the cognitive-educational group (Figure 5.3).  
 
 
Figure 5.4 Radar chart of questionnaire responses of the REMINDER & COGNITIVE-
EDUCATIONAL strategy group at baseline 
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Case Examples of Individuals who received a Reminder and Cognitive-Educational 
Strategy 
 
Case 6: Participant 31 (Table 5.6) 
Participant 31, is 75 years old and has been taking metformin extended-release 500mg once 
daily for the last 12 weeks for the treatment of type 2 diabetes. She takes five prescription 
medications for the treatment of diabetes, depression, osteoarthritis and hypothyroidism.  
 
Table 5.6 Individual scores to validated scales at baseline (Participant 31) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
3 2 24 12 10 2 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 3, both unintentionally and intentionally non-adherent. 
BMQ-S: The BMQ-S indicates that her beliefs that her medicines are necessary are strong 
and concerns about her medicine are relatively weak.  
BIPQ: From the BIPQ, the participant seems to have a poor understanding of her medical 
condition. 
Discussion: It was evident from the discussion that the participant lacked knowledge on 
her medical conditions but also on the purpose and benefits of all her medicines. Through 
further discussion, it was determined that the participant stopped taking the metformin when 
she was feeling “better” and thus forgot to take the medicine. The participant was also 
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uncertain as to why it was important to continue to take the medicine when she felt better. 
She did not understand why people have illnesses and how tablets “know where to go.” 
Adherence Strategy: The participant was educated on her medical conditions and on her 
medicines. Information provided on her illnesses, particularly type 2 diabetes, included the 
characteristics of diabetes, symptoms and risks associated with uncontrolled blood glucose 
levels. The participant was educated on how the metformin works, the benefits of taking 
metformin and the common side effects. The importance of adhering to her medications was 
emphasised throughout the discussion. Since she was quite forgetful and had difficulty 
managing her medicines, a dose administration aid was initiated by the pharmacy.  
 
 
Case 7: Participant 41 (Table 5.7) 
Participant 41 is 57 years old and currently taking three prescription medicines and was 
prescribed rosuvastatin 10mg once daily, four weeks ago for the treatment of dyslipidaemia. 
 
Table 5.7 Individual scores to validated scales at baseline (Participant 41) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
4 2 24 24 8 10 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 4, both unintentionally and intentionally non-adherent. 
BMQ-S: His beliefs that medicines are necessary are strong; however these beliefs are 
balanced by his strong concerns about his medicines. 
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BIPQ: The BIPQ indicated that his illnesses significantly affected his life and he had strong 
concerns about his illnesses. The BIPQ also suggested that he had a good understanding 
of his illnesses, but discussion with the participant led the researcher to believe the contrary. 
Discussion: The participant reported he was “terrible at taking medicines.” He is careless 
at times when taking his medicine and forgets to take his medicine at least once a week. 
Participant 41 often stops his medicines when he is feeling better and when experiencing 
side effects, such as dizziness.  
Adherence Strategy: The researcher supplied and showed the participant how to use a 
dosette box to assist him with managing his medicines. Education was also provided on all 
of his medicines, medical conditions and importance of adherence. The participant was 
advised on the benefits of the medicines (e.g. rosuvastatin lowers cholesterol levels, which 
minimises the risk of cardiovascular events), how taking each of the medications would 
improve his medical conditions and hence the importance of taking his medications as 
prescribed. Information about the common side effects was provided, including how to 
manage the side effects, in particular, the dizziness he was experiencing. After discussion 
with the participant’s GP, the participant was advised to take the rosuvastatin at night before 
bed instead of in the morning to see whether that helps minimise the dizziness.  
 
Summary of Reminder and Cognitive-Educational Strategy 
These participants indicated that they were non-adherent due to forgetfulness or 
carelessness and had poor knowledge about their illness and treatment. A combination of a 
reminder and cognitive-educational strategy were implemented to support their adherence. 
Indications for this type of strategy to be implemented included both unintentional non-
adherence identified using the MAQ and poor understanding on medicine and illness 
identified using the BIPQ or through discussion. This was evident on the group radar chart 
(Figure 5.4) and on an individual level.  
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5.3.6 Behavioural-Counselling Strategy 
All participants in the behavioural-counselling group were identified by the MAQ as either 
intentionally non-adherent or a mix of both types of non-adherence (Figure 5.5). There was 
a low mean BMQ-S necessity score in this group when compared to the reminder (Figure 
5.2) and cognitive-educational group (Figure 5.3). The mean BIPQ treatment control score 
was high. Unlike the cognitive-educational group, the behavioural-counselling group had a 
high mean BIPQ treatment coherence score, indicating that these participants had a clear 
perceived understanding of their illness and treatment (Figure 5.5). 
 
 
Figure 5.5 Radar chart of questionnaire responses of the BEHAVIOURAL-
COUNSELLING strategy group at baseline 
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Case Examples of Individuals who received a Behavioural-Counselling Strategy 
 
Case 8: Participant 7 (Table 5.8) 
Participant 7 is 35 years old and has been taking ramipril 10mg for the last four weeks. 
 
Table 5.8 Individual scores to validated scales at baseline (Participant 7) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
3 2 15 18 5 10 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 3, both unintentionally and intentionally non-adherent. 
BMQ-S: The BMQ-S indicated that her concerns about her medicine outweighed her 
perceived necessity of the medicine. 
BIPQ: The participant perceived that she had little control over her illness, that her treatment 
was only moderately helpful and that she understood her condition very clearly. 
Discussion: It was discovered that the participant has tried many other medicines to lower 
blood pressure. The participant believes that it is highly unlikely that the new 
antihypertensive medicine will improve her blood pressure. Pessimism about the new 
medication to treat her hypertension was picked up during the discussion with the participant. 
Adherence Strategy: The researcher provided health coaching by exploring the 
participant’s views of treatment and helped the participant to establish goals of treatment; 
for example, blood pressure target. Once goals of treatment were established, strategies to 
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attain these goals were discussed, including adhering to her medication and maintaining 
daily physical exercise. The researcher measured the participant’s blood pressure and 
provided her with a blood pressure monitoring diary. The participant was advised to check 
her blood pressure at the pharmacy on a regular basis to help her observe the efficacy of 
her medication.  
 
Case 9: Participant 54 (Table 5.9) 
Participant 54 initiated valsartan 40mg once daily 12 weeks ago for the treatment of 
hypertension. The participant is 72 year old and is currently taking five prescription 
medicines and one complementary medicine. 
 
Table 5.9 Individual scores to validated scales at baseline (Participant 54) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
1 1 20 17 8 5 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 1, intentionally non-adherent (ceased medicines when feeling better). 
BMQ-S: The participant perceives their medicine is necessary; however, also holds strong 
concerns about his medicine. 
BIPQ: The responses to the BIPQ indicated that the participant has a moderate 
understanding of his illness. 
Discussion: The researcher further explored the participant’s beliefs and perceptions of his 
medicines. The participant believes that “taking medicines for a long time would reduce the 
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effectiveness of the medicine.” The participant also believed that taking the same medication 
for a long time “must not be good for the body.” Therefore, he had made an appointment 
with a new GP to prescribe him a new medicine for hypertension (valsartan).  
Adherence Strategy: The researcher also explored the participant’s treatment goals, 
educated the participant on the silent nature of hypertension and the importance of 
medication adherence. Education on his medications was provided in the hope of changing 
his beliefs, including how medicines work and how some medicines may be effective for one 
person and not another and hence sometimes medicines are prescribed based on a trial 
and error approach. During the baseline interview, the researcher conducted a blood 
pressure measurement and advised him to regular check his blood pressure to monitor the 
effectiveness of the medication. 
 
Summary of Behavioural-Counselling Strategies 
Behavioural-counselling strategies implemented included health coaching and exploring 
beliefs about medicines and illness perceptions in more depth. Health coaching is used as 
an adherence intervention by facilitating the establishment of treatment goals to support 
adherence to medications (Case 8). The health coaching provided in this study was 
considerably more abbreviated compared to the health coaching described to improve 
adherence in the literature.226,250 Health coaching with evidence in the literature usually 
involves multiple sessions over a long period of time and conducted by a trained 
personnel.250 Our goal was to provide a relatively quick intervention to improve medication 
adherence that may have the potential to be readily translated into clinical practice.  
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5.3.7 Social Support Strategy 
The discussion with the participant and caregiver was the driving force in the decision to 
implement a social support strategy to improve adherence. Most participants were identified 
as unintentionally non-adherent due to forgetfulness and carelessness using the MAQ 
(Figure 5.6). The mean BMQ-S necessity score was high and BMQ-S concerns score was 
low, compared to participants who received a behavioural-counselling strategy (Figure 5.5). 
The mean BMQ-S scores appear similar to those that received a reminder strategy (Figure 
5.2). Both the mean BIPQ treatment control score and mean BIPQ treatment coherence 
score were high, showing that these participants believed the medicine was helpful and 
believed that they had a clear understanding of their illness (Figure 5.6). From the discussion 
with these participants, it was evident that they may need some support with managing their 
medications. See individual cases for further details (Table 5.10 and Table 5.11). 
 
Figure 5.6 Radar chart of questionnaire responses of the SOCIAL SUPPORT strategy 
group at baseline 
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Case Examples of Individuals who received a Social Support Strategy 
 
Case 10: Participant 80 (Table 5.10) 
Participant 80 is 65 years old and was prescribed amlodipine 10mg once daily, four weeks 
ago to lower his blood pressure. 
 
Table 5.10 Individual scores to validated scales at baseline (Participant 80) 
MAQ BMQ-S BIPQ 
Score Type Necessity Concerns Treatment 
Control 
Treatment 
Coherence 
2 0 24 9 10 8 
MAQ Score: 1 (low non-adherence) to 4 (high non-adherence). Type: 0 = Unintentional non-adherence, 1 = Intentional 
non adherence, 2 = Mix of both types.                                            
BMQ-S: Necessity: 5 (low BMQ-S necessity score) to 25 (high BMQ-S necessity score), Concerns: 5 (low BMQ-S 
concerns score) to 25 (high BMQ-S concerns score).             
BIPQ: Treatment Control: 1 (treatment not helpful at all) to 10 (extremely helpful), Treatment Coherence: 1 (do not 
understand at all) to 10 (understand very clearly). 
 
Intervention 
MAQ: Score of 2, unintentionally non-adherent. 
BMQ: Responses to the BMQ-S indicate that the participant believed their medicine was 
necessary and had relatively minimal concerns about his medicine. 
BIPQ: Participant 80 felt that he had moderate control over his illness, perceived that the 
medicines were extremely helpful and had a good perceived understanding of his illness. 
Discussion: From the discussion with the participant, the participant had great difficulty in 
remembering to take his medicines due to early onset dementia. His daughter who was 
there at the baseline interview told the researcher that she takes care of him at home; 
however, did not look after his medicines. 
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Adherence Strategy: Therefore, the researcher advised the daughter to support the 
participant with his medications. Since the participant was currently taking 12 medicines, a 
dose administration aid was also initiated by the pharmacy to assist the daughter in 
supporting the participant with his medications. 
 
 
Summary of Social Support Strategy 
Social support strategies were indicated in participant’s identified as requiring support with 
managing their medications. Decision to implement this type of strategy relied on the 
discussion with the participant and carer, more so than the responses to the adherence 
scales. Discussion with these participants identified a need of support from a family member 
with their medication-taking behaviour. In the literature, social support strategies to improve 
medication adherence typically involved peer support group therapy. Overall these peer 
support groups have not been very successful at improving adherence (Section 1.6.2). Our 
study on the other hand, involved a close family member to support the participant with their 
medication-taking behaviour or supporting their decision by discussing with their GP.  
 
 
5.4 Flow Diagram of Tailoring Adherence Intervention (Post-Implementation) 
After data collection was complete, we explored the common responses to the scales and 
discussion with the participants in each of the types of tailored strategies. The MAQ was 
used to identify medication-taking behaviour and whether the participant’s non-adherence 
was unintentional, intentional or a mix of both. The BMQ-S provided information on the 
participant’s beliefs that medicines were necessary and their concerns regarding their 
medicines. The BIPQ explored the participant’s illness perceptions that have been 
associated with adherence. This information guided the discussion about what may be 
influencing the participant’s non-adherence. This helped inform the implementation of a 
tailored strategy to improve their medication adherence. From this data, I was able to 
generate a flow diagram that may help explain my thought process when deciding which 
strategy to implement (Figure 5.7). Approximately 63% of the participants fit in this model. 
The responses to the validated scales helped to inform the discussion with the participant 
to identify or confirm the reason for non-adherence. The selection of the tailored strategy 
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relied on this discussion with the participant, which may explain why 37% of participants did 
not fit into this model, as shown in Figure 5.7. It was quite easy to select an appropriate 
tailored strategy to improve adherence for each individual based on the responses to the 
MAQ, BMQ-S, BIPQ and discussion. However, to describe how each of these groups were 
treated was much more difficult due to the many different variables identified in the 
discussion. The groups were indistinct and there was some overlap, particularly between 
the cognitive-educational and behavioural-counselling strategy groups.   
We hope that with a larger study, a potential “toolkit”/flow diagram could be designed to 
assist health professionals to implement a tailored intervention to improve medication 
adherence based on their responses to the MAQ, BMQ-S and BIPQ. This flow diagram 
would help health professionals to select the most appropriate intervention to improve the 
patient’s adherence to the medication.  
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Figure 5.7 Flow diagram of outcomes of the adherence scales used to inform the 
discussion with the participant and implementation of the tailored strategy 
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5.5 Conclusions 
Chapter Five described the targeted and tailored intervention which was informed by 
responses to validated scales (MAQ, BMQ-S and BIPQ) and discussion with the participant. 
The responses to the scales provided insight into the participant’s reasons for non-
adherence, which guided the discussion and implementation of a tailored strategy to 
improve adherence. As illustrated in the case examples, this intervention is simple and easy 
to administer, hence would have the potential for implementation in clinical practice.  
The radar charts were presented in Chapter Five to provide a graphical representation of 
the similarities and differences in responses to the scales between participants who received 
different tailored strategies. From these radar charts, we can visually observe that these 
participants had different barriers to adherence, beliefs and illness perceptions that may 
explain their non-adherence. These responses to the adherence scales or patterns of the 
radar charts may help in the implementation of a tailored intervention in practice. 
Chapter Six will explore how adherence, beliefs about the medicine and illness perceptions 
changed over time in the study sample 
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CHAPTER SIX: RESULTS 3 - CHANGES IN 
ADHERENCE OVER SIX MONTHS 
 
6.1 Introduction 
The intervention targeted to non-adherent participants and tailored to the participant-specific 
reasons for non-adherence significantly improved adherence at three months, as presented 
in Chapter Four. This significant improvement in adherence was sustained at six months. 
Chapter Five provided detail on the intervention that included how the responses to the 
adherence scales and discussion with the participant informed the tailored strategy. 
This chapter addresses the following hypothesis: 
- Hypothesis 3: Adherence, and reasons for non-adherence (beliefs about medicines   
and illness perceptions), will change over time in all groups studied.   
Chapter Six explores the differences between the intervention, control and adherent groups 
in relation to adherence to the medication (MAQ), beliefs about the medicine (BMQ-S) and 
illness perceptions (BIPQ) over the six months and changes over time. We were interested 
in exploring the changes in the groups to see if there were patterns emerging in relation to 
adherence. Changes in adherence, beliefs and illness perceptions were also explored for 
each of the different types of adherence strategies implemented to determine if there were 
any patterns to explain how the intervention improved medication adherence.  
 
 
6.2 Differences between the Adherent, Intervention and Control Groups 
At baseline, there were differences in medication adherence, beliefs about medicines and 
illness perceptions between the adherent and non-adherent (intervention and control) 
groups. Over time, adherence, beliefs about the medication and illness perceptions changed 
differently in each of the groups. 
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6.2.1 Adherence over time 
Medication adherence changed over time in the adherent, intervention and control groups, 
as shown in Figure 6.1. At baseline, the mean MAQ score was not different between the 
intervention and control group. However, at three and six months the mean MAQ score 
reduced significantly in the intervention group, resembling more closer to that observed in 
the adherent group. Conversely, the mean MAQ score did not change significantly in the 
control group. In the adherent group, there was a small but significant rise in the MAQ score 
at three months but this reduced at six months. See Appendix E for tables of mean MAQ 
score over time in the adherent, intervention and control groups. 
 
 
 
Figure 6.1 Changes in mean MAQ scores (± 95% confidence intervals) in the adherent, 
intervention and control groups over time  
 
 
 
 
 
 125 
 
6.2.2 BMQ-S Necessity over time 
Figure 6.2 presents the mean BMQ-S necessity scores at baseline, three and six months in 
the adherent, intervention and control groups. At baseline there were no significant 
differences in the BMQ-S necessity scores between the three groups. However, over the 
study period, the BMQ-S necessity scores increased in the intervention group and 
decreased in the control group. The BMQ-S necessity scores in the control group were 
significantly lower than both the adherent and intervention groups at six months. This 
suggests that the beliefs held by the participants in the adherent and intervention groups 
towards the necessity of their medicines were similar and stronger than those held by 
participants in the control group at the end of the study.  
 
 
 
 
Figure 6.2 Changes in mean BMQ-S necessity scores (± 95% confidence intervals) in the 
adherent, intervention and control groups over time 
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6.2.3 BMQ-S Concerns over time 
The changes in the mean BMQ-S concern scores in the adherent, intervention and control 
groups over time are shown in Figure 6.3. At baseline there was no significant difference 
between the three groups, although the BMQ-S concerns score was lower in the adherent 
group compared with the non-adherent (intervention and control) group. Over the study 
period the BMQ-S concerns score decreased for both the adherent group and the 
intervention group and increased for the control group. This suggests that the strength of 
concerns beliefs towards medicines reduced in those participants in the adherent and 
intervention groups and increased in those participants in the control group. Appendix F 
provides the mean BMQ-S necessity and concerns scores over time in the adherent, 
intervention and control groups. 
 
 
 
 
Figure 6.3 Changes in mean BMQ-S concerns scores (± 95% confidence intervals) in the 
adherent, intervention and control groups over time 
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6.2.4 BIPQ Treatment Control over time 
Although not statistically significant, Figure 6.4 shows that the intervention and control group 
had a lower mean BIPQ treatment control score at baseline than the adherent group, 
reflecting that the non-adherent (intervention and control) group may have felt that their 
medication was less helpful in treating their illness. As time progressed, this changed with 
the BIPQ treatment control score increasing in the intervention group suggesting that they 
perceived their medication was more helpful in treating their illness. In contrast the score 
decreased in the control group suggesting that they perceived their medication was less 
helpful in treating their illness. In other words, the intervention group moved in a direction 
closer to that of the adherent group in regards to how helpful they perceived their medication 
and the control group moved further away from the adherent group. 
 
 
 
Figure 6.4 Changes in mean BIPQ treatment control scores (± 95% confidence intervals) 
in the adherent, intervention and control groups over time 
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6.2.5 BIPQ Treatment Coherence over time 
Figure 6.5 presents the mean BIPQ treatment coherence scores in the three groups over 
time. Participants in the adherent group at baseline had a better understanding of their 
illness and treatment than the non-adherent (intervention and control) group at baseline. As 
time progressed, the mean BIPQ treatment coherence scores increased in the intervention 
group suggesting that their understanding of their illness and treatment improved. In the 
control group the mean BIPQ treatment coherence scores decreased suggesting that their 
understanding of their illness and treatment was not as clear over time. From Figure 6.5, we 
can see that over time, the three groups had different changes in their understanding of their 
illness and treatment. For more details on changes in illness perceptions over time in the 
adherent, intervention and control group, see Appendix G. 
 
 
Figure 6.5 Changes in mean BIPQ treatment coherence scores (± 95% confidence 
intervals) in the adherent, intervention and control groups over time 
 
 
 129 
 
The targeted and tailored intervention changed beliefs about medicines and illness 
perceptions over time, which was mirrored by a significant improvement in medication 
adherence. The changes in beliefs about medicines and illness perceptions in the 
intervention group moved towards a pattern similar to that of the adherent group. The control 
group seemed to have more negative beliefs about the medicines and poorer illness 
perceptions over time. To better understand how the intervention improved adherence, the 
changes in beliefs about the medication and illness perceptions were explored within each 
of the tailored strategies. 
 
 
6.3 Changes in each of the Tailored Strategy Groups 
 
6.3.1 Reminder Strategy Group (n=27) 
Participants identified with forgetfulness or carelessness as a barrier to their adherence were 
provided with a reminder strategy to support their adherence. The reminder strategy group 
had a higher mean BMQ-S necessity score, a lower mean BMQ-S concerns score and a 
higher mean BIPQ coherence score than the intervention group at baseline.  
The mean MAQ score in the reminder strategy group reduced significantly at three and six 
months (p<0.001). The mean BMQ-S concerns score was significantly lower at six months 
compared to baseline and three months (Table 6.1). The mean BIPQ coherence score was 
significantly higher at 3 months and 6 months, compared to baseline (Table 6.1).  
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Table 6.1 Change in mean MAQ, BMQ-S, and BIPQ treatment and coherence scores over 
time in the REMINDER strategy group 
 
 
Reminder  
Time 
 
p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ score 
 
 
1.30±0.47 
 
0.33±0.55 0.30±0.54 <0.05* <0.05* 0.7457 
Mean BMQ-S 
Necessity score 
 
20.07±2.81 20.00±2.73 20.19±2.84 0.8591 0.8274 0.6959 
Mean BMQ-S 
Concerns score 
 
12.19±2.99 11.44±2.67 10.59±3.13 0.1546 <0.05* <0.05* 
Mean BIPQ 
Treatment Control 
score 
 
8.59±1.50 8.81±1.33 8.63±1.62 0.5229 0.9188 0.5971 
Mean BIPQ 
Coherence score 
 
8.26±1.53 8.81±1.39 9.15±0.95 <0.05* <0.05* 0.2403 
 
 
 
At baseline, all participants who received a reminder strategy to improve adherence were 
identified as unintentionally non-adherent due to forgetfulness or carelessness, based on 
the MAQ (Figure 6.6). The radar charts in Figure 6.6 are a visual representation of how 
adherence, beliefs about medicines and illness perceptions changed over time in the 
reminder strategy group. It can be seen quite clearly in the three- and six-month radar charts 
that most of these participants were no longer unintentionally non-adherent to their medicine. 
As we progress through the radar charts, baseline to three months to six months, it can be 
seen that adherence improves, concerns about medicines declines and treatment 
coherence score improves (Figure 6.6).  
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Figure 6.6 Radar charts at baseline, 3 months and 6 months for the REMINDER strategy 
group 
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6.3.2 Cognitive-Educational Strategy Group (n=9) 
The participants who received a cognitive-educational strategy to improve their adherence, 
were identified with poor understanding of their illness and treatment (Chapter Five). In 
comparison to the intervention group, the cognitive-educational strategy group had a lower 
mean BIPQ coherence score at baseline. These participants were provided with information 
on adherence, the benefits of their medication, potential adverse effects and how to manage 
their illness. In this group the cognitive-educational strategy seems to have improved their 
understanding of their illness and treatment, as evident from the increase in the mean BIPQ 
coherence score (Table 6.2).  
The mean MAQ score was significantly lower at three and six months than at baseline in the 
cognitive-educational strategy group. There were no significant changes in the mean BMQ-
S scores. At three and six months, the mean BIPQ coherence score increased significantly 
from baseline in the group that received a cognitive-educational strategy (Table 6.2). This 
change reflects that the strategy improved the participant’s understanding of their illness 
and treatment. 
 
Table 6.2 Change in mean MAQ, BMQ-S, and BIPQ treatment and coherence scores over 
time in the COGNITIVE-EDUCATIONAL strategy group 
 
 
 Cognitive-
Educational 
Time 
 
p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ score 
 
 
1.33±0.71 0.22±0.44 0.33±0.71 <0.05* <0.05* 0.6811 
Mean BMQ-S 
Necessity score 
 
19.33±4.18 19.56±4.03 19.89±4.04 0.7824 0.6625 0.6406 
Mean BMQ-S 
Concerns score 
 
13.44±3.88 13.33±2.96 12.89±3.37 0.9019 0.7124 0.5776 
Mean BIPQ 
Treatment Control 
score 
 
7.56±2.60 8.33±1.94 9.00±1.12 0.1739 0.0827 0.0805 
Mean BIPQ 
Coherence score 
 
5.33±3.08 9.00±1.22 9.22±1.09 <0.05* <0.05* 0.6646 
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Changes in adherence, beliefs about medicines and illness perceptions over time in the 
cognitive-educational strategy group can be observed in the radar charts in Figure 6.7. At 
baseline, the mean BIPQ treatment coherence score was low, indicating poor understanding 
of illness. As we move to the three- and six-month radar chart, we can see an increase in 
this score, reflecting an improvement in understanding. Most participants in the cognitive-
educational strategy group were identified as being intentionally non-adherent. From the 
radar charts, we can see that most of these participants were no longer intentionally non-
adherent (Figure 6.7). 
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Figure 6.7 Radar charts at baseline, 3 months and 6 months for the COGNITIVE-
EDUCATIONAL strategy group 
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6.3.3 Reminder and Cognitive-Educational Strategy Group (n=15) 
The reminder and cognitive-educational strategy group were identified with both 
forgetfulness and poor understanding of illness and treatment as barriers to their adherence. 
These participants were provided with a reminder strategy and information on their illness 
and medication to support their adherence. At baseline, the mean BIPQ coherence score 
was lower than the intervention group. In contrast to the cognitive-educational strategy group, 
the mean BIPQ coherence score did not improve significantly over time. One explanation 
may be the education provided on the medication and illness was not as thorough because 
a reminder strategy was also implemented. For these participants, the main barrier to 
adherence may have been forgetfulness and hence an improvement in adherence was 
observed. 
At three and six months, the mean MAQ score was lower than at baseline in the reminder 
and cognitive-educational strategy group. There were no significant changes in the mean 
BMQ-S and mean BIPQ scores (Table 6.3). 
 
 
Table 6.3 Change in mean MAQ, BMQ-S, and BIPQ treatment and coherence scores over 
time in the REMINDER & COGNITIVE-EDUCATIONAL strategy group 
 
Reminder and 
Cognitive-
Educational 
Time 
 
p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ score 
 
 
2.07±1.03 0.60±0.63 0.73±0.70 <0.05* <0.05* 0.4985 
Mean BMQ-S 
Necessity score 
 
18.67±3.44 18.87±3.00 19.80±3.41 0.7451 0.1713 0.1954 
Mean BMQ-S 
Concerns score 
 
15.60±3.25 16.00±3.61 14.73±3.99 0.6158 0.3699 0.1916 
Mean BIPQ 
Treatment Control 
score 
 
7.73±2.09 8.13±2.29 8.13±2.03 0.3478 0.1887 1.0000 
Mean BIPQ 
Coherence score 
 
6.13±3.44 7.07±3.17 6.80±3.17 0.3265 0.3625 0.6946 
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The radar charts presented in Figure 6.8 show the changes in adherence, beliefs about 
medicines and illness perceptions from baseline to six months in the reminder and cognitive-
educational strategy group. From the baseline radar chart, we can see that all participants 
were unintentionally non-adherent to their medication due forgetfulness or carelessness, 
and had a relatively poor understanding of their illness. Moving on to the three and six month 
radar charts, it shows that most participants are no longer non-adherent and perceived 
coherence has slightly improved (Figure 6.8). 
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Figure 6.8 Radar charts at baseline, 3 months and 6 months for the REMINDER AND 
COGNITIVE-EDUCATIONAL strategy group 
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Mean MAQ decreased significantly at three months in the behavioural-counselling strategy 
group, but this was not sustained at six months. The mean BMQ-S necessity score 
increased over time and the mean BMQ-S concerns score decreased over time. The mean 
BIPQ treatment control score increased over time, reflecting that the medicine was 
perceived as more helpful in treating their illness (Table 6.4). The changes in the mean 
BMQ-S and BIPQ scores were not significant, which may be explained by the small sample 
size in this group (n=4). 
 
Table 6.4 Change in mean MAQ, BMQ-S, and BIPQ treatment and coherence scores over 
time in the BEHAVIOURAL-COUNSELLING strategy group 
 
 
Behavioural-
Counselling  
Time 
 
p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ score 
 
 
2.00±1.15 0.25±0.50 0.50±1.00 <0.05* 0.0577 0.7177 
Mean BMQ-S 
Necessity score 
 
18.50±2.65 20.50±2.08 21.75±2.87 0.4437 0.2444 0.2783 
Mean BMQ-S 
Concerns score 
 
14.50±3.70 13.50±3.32 12.25±4.03 0.5137 0.2289 0.1411 
Mean BIPQ 
Treatment Control 
score 
 
7.75±2.06 8.25±2.06 10.00±0.00 0.6376 0.1170 0.1881 
Mean BIPQ 
Coherence score 
 
8.25±2.36 8.50±1.73 8.00±2.16 0.6376 0.3910 0.1817 
 
 
Figure 6.9 is a pictorial representation of the changes in adherence, beliefs about medicines 
and illness perceptions in the behavioural-counselling strategy group. As observed on the 
baseline radar chart, all participants in this group were identified with intentional non-
adherence due to ceasing the medicine when feeling well. As we progress through the radar 
charts from baseline to three months and six months, the mean BMQ-S necessity score 
increases and the mean BMQ-S concerns score decreases in the behavioural-counselling 
strategy group (Figure 6.9).                                                                                                                                                                                                      
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Figure 6.9 Radar charts at baseline, 3 months and 6 months for the BEHAVIOURAL-
COUNSELLING strategy group 
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6.3.5 Social Support Strategy Group (n=5) 
Five participants in the intervention group were identified as requiring social support with 
their medication adherence; for example, support from a family member with taking their 
medication. Compared to the intervention group, this strategy group had a higher mean 
BMQ-S necessity score and a lower BMQ-S concerns score at baseline. The social support 
strategy group had higher mean BIPQ treatment control and coherence scores than the 
intervention group at baseline. 
At three months, the mean MAQ score was lower than at baseline in the social support 
strategy group. This significant decrease in mean MAQ score was not sustained at six 
months. There were no significant changes in the mean BMQ-S and mean BIPQ scores 
(Table 6.5). 
 
Table 6.5 Change in mean MAQ, BMQ-S, and BIPQ treatment and coherence scores over 
time in the SOCIAL SUPPORT strategy group 
 
 
Social Support  
Time 
 
p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ score 
 
 
1.80±0.45 0.80±0.84 1.00±0.71 <0.05* 0.0993 0.3739 
Mean BMQ-S 
Necessity score 
 
21.20±2.59 21.40±2.19 21.40±3.36 0.8276 0.7489 1.0000 
Mean BMQ-S 
Concerns score 
 
13.40±4.04 11.40±1.52 12.25±4.03 0.2577 1.0000 0.2204 
Mean BIPQ 
Treatment Control 
score 
 
9.00±2.24 9.00±2.24 7.80±2.17 1.0000 0.1778 0.1778 
Mean BIPQ 
Coherence score 
 
8.20±1.10 8.60±1.67 7.60±1.67 0.6213 0.3739 0.2663 
 
Figure 6.10 is a visual representation of changes in adherence, beliefs about medicines and 
illness perceptions in the social support strategy group. Over time, we can observe an 
improvement in adherence; however, relatively little change in the beliefs about medicines 
and illness perceptions were observed in this group (Figure 6.10). 
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Figure 6.10 Radar charts at baseline, 3 months and 6 months for the SOCIAL SUPPORT 
strategy group 
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6.3.6 Overall View of the Changes in Adherence Scale Scores over time for each 
Tailored Strategy 
Figure 6.11 and 6.12 are an overall summary of the changes in the mean scores of the MAQ, 
BMQ-S and two items of the BIPQ (treatment control and coherence) in each of the tailored 
strategy groups at three and six months, respectively. At three months, little change was 
visually observed in the mean BMQ-S necessity score in all of the strategy groups, with the 
exception of the behavioural-counselling strategy group. Concerns about medicine reduced 
in the reminder, behavioural-counselling and social support strategy groups. All five groups 
had little change in the mean BIPQ treatment control scores. At three months, the cognitive-
educational group had a significant improvement in the BIPQ treatment coherence score, 
reflecting a better perceived understanding of their illness. These changes were sustained 
at six months (Figure 6.12). 
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Figure 6.11 Change in Questionnaire Scores at three months for each Strategy Type in the Intervention Group 
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Figure 6.12 Change in Questionnaire Scores at six months for each Strategy Type in the Intervention Group
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6.4 Discussion  
 
Improved adherence during the study period reflected reduced concerns towards medicines 
and improved perceived understanding of illness and treatment. A close relationship 
between good adherence and strong beliefs that the medicine is necessary and fewer 
concerns about the medicine has been well-documented in the literature.88,131 In the 
intervention group, there was an improvement in perceived understanding of their illness 
and treatment over the study period, which may help to explain the sustained improvement 
in adherence.  
When we consider the individual adherence strategies employed, the results from the 
adherence questionnaires explain how the intervention impacted on an individual’s 
knowledge, understanding and beliefs and how this translated into improved adherence. In 
participants where forgetfulness or carelessness was a barrier to adherence and they 
received a reminder intervention their changes in beliefs towards their medicines or their 
illness as measured by the BMQ-S and BIPQ were minimal. This is to be expected as the 
adherence strategy was purely to support their forgetfulness. In contrast, participants who 
received a cognitive-educational intervention (information on their treatment and illness) had 
significant changes in their knowledge and understanding of their illness. For these 
individuals this change reflected an improvement in their adherence. Studies providing 
education to improve participant’s knowledge on their treatment and illness have shown to 
improve understanding of illness and treatment, similar to that observed in this study. 
However, these studies did not show an improvement in adherence, which may be because 
the intervention was not targeted to non-adherent participants.268,308 Those participants with 
negative beliefs about their medicine, discussing their concerns and motivation and/or 
establishing health goals resulted in changes in their beliefs towards their medicines, 
particularly a reduction in concerns towards medicines. Reduced concerns in regards to 
medicines has been significantly associated with better adherence.44,131 These changes in 
beliefs and illness perceptions may explain the significant improvement in adherence 
observed in the behavioural-counselling strategy group. 
There were differences in the beliefs towards medicines and illness perceptions between 
the control (non-adherent) group and the adherent group over time. The adherent group felt 
that over time their illness had a reduced impact on their lives, they had a greater control 
over their illness and they had less concerns about their illness. Other studies have found 
that participants with good adherence to their medication, felt that they had greater control 
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over their illness and were less emotionally affected by their illness.125,135 The adherent 
group held strong beliefs that their medicine was necessary, which remained steady over 
the six month study period. The adherent group also had fewer concerns in regards to their 
medicine and this declined over time. These changes may be a reflection of participants 
who are established on their medication and their medical condition may now be well-
controlled, reinforcing beliefs in the necessity of their medicines to achieve this control.  
In contrast, the control group felt their illness was affecting their lives more, felt that their 
medicine was less helpful, experienced more severe symptoms and were more emotionally 
affected by their illness at six months. Since these participants were non-adherent to their 
medication, these participants may not have received the full benefits of their medication, 
leading to the negative view observed in this control group. It cannot be confirmed whether 
the negative changes in the beliefs about medicines and illness perceptions over time are a 
cause of non-adherence or an effect of non-adherence. For example, did non-adherence to 
their medication lead to poor control of illness, which led to more severe symptoms of illness 
and greater concerns, or did poor control of illness, severe symptoms and greater concerns 
lead to non-adherence? Studies have found a relationship between the effect of the illness, 
emotional response towards the illness and adherence.40,95,125,134 Nicklas et al. found that 
participants non-adherent to their chronic pain medication were more emotionally affected 
by their illness.125 Beliefs that their medicine was necessary was relatively weaker in the 
control group than the adherent group. A declining trend in the beliefs that the medicine was 
necessary was observed over time. This was also observed in a study which implemented 
a text message program designed to modify beliefs to improve adherence to asthma 
medications. At 18 weeks, the control group had a decline in the BMQ-S necessity score.130 
Massey et al. measured self-reported adherence, beliefs about medicines (BMQ-S) and 
illness perceptions (BIPQ) in participants six weeks and six months after kidney 
transplantation. Medication non-adherence significantly increased from 17% at six weeks to 
27% at six months port-transplantation. This study found the mean BMQ-S necessity score 
in the population was significantly lower at six months. The mean BMQ-S concerns score 
did not significantly change over time.41  
 
6.5 Conclusions 
Improvements in adherence in the intervention group were supported by the positive 
changes in the beliefs about medicines and illness perceptions. The targeted and tailored 
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intervention changed beliefs about medicines and illness perceptions in a direction that 
mirrors the beliefs observed in an adherent population. The intervention group had less 
concerns about their medicines, better control over their illness and a clearer understanding 
of their illness and treatment over time. Changes in adherence, beliefs about medicines and 
illness perceptions in the intervention group at three and six months reflect patterns seen in 
the adherent group. These pattern changes in adherence, beliefs about medicines and 
illness perceptions are different to that observed in the control group. Improvement in beliefs 
about medicines and illness perceptions may help to explain how the intervention improved 
adherence. 
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CHAPTER SEVEN: DISCUSSION 
 
7.1 Introduction 
Medications remains one of the most frequently used treatments for managing chronic 
diseases.309 However, many patients do not adhere to their medications due to an 
unconscientious and uninformed decision, leading to adverse health outcomes.11,27,73 As 
discussed in Chapter One, medication non-adherence affects approximately 50% of patients 
prescribed chronic medications. Patients are non-adherent to their medication due to many 
different reasons, including forgetfulness, concerns about medicines and poor 
understanding of their treatment. Previous studies have aimed to improve medication 
adherence through interventions, such as reminders, education and motivational 
interviewing.219,236,266 Current interventions to improve adherence have had mixed 
results.13,15 Adherence interventions to date have often been implemented in a population 
without first identifying whether the patient was currently adherent or non-adherent and 
hence may provide an intervention to an individual who was already adherent to their 
medication. Interventions that have been tailored, were often tailored to a specific disease 
population or tailored a particular type of intervention, rather than tailored to the participant-
specific reasons for non-adherence. Promising interventions include multifaceted 
interventions, tailored interventions and targeted interventions, such as the Measurement-
Guided Medication Management (MGMM).214,216 To target and tailor an adherence 
intervention we require a measure that can identify medication-taking behaviour and explore 
the reasons for non-adherence in a practical way. The overall aim of this thesis was to 
improve medication adherence using a targeted and tailored intervention informed by 
validated adherence scales. 
 
7.2 Validated Adherence Scales 
Chapter Two presented the systematic review on validated adherence scales. The 
systematic review identified 43 adherence scales that have been correlated with a 
comparison measure of adherence. The adherence scales elicit different facets of 
adherence: medication-taking behaviour, barriers to adherence and beliefs associated with 
adherence.  
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Measurement-Guided Medication Management uses a measure of adherence to guide the 
intervention. In the literature, MEMS is used to identify medication-taking behaviour and this 
information is used to guide the feedback.214 Eliciting barriers to adherence and beliefs 
associated with adherence can be used to identify patient-specific reasons for non-
adherence. Adherence scales can be used in a similar manner to MEMS in the MGMM 
intervention to inform the discussion with the participant about reasons for non-adherence 
and guide the implementation of a tailored strategy to improve adherence. 
From the systematic review, the MAQ and BMQ-S were selected for use in a targeted and 
tailored intervention.213 The MAQ was used to identify medication-taking behaviour and the 
type of non-adherence the participant was exhibiting. The MAQ is one of the most commonly 
used scales and has been validated against a range of objective measures including MEMS 
and clinical outcomes.18,72,293,296 The BMQ-S has been extensively used in many different 
disease populations to elicit patient’s beliefs that the medicine is necessary and concerns 
about their medicine.4,89,117,124 The relationship between illness perceptions and medication 
adherence has also been well-established in the literature.136-139 The BIPQ was also 
included in the intervention to shed more light on the complex nature of adherence.139 
 
7.3 Targeted and Tailored Intervention  
In Chapter Three and Five of the thesis, the use of validated scales in a similar manner to 
an MGMM approach was described. The intervention involved the use of questionnaires 
(MAQ, BMQ-S and BIPQ), discussion with the participant about their adherence and the 
implementation of a tailored strategy to improve adherence (Chapter Five). The MAQ was 
used to identify non-adherence and to distinguish whether non-adherence to the medication 
was unintentional, intentional or a mix of both. The BMQ-S elicited beliefs about medicines 
and the BIPQ was used to explore the participant’s illness representations. The responses 
to these tools informed the discussion with the participant about reasons for their non-
adherence. This guided the implementation of an evidence-based tailored strategy to 
support adherence. This intervention was simple and quick to administer. The improvement 
in adherence observed in our study, reported in Chapter Four, is consistent with other 
studies that targeted an intervention to a non-adherent sample,247,310 and tailored an 
adherence strategy to the participant-specific reasons for non-adherence.130,153,219,229,230 
The changes that were observed in the participant’s beliefs and illness perceptions in the 
intervention group compared to the control group may help explain how the intervention 
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improved adherence (Chapter Four). The intervention group had a significantly higher 
necessity score on the BMQ-S than the control group, reflecting an increase in the strength 
of the participant’s belief in the necessity of medicines due to the intervention. The 
association between beliefs that medicines are necessary and medication adherence has 
been well-established in the literature.4,95,126,127,130,131 However, few studies have used the 
BMQ-S, as we did in our study, to explain how an intervention may have impacted 
adherence. The BIPQ was used to explore the participant’s illness perceptions, in particular, 
the participant’s understanding of their illness and whether they perceived their medicines 
as helpful. This information helped to identify participants who may benefit from information 
on their medicine and illness. The intervention group had a significantly higher BIPQ 
treatment coherence score than the control at three and six months, which indicates a 
clearer perceived understanding of their illness. Similarly, the intervention group believed 
their medicine was more helpful than the control group at three and six months.  
Improvement in adherence observed in the intervention group at three months was 
sustained at six months. The sustained improvement in adherence was mirrored by 
sustained improvements in beliefs about medicines and illness perceptions. Improvement in 
adherence, beliefs about medicines and illness perceptions is likely due to the impact of the 
targeted and tailored nature of the intervention.  
 
7.4 Changes in Adherence, Beliefs about Medicines and Illness Perceptions 
over Time 
At the start of the study, the adherent group and non-adherent (intervention and control) 
group were distinctly different in terms of not only their adherence but their beliefs towards 
the medicine and illness perceptions. Over time these differences changed. In the 
intervention group, there was a significant improvement in adherence, which was mirrored 
by a strengthening in their beliefs about medicines and an improvement in their illness 
perceptions, in particular, in their understanding of their treatment and illness. These 
changes reflected the beliefs towards medicines and illness perceptions in the adherent 
group, suggesting that the intervention had improved adherence and impacted on beliefs 
and illness perceptions in a way that facilitated adherent behaviour. The changes in 
adherence, beliefs about medicines and illness perceptions were also explored in the 
different tailored strategy groups. Exploring the changes in each of the tailored strategy 
groups demonstrates how the intervention impacted the beliefs about medicines, illness 
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perceptions and how this translated into an improvement in adherence (Chapter Six). 
Changes in the BIPQ treatment coherence and treatment control scores were driven by 
participants who received a cognitive-educational intervention (see Chapter Six, Figure 6.11 
and 6.12). Improved BIPQ treatment coherence and treatment control scores has been 
associated with improved adherence.40 
Participants in the control group had negative changes in their illness perceptions over time. 
These participants had poorer understanding of their illness, perceived their medicine as 
less helpful and were more emotionally affected by their illness over time. Similar 
observations can be seen in other studies. For example, a study found that perceived 
necessity of immunosuppressant after kidney transplantation significantly declined over time, 
which was associated with a worsening of medication adherence six months after 
transplantation.41 Shiyanbola et al. examined whether concerns about medicines changed 
over time and the characteristics of the patients in whom beliefs changed over two years. In 
this study, good medication adherence was associated with less concerns about their 
medicines, which may be due to better health or a reduction in symptoms.44  
 
7.5 Limitations of the Study 
Our study had a number of limitations. One of the limitations of this study was the use of a 
subjective measure of adherence. A systematic review on validated adherence scales was 
conducted, from which we selected the most appropriate measure of adherence, the MAQ. 
There are limitations to using self-report methods to identify medication adherence. Self-
report measures are prone to overestimating adherence due to social desirability bias. This 
is unlikely to be a problem in this study given our use of a highly sensitive indicator of 
possible non-adherence: an MAQ score > 0. This cut-off has been used in previous 
studies.72,95,204,307 Indeed, with approximately 80% of the enrolled population being identified 
as non-adherent, a more likely problem is that participants identified as non-adherent 
according to the MAQ may have been classified as adherent using a different measure (such 
as MEMS or a medication possession ratio based on dispensing history). In any case, the 
overall effect of the MAQ incorrectly identifying non-adherence would be expected to reduce 
rather than increase the effects of the intervention. Assessing Pharmaceutical Benefits 
Scheme (PBS) data was also attempted; however, the high cost of receiving this information 
made this option not possible. This data would have provided us with information on the 
date of prescribing, date of dispensing of the medicines. Pharmacy prescription refill data 
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was another option that was attempted; however, we were only able to obtain consent to 
assess this data from fourteen participants and hence were not able to model these results.  
Some studies have shown that improving adherence to medications, improves clinical 
outcomes, such as blood pressure control, blood glucose levels, and lower lipid levels.311-
313 Our study was not powered to measure clinical outcomes (but was powered on the basis 
of a change in MAQ that has been demonstrated to influence clinical outcomes). Given the 
success of the intervention, we hope to conduct a study powered to show the effect of the 
intervention on clinical outcomes.  
The process of following up participants at three months and six months may have 
influenced adherence to medications independently of the intervention. Whether or not this 
effect occurred is hard to judge, but any effect would be small and affect both the control 
and intervention group. MAQ scores in the control group did not change to a statistically 
significantly degree during the follow up. 
Recruiting participants from a convenience sample of only two community pharmacies would 
have led to selection bias, and may have led to over- and/or under-representation of 
participant demographics. The two selected pharmacies service a broad range of patients 
and were located in different socioeconomic areas. Based on the Socio-Economic Index for 
Areas (SEIFA) that ranges from 1 (low) to 10 (high), one pharmacy had an index of 2 and 
the other 9. SEIFA is an index that ranks Australian suburbs based on socioeconomic factors, 
such as income and level of education, which was developed by the Australian Bureau of 
Statistics.314 Furthermore, participants were recruited from two community pharmacies that 
were known to the researcher. Some participants were known to the researcher prior to the 
study, which may have influenced the results. However, this effect, if any, would have been 
observed in both the intervention and control group. Conducting the study in pharmacies 
known to the researcher improved the ease of data collection. The research may be more 
difficult in pharmacies that do not have an established relationship with the researchers. 
This study could be further strengthened with an exit survey to explore the participant’s 
opinions and thoughts about the intervention. This information could be used to better tailor 
interventions. An exit survey will be considered for further studies. 
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7.6 Future Directions and Conclusion 
A targeted and tailored intervention, based on discussion informed using validated 
adherence scales improved medication adherence. This intervention was easy to administer 
and quick enough that it could be incorporated into day-to-day practice. In our study we 
utilised the validated adherence questionnaires to assess patients on newly initiated therapy. 
The questionnaires have been utilised previously in patients prescribed chronic medication 
to assess their adherence to these. We believe that there should be no reason why the study 
method would not also have utility in supporting adherence in patients on chronic medication.  
If this targeted and tailored intervention proves successful in larger studies that assess 
clinical outcomes, it has the potential for widespread implementation for improving 
adherence to both recently initiated medications and existing therapy. 
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APPENDIX B: Participant Information 
Sheet 
Full Project Title  
Targeted and tailored interventions to improve medication adherence in chronic diseases 
Principal investigator:    Ms Uyen Nguyen, BPharm (Hons), PhD Candidate 
 
Associate investigators:  Dr Neil Cottrell, BSc (Hons) MSc PhD, Senior Lecturer 
                                               Dr Adam La Caze, BPharm (Hons) BA (Hons) PhD, Lecturer 
 
All investigators are affiliated with the School of Pharmacy, The University of Queensland. 
Your Consent 
You are invited to participate in this research project because you are presenting a medication 
started in the last 4 to 12 weeks for one of the following medical conditions: high blood pressure, 
diabetes, high cholesterol or other heart conditions.  
This Participant Information contains detailed information about the research project. Its purpose 
is to explain to you as openly and clearly as possible all the procedures involved in this project before 
you decide whether or not to take part in it. Please read this Participant Information carefully. Feel 
free to ask questions about any information in the document. If you wish, feel free to discuss the 
project with a relative or friend or your local health worker.  
Once you understand what the project is about and if you agree to take part in it, you will be asked 
to sign the Consent Form. By signing the Consent Form, you indicate that you understand the 
information and that you give your consent to participate in the research project. 
This information and consent form is 3 pages long and you will be given a copy to keep as a record. 
Purpose and Background 
The purpose of this project is to assess whether people who forget or choose not to take their 
medicines benefit from personalised support. A total of approximately 200 people will participate 
in this project. 
People with chronic medical conditions often have to take a number of medicines for a long 
period of time. People in this situation often do not take their medicines as agreed due to 
many different reasons. Identifying why this occurs and how best to support people in their 
medication taking may help manage their medical conditions. 
Procedures 
Participation in this project will involve completing a questionnaire in an interview on three 
occasions. The first interview will be today and the two other interviews will take place over the 
telephone at 3 months and 6 months after today. The questionnaire will take about ten minutes to 
complete. The first section consists of 4 Yes or No questions on the way you take your medicines. 
The next section will consist of 10 statements about your view and opinion of your medicines. In 
this section you will be asked to state your level of agreement or disagreement with each statement. 
The last section will consist of 8 questions on your view of illness. You will be asked to rate your 
answers on a scale of 0 to 10. You will be also asked to provide some information about yourself, 
such as your age and marital status. About a third of the participants in this study will have a longer 
interview with the researcher to discuss ways to help support the participants taking their 
medicines.  
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You will be contacted by telephone 3 months after the interview and then again at 6 months after 
this interview. The telephone calls will last for about 10 minutes. These telephone calls will involve 
the same questionnaire that you answered at the interview.  
There are no right or wrong answers to any of the questions in the interview; it is your view and 
opinion that is important. 
Possible Benefits 
Possible benefits include better understanding of medication and ways that may help you to 
improve medication-taking behaviour. 
Possible Risks 
This study involves completing a questionnaire through one interview and two telephone 
calls. There is no foreseeable added risk to you above the risks of everyday living. 
Privacy, Confidentiality and Disclosure of Information 
In all reports from this research, information will be provided in such a way that you cannot be 
identified. The results will be such that the individual issue could not be linked to that participant. 
The information collected will be stored in a locked filing cabinet in a locked office, with access only 
to the three researchers stated above. The information will be stored for a period of 5 years and 
then destroyed.  
 
Results of the Project 
You may request the study results when it is completed by providing an address that the report can 
be sent to or at a later date by contacting Uyen Nguyen (contact details below). 
Participation is Voluntary 
Participation in any research project is voluntary. If you do not wish to take part, you are not obliged 
to. If you decide to take part and later change your mind, you are free to withdraw from the project 
at any stage.  
Your decision whether to take part or not to take part, or to take part and then withdraw, will not 
affect your routine treatment or your relationship with the pharmacy staff.  
Before you make your decision, a member of the research team will be available to answer any 
questions you have about the research project. Sign the Consent Form only after you have had a 
chance to ask your questions and have received satisfactory answers. 
If you decide to withdraw from this project, please notify a member of the research team before 
you withdraw.  
Reimbursements 
No payment will be provided for participation in this study. If you have any queries or any problems 
concerning this project, please contact Uyen Nguyen: phone 07 3346 1996 or email 
t.nguyen63@uq.edu.au.  
 
This study has been cleared by one of the human ethics committees of the University of Queensland in 
accordance with the National Health and Medical Research Council's guidelines. You are of course, free to 
discuss your participation in this study with project staff (contactable on 3346 1996 or email 
t.nguyen63@uq.edu.au). If you would like to speak to an officer of the University not involved in the study, 
you may contact the Ethics Officer on 3365 3924. 
  
 189 
 
APPENDIX C: Participant Consent Form 
Full Project Title   
Targeted and tailored interventions to improve medication adherence in chronic diseases 
 
Principal investigator:      Ms Uyen Nguyen, BPharm (Hons), PhD Candidate 
Associate investigators:   Dr Neil Cottrell, BSc (Hons) MSc PhD, Senior Lecturer 
                                               Dr Adam La Caze, BPharm (Hons) BA (Hons) PhD, Lecturer 
 
All investigators are affiliated with the School of Pharmacy, The University of Queensland. 
 
I acknowledge that:  
(a) my participation is voluntary and that I am free to withdraw from the project at any time 
without explanation; 
(b) I will be given a copy of the participant information sheet to which this consent form 
relates to and the consent form to keep; 
(c) this project is for the purpose of research and not for profit;  
(d) any identifiable information about me which is gathered in the course of and as the result 
of my participating in this project will be (i) collected and retained for the purpose of this 
project and (ii) accessed and analysed by the researcher(s) for the purpose of conducting 
this project;  
(e) my anonymity is preserved and I will not be identified in publications or otherwise without 
my express written consent. 
 (f)  I may not directly benefit from participation in this project. 
 
By signing this document I agree to participate in this project.  
 
Full Name of Participant (printed):………………….……………….…………………………….……….…………………….   
Signature of Participant: ……………………………………….………..….   Date: ……………/……………/……………… 
Full Name of Witness to Signature of Participant (printed):…………………………………………………….…....  
Signature of Witness: ……………………………………...…….………..….   Date: ……………/……………/…………….. 
Full Name of Researcher (printed): ……………………………………………………………………………………………… 
Signature of Researcher: ……………………………………………………..   Date: …………../…………../……………… 
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APPENDIX D: Participant Survey 
Below are questions about how you take your recently prescribed medicine. There 
are no right or wrong answers. Please answer YES or NO.  
Item Question YES NO 
1 Do you ever forget to take your medicine? 1 0 
2 Are you careless at times about taking your medicine? 1 0 
3 When you feel better, do you sometimes stop taking your 
medicine? 
1 0 
4 Sometimes, if you feel worse when you take the medicine, 
do you stop taking it? 
1 0 
 
Below are statements other people have made about their medicines. We are 
interested in your personal views. There are no right or wrong answers. Please 
indicate the extent to which you agree or disagree with them.  
 
Item Statement Strongly 
Agree 
Agree Uncertain Disagree Strongly 
Disagree 
1 My health at present, 
depends on my medicines 
5 4 3 2 1 
2 Having to take medicines 
worries me 
 
5 4 3 2 1 
3 My life would be impossible 
without my medicines 
5 4 3 2 1 
4 Without my medicines I 
would be very ill 
5 4 3 2 1 
5 I sometimes worry about 
long-term effects of my 
medicines 
5 4 3 2 1 
6 My medicines are a mystery 
to me 
 
5 4 3 2 1 
7 My health in the future will 
depend on my medicines 
5 4 3 2 1 
8 My medicines disrupt my life 
 
5 4 3 2 1 
9 I sometimes worry about 
becoming too dependent on 
my medicines 
5 4 3 2 1 
10 My medicines protect me 
from becoming worse 
5 4 3 2 1 
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These questions are about your views on your illness. For the following questions, 
please circle the number that best corresponds to your views: 
 
How much does your illness affect your life? 
0               1               2              3             4             5            6            7            8            9           10                                    
no affect                                                                                                                  severely affects                     
at all                                                                                                                                       my life                               
How long do you think your illness will continue? 
0               1               2              3             4             5            6            7            8            9           10                                     
a very                                                                                                                                    forever                                                                    
short time 
How much control do you feel you have over your illness? 
0               1               2              3             4             5            6            7            8            9           10                      
absolutely                                                                                                               extreme amount           
no control                                                                                                                          of control 
How much do you think your treatment can help your illness? 
0               1               2              3             4             5            6            7            8            9           10                                 
not                                                                                                                                    extremely                                        
at all                                                                                                                                      helpful                                        
How much do you experience symptoms from your illness? 
0               1               2              3             4             5            6            7            8            9           10                                   
no symptoms                                                                                                               many severe         
at all                                                                                                                                 symptoms           
How concerned are you about your illness? 
0               1               2              3             4             5            6            7            8            9           10                                  
not at all                                                                                                                            extremely                        
concerned                                                                                                                       concerned                                                 
How well do you feel you understand your illness? 
0               1               2              3             4             5            6            7            8            9           10                                 
don’t understand                                                                                                            understand                           
at all                                                                                                                               very clearly 
How much does your illness affect you emotionally? (e.g. does it make you angry, scared, 
upset or depressed? 
0               1               2              3             4             5            6            7            8            9           10                                   
no at all                                                                                                                            extremely                                       
affected emotionally                                                                                        affected emotionally                                                             
Please list in rank-order the three most important factors that you believe caused your 
illness. The most important causes for me:     
1. _____________________ 2. _____________________ 3. __ ________________                                                                                         
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Below are questions about your background. Please tick one box for each question. 
 
1. Gender:               Male                                Female 
 
2. Age:        ______________________ 
                     
3. Highest Education Level: 
 
                                        Primary                             Secondary                       Tertiary 
 
4. Employment Status 
 
                                        Employed                         Unemployed                    Retired 
 
From the list below please select the number closest to YOUR FAMILY’s annual income (before tax). 
                                 
                 ≤ $30 000                      $51 000 to $70 000           $91 000 to $110 000       $131 000 - $150 000 
 
              $31 000 to $50 000      $71 000 to $90 000         $111 000 to $130 000      Over $150 000 
  
 
5. Marital Status (select the one that best describes you) 
 
                                Married                             Divorced                           Widowed                         Single  
 
6. Number of Medications Currently Taken _____________ 
 
7. Number of Vitamin/Herbal/Mineral supplements taken (if applicable)_______________ 
 
8. Medical Conditions: select all that apply to you from the following list 
 
                      High blood pressure            Asthma                         Diabetes                         Heart failure 
                      High cholesterol levels        Depression                    Osteoarthritis                 Stroke 
                      Other(s) __________________________________________________________________         
 
 Thank you for your time 
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APPENDIX E: Mean MAQ Scores Over 
Time 
 
Mean MAQ scores at baseline, 3 months and 6 months (Adherent Group) 
 
 
 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ 
Score ± sd  
 
0.00 0.22 ± 0.49 0.03 ± 0.18 <0.05*    0.3251     0.0564      
 
 
Mean MAQ scores at baseline, 3 months and 6 months (Intervention Group) 
 
 
 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ 
Score ± sd 
 
1.58 ± 0.79 0.42 ± 0.59 0.48 ± 0.68 <0.05* <0.05* 0.4543 
 
 
Mean MAQ scores at baseline, 3 months and 6 months (Control Group) 
 
 
 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean MAQ 
Score ± sd 
 
1.60 ± 0.67 1.58 ± 0.65 1.48 ± 0.83 0.7987 0.1961 0.2034 
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APPENDIX F: Mean BMQ-S Necessity and 
Concerns Scores Over Time 
 
Mean BMQ-S Necessity and Concerns scores at baseline, 3 months and 6 months 
(Adherent Group) 
 
Mean BMQ-
S Scores  
± sd 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean 
Necessity 
Score 
 
20.25 ± 4.84 20.28 ± 4.17 20.22 ± 3.89 0.9545 0.9608 0.8523 
Mean 
Concerns 
Score 
 
11.75  ± 3.13 11.41 ± 2.89 10.78 ± 2.81 0.4855 0.0594 <0.05* 
 
 Mean BMQ-S Necessity and Concerns scores at baseline, 3 months and 6 months 
(Intervention Group) 
 
Mean BMQ-
S Scores  
± sd 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean 
Necessity 
Score 
19.60 ± 3.18 19.80 ± 2.94 20.25 ± 3.17 0.5160 0.0963 0.1475 
Mean 
Concerns 
Score 
13.48 ± 3.50 13.00 ± 3.43 12.32 ± 3.75 0.1837 <0.05* 0.0511 
 
Mean BMQ-S Necessity and Concerns scores at baseline, 3 months and 6 months 
(Control Group) 
 
Mean BMQ-S 
Scores  
± sd 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Mean 
Necessity 
Score 
 
18.48 ± 3.63 18.53 ± 3.71 17.95 ± 3.20 0.8699 0.1854 0.0874 
Mean 
Concerns 
Score 
 
12.63 ± 4.20 13.05 ± 3.75 12.92 ± 3.38 0.1456 0.4558 0.6663 
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APPENDIX G: Illness Perceptions Over 
Time 
Mean BIPQ scores at baseline, 3 months and 6 months (Adherent Group) 
 
Mean BIPQ Scores  
± sd  
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Consequences  
How much does your 
illness affect your life? 
(0 = no affect at all – 10 = 
severely affects my life) 
5.13 ± 2.87 
 
5.03 ± 3.17 
 
4.06 ± 2.94 0.7932 <0.05* <0.05* 
Timeline 
How long do you think 
your illness will 
continue? 
(0 = very short time – 10 = 
forever) 
8.72 ± 2.64 
 
8.94 ± 2.35 
 
9.09 ± 2.16 0.4148 0.1359 0.3776 
Personal Control 
How much control do 
you feel you have over 
your illness? 
(0 = absolutely no control – 10 
= extreme amount of control) 
6.53 ± 2.73 
 
7.22 ± 1.91 
 
7.47 ± 1.90 0.1367 <0.05* 0.2833 
Treatment Control 
How much do you think 
your treatment can help 
your illness? 
(0 = not at all – 10 = extremely 
helpful) 
9.00 ± 1.44 
 
9.28 ± 1.39 
 
9.16 ± 1.42 0.1525 0.4926 0.5014 
Identity 
How much do you 
experience symptoms 
from your illness? 
(0 = no symptoms at all – 10 = 
many severe symptoms) 
3.63 ± 3.12 4.16 ± 3.05 
 
3.56 ± 2.71 0.1142 0.8523 0.1054 
Concern 
How concerned are you 
about your illness? 
(0 = not at all concerned – 10 = 
extremely concerned) 
5.53 ± 3.16 
 
5.34 ± 3.57 
 
4.47 ± 3.32 0.7251 <0.05* <0.05* 
Coherence 
How well do you feel you 
understand your illness? 
(0 = don’t understand at all – 
10 = understand very clearly) 
8.53 ± 1.92 
 
8.66 ± 1.82 
 
8.84 ± 1.74 0.6767 0.2991 0.1606 
Emotional 
Response 
How much does your 
illness affect you 
emotionally?  
(0 = not at all affected 
emotionally – 10 = extremely 
affected emotionally) 
3.56 ± 3.22 
 
4.16 ± 3.07 
 
3.38 ± 2.70 0.2082 0.6720 <0.05* 
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Mean BIPQ scores at baseline, 3 months and 6 months (Intervention Group) 
 
Mean BIPQ 
Scores  
± sd 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Consequences  
How much does your 
illness affect your life? 
(0 = no affect at all – 10 = 
severely affects my life) 
 
5.10 ± 3.02 
 
4.98 ± 3.07 
 
4.90 ± 2.86 0.7188 0.5654 0.7744 
Timeline 
How long do you think 
your illness will 
continue? 
(0 = very short time – 10 = 
forever) 
 
9.57 ± 1.14 
 
9.90 ± 0.66 
 
9.83 ± 0.62 <0.05* 0.0808 0.2086 
Personal Control 
How much control do 
you feel you have over 
your illness? 
(0 = absolutely no control – 
10 = extreme amount of 
control) 
 
5.70 ± 2.82 
 
6.50 ± 2.57 
 
5.90 ± 2.93 <0.05* 0.5578 0.0832 
Treatment Control 
How much do you think 
your treatment can 
help your illness? 
(0 = not at all – 10 = 
extremely helpful) 
 
8.20 ± 1.94 
 
8.55 ± 1.79 
 
8.58 ± 1.70 0.0961 0.1210 0.8836 
Identity 
How much do you 
experience symptoms 
from your illness? 
(0 = no symptoms at all – 10 
= many severe symptoms) 
 
4.32 ± 2.83 
 
4.52 ± 3.06 4.18 ± 2.78 0.5912 0.7171 0.3140 
Concern 
How concerned are 
you about your illness? 
(0 = not at all concerned – 10 
= extremely concerned) 
 
5.97 ± 3.46 
 
5.65 ± 3.21 
 
5.53 ± 3.32 0.2739 0.2604 0.6598 
Coherence 
How well do you feel 
you understand your 
illness? 
(0 = don’t understand at all – 
10 = understand very clearly) 
 
7.28 ± 2.64 
 
8.37 ± 2.09 
 
8.37 ± 2.11 <0.05* <0.05* 1.0000 
Emotional 
Response 
How much does your 
illness affect you 
emotionally?  
(0 = not at all affected 
emotionally – 10 = extremely 
affected emotionally) 
 
4.18 ± 3.41 
 
4.27 ± 3.15 
 
3.92 ± 3.02 0.8211 0.5745 0.2740 
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Mean scores of BIPQ at baseline, 3 months and 6 months (Control group) 
 
Mean BIPQ Scores  
± sd 
Time p-value 
Baseline 3 months 6 months 0 to 3 
months 
0 to 6 
months 
3 to 6 
months 
Consequences  
How much does your 
illness affect your life? 
(0 = no affect at all – 10 = 
severely affects my life) 
4.77 ± 3.01 
 
5.03 ± 3.09 
 
5.45 ± 2.92 0.2199 <0.05* <0.05* 
Timeline 
How long do you think 
your illness will 
continue? 
(0 = very short time – 10 = 
forever) 
8.85 ± 2.28 
 
8.92 ± 2.19 
 
9.12 ± 1.87 0.7632 0.2995 0.1928 
Personal Control 
How much control do 
you feel you have over 
your illness? 
(0 = absolutely no control – 10 
= extreme amount of control) 
6.08 ± 2.89 
 
5.53 ± 2.61 
 
4.98 ± 2.59 0.1186 <0.05* 0.0506 
Treatment Control 
How much do you think 
your treatment can help 
your illness? 
(0 = not at all – 10 = extremely 
helpful) 
8.00 ± 1.97 
 
7.63 ± 2.15 
 
7.22 ± 2.44 <0.05* <0.05* <0.05* 
Identity 
How much do you 
experience symptoms 
from your illness? 
(0 = no symptoms at all – 10 = 
many severe symptoms) 
4.25 ± 2.90 
 
4.37 ± 2.95 
 
4.98 ± 2.69 0.6831 <0.05* <0.05* 
Concern 
How concerned are you 
about your illness? 
(0 = not at all concerned – 10 = 
extremely concerned) 
5.37 ± 3.11 
 
5.78 ± 2.96 
 
6.12 ± 2.92 0.2780 <0.05* 0.3238 
Coherence 
How well do you feel you 
understand your illness? 
(0 = don’t understand at all – 
10 = understand very clearly) 
7.35 ± 2.36 
 
7.12 ± 2.54 
 
6.63 ± 2.71 0.4235 0.0525 <0.05* 
Emotional 
Response 
How much does your 
illness affect you 
emotionally?  
(0 = not at all affected 
emotionally – 10 = extremely 
affected emotionally) 
4.07 ± 3.05 
 
4.38 ± 3.04 
 
4.97 ± 2.91 0.2897 <0.05* <0.05* 
 
